<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        20-191-05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2005
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TRIPACEL VACCINE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DIPHTHERIA TOXOID,TETANUS TOXOID,ACELLULAR PERTUSSIS
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15,5,23
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        69.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SANOFI PASTEUR" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SANOFI PASTEUR
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 634]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ARAB COMPANY FOR PHARMACEUTICAL PRODUCTS (ARABIO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANOFI PASTEUR
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07CA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group:<br />TRIPACEL&reg; is a vaccine that is used to help prevent diphtheria, tetanus (lock jaw) and pertussis (whooping cough) infections<br />Therapeutic indications:<br />TRIPACEL&reg; is indicated for the primary immunization of infants from the age of 2 months and in children up to 6 years of age (prior to their 7th birthday) against diphtheria, tetanus and pertussis (whooping cough).<br />Children who have had diphtheria, tetanus or pertussis should still be immunized since these clinical infections do not always confer immunity.<br />Human ImmunodeficiencyVirus (HIV)-infected persons, both asymptomatic and symptomatic, should be immunized against diphtheria, tetanus and pertussis according to standard schedules.<br />TRIPACEL&reg; is not to be used for the treatment of disease caused by Corynebacterium diphtheriae, Clostridium tetani or Bordetella pertussis infections.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. Do not use TRIPACEL&reg;<br />Hypersensitivity<br />Known systemic hypersensitivity reaction or a life threatening reaction to any component of TRIPACEL&reg; after previous administration of the vaccine or a vaccine containing one or more of the same components are contraindications to vaccination. Because of uncertainty as to which component of the vaccine may be responsible, none of the components should be administered. Alternatively, such persons may be referred to an allergist for evaluation if further immunizations are considered.<br />Neurological Disorders<br />The following events are contraindications to administration of any pertussis-containing vaccine, including TRIPACEL&reg;:<br />Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within<br />7 days of a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause.<br />Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy. Pertussis vaccine should not be administered to persons with such conditions until a treatment regimen has been established and the condition has stabilized.<br />b. Take special care with TRIPACEL&reg;<br />General<br />Before administration of TRIPACEL&reg; health-care providers should inform the parent or guardian of the recipient to be immunized of the benefits and risks of immunization, inquire about the recent health status of the recipient, review the recipient&rsquo;s history concerning possible hypersensitivity to the vaccine or similar vaccine, previous immunization history, the presence of any contraindication to immunization and comply with any local requirements with respect to information to be provided to the parent or guardian before immunization and the importance of completing the immunization series. It is extremely important that the parent or guardian be questioned concerning any symptoms and/or signs of an adverse reaction after a previous dose of vaccine.<br />The rates and severity of adverse events in recipients of tetanus toxoid are influenced by the number of prior doses and level of pre-existing antitoxins.<br />Syncope (fainting) has been reported following vaccination with TRIPACEL. Procedures should be in place to prevent falling injury and manage syncopal reactions.<br />As with any vaccine, TRIPACEL&reg; may not protect 100% of vaccinated individuals. Administration Route Related Precautions: Do not administer TRIPACEL&reg; by intravascular injection: ensure that the needle does not penetrate a blood vessel. Intradermal or subcutaneous routes of administration are not to be utilized. TRIPACEL&reg; should not be administered into the buttocks.<br />Febrile and Acute Disease: Vaccination should be postponed in cases of an acute or febrile disease. However, a disease with low-grade fever should not usually be a reason to postpone vaccination.</p><p>If any of the following events occur within the specified period after administration of a whole-cell pertussis vaccine or a vaccine containing an acellular pertussis component, the decision to administer TRIPACEL&reg; should be based on careful consideration of potential benefits and possible risks.<br />&bull; Temperature of &ge;40.5&deg;C (105&deg;F) within 48 hours, not attributable to another identifiable cause;<br />&bull; Collapse or shock-like state (hypotonic-hyporesponsive episode - HHE) within 48 hours;<br />&bull; Persistent crying lasting &ge;3 hours within 48 hours;<br />&bull; Convulsions with or without fever within 3 days.<br />Hematologic<br />Because any intramuscular injection can cause an injection site hematoma in persons with any bleeding disorders, such as hemophilia or thrombocytopenia, or in persons on anticoagulant therapy, intramuscular injections with TRIPACEL&reg; should not be administered to such persons unless the potential benefits outweigh the risk of administration. If the decision is made to administer any product by intramuscular injection to such persons, it should be given with caution, with steps taken to avoid the risk of hematoma formation following injection.<br />Immune<br />The possibility of allergic reactions in persons sensitive to components of the vaccine should be evaluated. Hypersensitivity reactions may occur following the use of TRIPACEL&reg; even in persons with no prior history of hypersensitivity to the product components. Cases of allergic or anaphylactic reactions have been reported after receiving some preparations containing diphtheria and tetanus toxoids and/or pertussis antigens.<br />Epinephrine hydrochloride solution (1:1,000) and other appropriate agents should be available for immediate use in case an anaphylactic or acute hypersensitivity reaction<br />occurs. Health-care providers should be familiar with current recommendations for the initial management of anaphylaxis in non-hospital settings, including proper airway management.<br />Immunocompromised persons (whether from disease or treatment) may not obtain the expected immune response. If possible, consideration should be given to delaying vaccination until after the completion of any immunosuppressive treatment. Nevertheless, vaccination of persons with chronic immunodeficiency such as HIV infection is recommended even if the immune response might be limited.<br />Neurologic<br />A review by the US Institute of Medicine (IOM) found evidence for a causal relationship between tetanus toxoid and both brachial neuritis and Guillain-Barr&eacute; syndrome (GBS). If GBS occurred within 6 weeks of receipt of prior vaccine containing tetanus toxoid, the decision to give TRIPACEL&reg; or any vaccine containing tetanus toxoid should be based on careful consideration of the potential benefits and possible risks.</p><p>For infants or children at higher risk for seizures than the general population that an appropriate antipyretic may be administered (in the dosage recommended in its prescribing information) at the time of vaccination with a vaccine containing an acellular pertussis component (including TRIPACEL&reg;) and for the following 24 hours, to reduce the possibility of post-vaccination fever.<br />Hypotonic-hyporesponsive episodes (HHEs) rarely follow vaccination with whole-cell pertussis-containing DTP vaccines and occur even less commonly after acellular<br />pertussis-containing DTP and DT vaccines. A history of HHE is not a contraindication to the use of acellular pertussis vaccines, but recommends precaution in these cases.<br />Pediatrics<br />The potential risk of apnea and the need for respiratorymonitoring for 48 &ndash; 72 hours should be considered when administering the primary immunization series to very premature infants (born &le; 28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.<br />c. Using other medicines or vaccines<br />Vaccine-Drug Interactions<br />Immunosuppressive treatments may interfere with the development of the expected immune response<br />Concomitant Vaccine Administration<br />Administering the most widely used live and inactivated vaccines during the same patient visit has produced seroconversion rates and rates of adverse reactions similar to those observed when the vaccines are administered separately. Vaccines administered simultaneously should be given using separate syringes at separate sites. Simultaneous administration is suggested, particularly when there is concern that a person may not return for subsequent vaccination. Simultaneous administration of childhood vaccines such as TRIPACEL&reg;,MMR, varicella, pneumococcal conjugate and hepatitis B vaccines, is encouraged for children who are at the recommended age to receive these vaccines and for whom no contraindications exist.<br />TRIPACEL&reg; may be used to reconstitute Act-HIB&reg; [Haemophilus b Conjugate Vaccine (Tetanus Protein-Conjugate)] permitting the administration of these vaccines in a single dose.<br />d. Pregnancy and breast feeding<br />Tripacel&reg; is not intended for administration to women of child-bearing age.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>For routine immunization, TRIPACEL&reg; is recommend as a 4-dose series, with a single dose of 0.5 mL of TRIPACEL&reg; at 2, 4, 6 and 18 months of age.<br />If for any reason this schedule is delayed, it is recommended that 3 doses be administered with an interval of 2 months between each dose, followed by a fourth dose approximately<br />6 to 12 months after the third dose.<br />Whenever feasible, TRIPACEL&reg; should be used for all 4 doses in the vaccination series as there are no clinical data to support the use of TRIPACEL&reg; with any other licensed acellular pertussis combination vaccine in a mixed sequence.<br />Premature infants whose clinical condition is satisfactory should be immunized with full doses of vaccine at the same chronological age and according to the same schedule as full-term infants, regardless of birth weight.<br />Fractional doses (doses &lt;0.5 mL) should not be given. The effect of fractional doses on the safety and efficacy has not been determined<br />The childhood immunization series may be completed with a single 0.5 mL dose of DTaP<br />such as TRIPACEL&reg; between 4 and 6 years of age.<br />Inspect for extraneous particulate matter and/or discoloration before use. If these conditions exist, the product should not be administered.<br />Shake the vial well until a uniform, cloudy, suspension results. Cleanse the vial stopper with a suitable germicide prior to withdrawing the dose. Do not remove either the stopper or the metal seal holding it in place.<br />Aseptic technique must be used. Use a separate sterile syringe and needle or a sterile disposable unit, for each individual patient to prevent disease transmission. Needles should not be recapped but should be disposed of according to biohazard waste guidelines.<br />Before injection, the skin over the site to be injected should be cleansed with a suitable germicide. Administer the total volume of 0.5 mL intramuscularly (I.M.). In infants younger than 1 year, the anterolateral aspect of the thigh provides the largest muscle and is the preferred site of injection. In older children the deltoid muscle is usually large enough for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines Tripacel&reg; can cause side effects, although not every body gets them. The following side effects were observed during clinical trials with TRIPACEL&reg;.<br />Very Common: &ge;10%<br />Common: &ge;1% and &lt;10% Uncommon: &ge;0.1% and &lt;1% Rare: &ge;0.01% and &lt;0.1%<br />Gastrointestinal Disorders<br />Common: vomiting.</p><p>Nervous System Disorders<br />Very Common: drowsiness. Uncommon: convulsion. Rare: HHE<br />General Disorders and Administration Site Conditions<br />Very Common: injection site tenderness, swelling, redness, fever, irritability, decreased feeding (anorexia).<br />Common: crying, pallor<br />Rare: listlessness<br />The following additional adverse events have been spontaneously reported during the post-marketing use of TRIPACEL&reg; worldwide. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure.<br />Blood and Lymphatic Disorders<br />Lymphadenopathy<br />Cardiac Disorders<br />Cyanosis<br />Gastro-intestinal Disorders<br />Nausea, diarrhea<br />General Disorders and Administration Site Conditions<br />Injection site reactions: pain, rash, nodule, mass<br />Large injection site reactions (&gt;50 mm), including extensive limb swelling which may extend from the injection site beyond one or both joints have been reported in children following TRIPACEL&reg; administration. These reactions usually start within 24 - 72 hours after vaccination, may be associated with erythema, warmth, tenderness or pain at the injection site and resolve spontaneouslywithin 3 - 5 days. The risk appears to be<br />dependent on the number of prior doses of acellular pertussis containing vaccine, with a greater risk following the 4th and 5th doses.<br />Infections and Infestations<br />Injection site cellulitis, injection site abscess<br />Immune System Disorders<br />Hypersensitivity, allergic reaction, anaphylactic reaction (edema, face edema) Pruritus, generalized rash and other types of rash (erythematous,macular, maculo- papular)<br />Nervous System Disorders<br />Convulsions: febrile convulsion, grand mal convulsion, partial seizures</p><p>HHE, hypotonia, somnolence and Syncope (fainting).<br />Psychiatric Disorders<br />Screaming<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, tell your doctor, healthcare provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children<br />Store at 2&deg; to 8&deg;C (35&deg; to 46&deg;F). Do not freeze. Discard product if exposed to freezing. Do not use after expiration date.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances in each dose (0.5 mL) are:<br />Diphtheria Toxoid 15 Lf Tetanus Toxoid 5 Lf Acellular Pertussis<br />Pertussis Toxoid (PT) 10 &mu;g Filamentous Haemagglutinin (FHA) 5 &mu;g Pertactin (PRN) 3 &mu;g Fimbriae Types 2 and 3 (FIM) 5 &mu;g</p><p><strong>The other ingredients are Excipients:</strong><br />Aluminium Phosphate (adjuvant) (aluminum 0.33 mg) 1.5 mg<br />2-phenoxyethanol 0.6% v/v<br />Manufacturing Process Residuals: formaldehyde and glutaraldehyde are present in trace amounts.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                TRIPACEL® is a suspension for injection, supplied in single dose vials.
The vials are made of Type 1 glass. The vial stopper for this product does not contain latex (natural rubber).
TRIPACEL® is available in a package of:
1 single dose vial
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Sanofi Pasteur Limited</strong><br />Toronto, Ontario, Canada<br />Tel: +1 (416) 667 2701<br />Fax: +1 (416) 667 2912<br />For any information about this medicinal product please contact the local representative of the Marketing Authorisation Holder:<br />Abdulrehman Algosaibi G.T.C King AbdulAziz Avenue &ndash; Riyadh Tel: (01) 4793000<br />Fax: (01) 4771374<br />E-mail: msaidum@aralgosaibico.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>مجموعة</strong><strong> المُعالَجَةِ الدَّوَائِيَّة:</strong></p><p>تريباسيل&reg;&nbsp; لقاح يستخدم في منع الإصابة بعدوى الخُنَاقِ (الدفتيريا) و الكُزاز (التتانوس) والشَّاهوق (السعال الديكي)</p><p>يشار باستخدام تريباسيل&reg;&nbsp; للتطعيم الأولي للأطفال من سن شهرين وحتى عمر 6سنوات (السعال الديكي)</p><p>يجب تطعيم جميع الأطفال حتى من سبق لهم الإصابة بعدوى الخُنَاقِ و الكُزاز والشَّاهوق (السعال الديكي) حيث أن هذه الأنواع من العدوى السريرية لا تمنح المناعة دائماً&nbsp;&nbsp;</p><p>يجب تطعيم المصابين بفيروس نقص المناعة المكتسبة البشري (الإيدز) ضد عدوى الخُنَاقِ و الكُزاز والشَّاهوق (السعال الديكي) وفقا للجدول الزمني القياسي للتطعيم سواء ظهرت عليهم الأعراض أم لم تظهرِ</p><p>لا يجب استخدام تريباسيل&reg; في علاج المرض الناتج عن الإصابة بالعدوى الوَتَدِيَّةُ الخُناقِيَّة</p><p>أو البُورْديتيلَةُ الشَّاهوقِيَّة أوالمِطَثِّيَّةُ الكُزازِيَّة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ا)لا تستخدم</strong><strong> تريباسيل&reg; في الأحوال التالية</strong></p><p><strong>الحساسية</strong></p><p>لا يجب حقن اللقاح في حالة وجود تفاعل حساسي جهازي أو تفاعل مهدد للحياة&nbsp; ضد أي من مكونات تريباسيل&reg; بعد حقن سابق للقاح أو للقاح مشابه يحتوي على مكون واحد أو أكثر من نفس مكونات تريباسيل&reg; أوفي حالة عدم التأكد من مكون اللقاح المسؤول عن الحساسية وفي المقابل يمكن تحويل هؤلاء الأشخاص لأخصائي في أمراض الحساسية للتقييم في حالة التفكير في إجراء تطعيمات إضافية</p><p><strong>الاضطرابات العصبية</strong></p><p>تشكل الأحداث التالية موانع لاستخدام أي لقاح يحوي بكتيريا السعال الديكي بما في ذلك تريباسيل&reg;</p><p>حدوث الاعتلال الدماغي(مثل الغيبوبة وانخفاض مستوى الوعي والنوبات التشنجية المطولة) خلال 7أيام من حقن جرعة سابقة من لقاح يحوي بكتيريا السعال الديكي ولا يكون راجعا لأي سبب آخر يمكن التعرف عليه</p><p>حدوث اضطراب عصبي مُتَرَقِّي/ تصاعدي بما في ذلك التشنجات الطفولية والصرع الخارج عن التحكم والاعتلال الدماغي المُتَرَقِّي/ التصاعدي</p><p>لا يجب حقن الأشخاص الذين يعانون من هذه الحالات المرضية بلقاح السعال الديكي حتى يتم إتباع نظام علاجي يؤدي لاستقرار تلك الحالات</p><p><strong>ب)يراعى الحرص بوجه خاص في حالة استخدام تريباسيل&reg; في الحالات التالية:</strong></p><p><strong>احتياطات عامة</strong></p><p>قبل حقن تريباسيل&reg; يجب على مقدم الرعاية الصحية إبلاغ والد متلقي اللقاح أو ولي أمره بفوائد ومخاطر التطعيم كما يجب أن يستفهم منه عن الوضع الصحي لمتلقي اللقاح ومراجعة تاريخ متلقي اللقاح&nbsp; فيما يتعلق بأي حساسية محتملة من لقاح تريباسيل&reg; أو أي لقاح مشابه وكذلك الاستفهام عن تاريخ التَحْصِينٌ السابق وحول وجود أي موانع للتَحْصِينٌ مع الامتثال لأي متطلبات محلية فيما يتعلق بتقديم المعلومات ذات الصلة للوالد أو ولي الأمر قبل التَحْصِينٌ وإيضاح أهمية إتمام سلسلة التَحْصِينٌ ومن بالغ الأهمية أن يتم الاستفهام من الوالد أو ولي الأمر فيما يتعلق بأي أعراض/علامات سريرية لتفاعل سلبي بعد تناول جرعة سابقة من اللقاح،</p><p>ويتأثر معدل وشدة الآثار السلبية في متلقي ذوفانُ الكُزاز بعدد الجرعات السابقة ومستوى ضدّ الذيفان/ مضادات السموم الموجودة مسبقا وقد وردت تقارير حول حدوث غَشْيَةٌ (إغماء) بعد حقن لقاح تريباسيل&reg; ولذلك فلابد من وجود إجراءات جاهزة لمنع الإصابة نتيجة للسقوط ولمعالجة الغَشْيَةٌ</p><p>وكما هو الحال مع أي لقاح آخر فقد لايمنح تريباسيل&reg; مناعة بنسبة 100% من الأفراد الملقحين</p><p><strong>الاحتياطات المتعلقة بطريق التناول</strong></p><p>لا تحقن لقاح تريباسيل&reg; بطريق داخل وعائي واحرص على عدم اختراق الإبرة لأي وعاء دموي وكذلك فلا يجب استخدام طرق الحقن داخل الجلدية أو تحت الجلدية كما لايجب حقنه داخل الإلية</p><p><strong>الأمراض الحادة والحموية</strong></p><p>يجب تأجيل التَحْصِينٌ في حالات الأمراض الحادة والحموية إلا أن الأمراض المصحوبة بحمى منخفضة لا يجب أن تشكل سببا لتأجيل التَحْصِينٌ</p><p>في حالة حدوث أي من الأحداث التالية خلال الفترة المحددة لحقن لقاح من خلايا السعال الديكي الكاملة&nbsp; أو لقاح يحوي مكون لاخلوي للسعال الديكي يجب أن يستند قرار حقن تريباسيل&reg; على دراسة متأنية للفوائد والمخاطر المحتملة</p><p>*درجة حرارة &ge; 40.5درجة مئوية خلال 48ساعة ولا يمكن إرجاعها لأي سبب آخر يمكن التعرف عليه</p><p>*انهيار أو حالة أشبه بالصدمة (نوبة ناقِصُة التَّوَتُّر-ناقصة الاستجابة) خلال 48ساعة</p><p>*بكاء مستديم يستمر لمدة&ge;3ساعات خلال 48ساعة</p><p>*تشنجات مصحوب أو غير مصحوب بحمى خلال 3أيام</p><p><strong>دموية</strong></p><p>قد يسبب حقن تريباسيل&reg; بالعضل ورما دمويا موضعيا في الأشخاص المصابين باضطرابات نزفية كالناعور أو نقص الصفائح الدموية أو من يتعاطون علاجا مضاد للتجلط وبالتالي فلا يجب حقن تريباسيل&reg; في هؤلاء الأشخاص ما لم تكن كفة الفوائد أرجح من كفة المخاطر وفي حالة اتخاذ قرار بحقن أي منتج/مستحضر بالعضل لهؤلاء الأشخاص فيجب مراعاة الحرص مع اتخاذ الاحتياطات لتجنب مخاطر تكون الورم الدموي بعد الحقن</p><p><strong>مناعية</strong></p><p>يجب تقييم إمكانية حدوث تفاعلات حساسية في الأشخاص الذين يعانون من حساسية لمكونات اللقاح</p><p>ويجوز أن تحدث تفاعلات حساسية بعد حقن تريباسيل&reg; حتى في الأشخاص الذين لم يسبق إصابتهم بحساسية من أي من مكونات المستحضر وقد وردت تقارير تفيد حدوث تفاعلات تَأَقِيَّة بعد حقن مستحضرات تحوي ذوفاناتُ الخُنَاقِ و الكُزاز و/أو مستضدات السعال الديكي</p><p>وفي هذه الحالات يجب توافر محلول كلوريد الإبنفرين (1000:1) وغيره من المستحضرات المناسبة للاستخدام الفوري في حالة حدوث تفاعلات الحساسية الحادة أو التفاعلات التَأَقِيَّة كما يجب أن يكون مقدمو الرعاية الطبية على دراية بالتوصيات الحالية للمعالجة الأولية للتَأَقِيَّ خارج إطار المستشفى بما في ذلك معالجة المجرى الهوائي</p><p>ومن جهة أخرى فقد لا يحصل الأشخاص مَنْقوصُي المَناعَة (سواء بسبب المرض أم العلاج) على الاستجابة المناعية المتوقعة ولذلك يجب التفكير في تأجيل التَحْصِينٌ إن أمكن حتى إتمام أي علاج كابِتُ للمَناعَة ومع ذلك يوصى بتَحْصِينٌ الأشخاص المصابين بنقص المناعة المزمن كالمصابين بعدوى الإيدز حتى إن كانت الاستجابة المناعية محدودة</p><p><strong>عصبية</strong></p><p>وجد بحث أجراه المعهد الطبي الأمريكي مايدل على وجود علاقة سببية فيما بين ذوفانُ الكُزاز وحدوث الالتهاب العصبي العضدي ومُتَلاَزِمَةُ غيَّان-باريه&nbsp; وفي حالة حدوث مُتَلاَزِمَةُ غيَّان-باريه&nbsp;&nbsp; خلال 3أسابيع من تلقي&nbsp; لقاح سابق يحتوي على الكُزاز فلابد أن يكون أي قرار لحقن تريباسيل&reg; أو أي لقاح آخر يحوي ذوفانُ الكُزاز مستندا إلى موازنة دقيقة ومتأنية بين المخاطر والفوائد المحتملة</p><p>وبالنسبة للأطفال بمن فيهم حديثي الولادة المعرضون لمخاطرة أكبر لحدوث التشنجات مقارنة بالتعداد العام يجوز حقن مخفضات الحرارة المناسبة (بالجرعة الموصوفة في نشرتها) بالتزامن مع التَحْصِينٌ بلقاح يحوي مكون لاخلوي من بكتريا السعال الديكي(بما في ذلك تريباسيل&reg;) وعلى مدى الـ24ساعة التالية لتقليل إمكانية حدوث حمى ما بعد التَحْصِينٌ ولكن نوبات نقِصُ التَّوَتُّر-نقص الاستجابة نادرا ما تعقب التَحْصِينٌ باللقاح الثلاثي الذي يحوي خلايا السعال الديكي الكاملة وهي أكثر ندرة في الحدوث بعد حقن اللقاح الثلاثي أو الثنائي المحتوي على السعال الديكي اللاخلوي وحتى وجود تاريخ إيجابي بالنسبة لنوبات نقِصُ التَّوَتُّر-نقص الاستجابة لا يشكل مانعا لاستخدام لقاحات السعال الديكي اللاحيوية ولكن يوصى بالحرص في تلك الحالات</p><p><strong>الطفولية</strong></p><p>يجب أخذ المخاطرة المحتملة لحدوث انقطاع النفس في الاعتبار وكذلك الحاجة إلى المراقبة التنفسية لمدة 48-72ساعة عند إعطاء سلسلة التطعيمات الأولية للأطفال شديدي الابتسار(المولودين بعد&le;28أسبوع من الحمل) وخاصة من لهم تاريخ إيجابي سابق بالنسبة لعدم النضج التنفسي ومع ذلك فلايجب حجب أو تأجيل التَحْصِينٌ نظرا للفائدة الكبيرة للتَحْصِينٌ في هذه الفئة من الأطفال</p><p><strong>ج)استخدام أدوية أو لقاحات أخرى</strong></p><p><strong>التفاعلات بين اللقاحات والعقاقير</strong></p><p>قد تتداخل اللقاحات الكابتة للمناعة سلباً مع تطور الاستجابة المناعية المتوقعة</p><p><strong>الحقن المتزامن للقاح</strong></p><p>أدى حقن اللقاحات الحية وغير المنشطة الواسعة الاستخدام في نفس الجلسة إلى معدلات انْقِلاَبُ تَفاعُلِيَّةِ المَصْل ( انْقِلاَبٌ سيرولوجيّ) ومعدلات تفاعلات سلبية مشابهة لتلك التي تُلاحظ عن حقن اللقاحات بصفة منفصلة ويجب استخدام محاقن منفصلة للحقن المتزامن للقاحات وكذلك في مواضع حقن منفصلة ويوصى بالحقن المتزامن بوجه خاص&nbsp; في الحالات التي قد لا تعود لتلقي التَحْصِينٌ التالي وكذلك يُشجع الحقن المتزامن في الأطفال للقاحات مثل تريباسيل&reg; ولقاح الحصبة والنكاف والحصبة الألمانية والجديري ولقاح الالتهاب الكبدي الفيروسي ب ولقاح المُكَوَّراتِ الرِّئَوِيَّة المُتَقارِن في العمر الموصى به وذلك في حالة عدم وجود موانع طبية للتَحْصِينٌ</p><p>ويجوز استخدام تريباسيل&reg; لاستنشاء Act-HIB&reg; (اللقاح المُتَقارِن للمُسْتَدْمِيَة&nbsp; ب وبروتين الكُزاز المُتَقارِن )</p><p>بما يسمح بحقن تلك اللقاحات في جرعة واحدة</p><p><strong>د)الحمل والرضاعة الطبيعية</strong></p><p>لا يجب حقن تريباسيل&reg; في السيدات في عمر الحمل</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>بالنسبة للتحصين الروتيني يوصى بحقن تريباسيل&reg; في سلسلة مكونة من 4جرعات حجم كل جرعة منها 0.5ملم في الشهر 2 و4 و6 و 18 ولكن يوصى في حالة تأخر هذا الجدول الزمني لأي سبب بإعطاء 3جرعات تفصل بين كل جرعة وأخرى مدة شهرين تليها جرعة&nbsp; رابعة بعد 6-12 شهر من الجرعة الثالثة</p><p>ويجب استخدام تريباسيل&reg; في الجرعات الأربع كلما أمكن حيث لا توجد بيانات سريرية تؤيد استخدام تريباسيل&reg; مع أي لقاح توليفي مرخص آخر للسعال الديكي اللاخلوي في تسلسل مختلط</p><p>أما الأطفال المبتسرين الذين تكون حالتهم السريرية مرضية فيجب تحصينهم بجرعات كاملة من اللقاح في نفس الأعمار الزمنية ووفقا لذات الجدول الزمني كالأطفال المولودين عن عمر حملي كامل بغض النظر عن الوزن عند الولادة</p><p>لا يجب إعطاء الجرعات التجزيئية(الجرعات&lt;0.5ملم) نظرا لأن تأثير الجرعات التجزيئية على السلامة والفاعلية لم يتم تحديده</p><p>ويجوز إتمام سلسلة تحصينات فترة الطفولة باستخدام جرعة 0.5ملم واحدة من اللقاح الخماسي DTaP&nbsp;مثل تريباسيل&reg;&nbsp; مابين 4 و6سنوات من العمر</p><p>قم بفحص خارجي لاكتشاف أي مادة جُسَيمانِيّة غريبة و/أو&nbsp; تغيرات لونية قبل الاستخدام وفي حالة وجود تلك الأمور لا يجب حقن المستحضر</p><p>رج القنينة جيدا حتى ينتج معلق متجانس غائم ثم طهر سدادة القنينة بمبيد&nbsp; مناسب للجراثيم قبل سحب الجرعة مع عدم نزع السدادة أو الختم المعدني الذي يثبتها في مكانها</p><p>لابد من استخدام أسلوب معقم وذلك باستخدام محقن وإبرة منفصلين معقمين أو وحدة للاستخدام الواحد لكل مريض لمنع انتقال الأمراض ولايجب إعادة تغطية الإبرة بل يتم التخلص منها وفقا للخطوط الإرشادية الخاصة بالتخلص من النفايات الحيوية الخطرة، وأيضا يجب تنظيف الجلد فوق منطقة الحقن باستخدام مبيد&nbsp; مناسب للجراثيم قبل حقن حجم كلي قدره 0.5ملم بالعضل وفي الأطفال الأقل من سنة واحدة يوفر السطح الأمامي الوحشي للفخذ العضلة الأكبر والموقع المفضل أما في الأطفال الأكبر سنا فالعضلة الدَّالِيَّة عادة ما تكون كبيرة بدرجة كافية للحقن</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>تريباسيل&reg; مثله مثل كافة الأدوية يمكن أن يسبب آثارا جانبية إلا أنها لا تحدث في جميع المرضى وقد لوحظت آثار جانبية خلال التجارب السريرية على تريباسيل&reg;&nbsp;</p><p>شائعة جدا&ge; 10%</p><p>شائعة: &ge; 1%- &lt;10%</p><p>غير شائعة: &ge; 0.1%- &lt;1%</p><p>نادرة: &ge; 0.01%- 0.1%</p><p>اضطرابات الجهاز الهضمي</p><p>شائعة: القيء</p><p>اضطرابات الجهاز العصبي</p><p>شائعة جداً: نعاس- غير شائعة: تشنجات-نادرة: نوبات نقص التوتر-نقص الاستجابة</p><p><u>الاضطرابات العامة وحالة موضع الحقن</u></p><p>شائعة جداً:إيلام وتورم واحمرار وحمى وتهيج وفقدان الشهية(نقص الرضاعة)</p><p>شائعة:البكاء والشحوب</p><p>نادرة: خمول</p><p>وردت تقارير تلقائية نتيجة لاستخدام تريباسيل&reg; الأحداث السلبية الإضافية التالية خلال الفترة التالية للتسويق في جميع أنحاء العالم ولكن نظرا لكون التقارير المتعلقة بتلك الأحداث طوعية وصادرة من تعداد غير معروف الحجم على وجه التأكيد فليس من الممكن تقدير تواترها بشكل موثوق به أو إثبات وجود علاقة سببية مع التعرض للقاح</p><p>الاضطرابات الدموية واللمفاوية</p><p>اعتلال الغدد اللمفاوية</p><p>الاضطرابات القلبية</p><p>الازرقاق</p><p>اضطرابات الجهاز الهضمي</p><p>الغثيان والإسهال</p><p><u>الاضطرابات العامة وحالة موضع الحقن</u></p><p>تفاعلات مواضع الحقن: ألم - طفح جلدي-عقدة-كتلة</p><p>تفاعلات مواضع الحقن الكبيرة (&gt;50ملم) بما في ذلك تورم مكثف بالطرف السفلي يمكن أن يمتد من موضع الحقن إلى أحد مفصلي الطرف السفلي أو كليهما في الأطفال عقب حقن تريباسيل&reg;&nbsp; حسب بعض التقارير وعادة ما تبدأ تلك التفاعلات خلال 24-72 ساعة عقب التحصين ويجوز أن يقترن&nbsp; بسخونة أو إيلام أو ألم أو حُمَامَى في موضع الحقن ثم تبْرَأ خلال 3-5 أيام،</p><p>ويبدو أن المخاطرة تعتمد على عدد الجرعات السابقة من اللقاح المحتوي على السعال الديكي اللاخلوي وتكون المخاطرة أكبر ما يكون عقب الجرعتين الرابعة والخامسة</p><p>الإنتانات والاحْتِشَارات (العدوى الطفيلية)</p><p>اِلْتِهابُ النّسِيجِ الخَلَوِيّ بموضع الحقن وتكون خراج بموضع الحقن</p><p>اضطرابات الجهاز المناعي</p><p>فرط الحساسية وتفاعلات الحساسية وتفاعل التَّأَقِيُّ (وذمة&nbsp; ووذمة وجهية) وحكة وأنواع أخرى من الطفح الجلدي(طفح حُمَامَوِيّ/حطاطي- بقعي)</p><p>اضطرابات الجهاز العصبي</p><p>تشنجات:تشنجات حموية وتشنجات صرعية كبرى وتشنجات جزئية</p><p>نوبات نقص التوتر-نقص الاستجابة والغشية(الإغماء) والنَيْمُومَة</p><p>اضطرابات نفسية</p><p>الصراخ</p><p>-في حالة تفاقم أي آثار جانبية لديك أو ملاحظتك لأي آثار جانبية ليست مدرجة بالنشرة يُرجى إبلاغ طبيبك أو مقدم الرعاية الصحية أو الصيدلي الذي تتعامل معه</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ تريباسيل&reg;&nbsp; بعيدا عن متناول ومرأى الأطفال</p><p>خزن تريباسيل&reg;&nbsp; في درجة حرارة 2-8مئوية(35-46فهرنهايت)&nbsp;</p><p>تجنب التجميد وتخلص من المستحضر في حالة تعرضه للتجميد ولا تستخدم المستحضر بعد انتهاء تاريخ الصلاحية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المواد الفعالة في كل جرعة (0.5ملم) هي:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:89px">&nbsp;</td><td style="width:82px">&nbsp;</td><td style="width:156px">&nbsp;</td><td style="width:172px">ذوفانُ الخناق(الدفتريا)</td></tr><tr><td style="width:89px">&nbsp;</td><td style="width:82px">&nbsp;</td><td style="width:156px"><p>السعال الديكي اللاخلوي</p>5عامل مميت</td><td style="width:172px"><p>ذوفانُ الكزاز</p>15عامل مميت</td></tr><tr><td style="width:89px">3 ميكروجم</td><td style="width:82px">5 ميكروجم برتاكتين</td><td style="width:156px">10ميكروجم راصَّةٌ دموية</td><td style="width:172px">ذوفانُ السعال الديكي</td></tr><tr><td style="width:89px">&nbsp;</td><td style="width:82px">&nbsp;</td><td style="width:156px">5 ميكروجم</td><td style="width:172px">الأنواع الخَمَلِيَّة 2و3</td></tr></tbody></table><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>المكونات الأخرى هي سِواغات</strong></p><p>هيدروكسيد الألمنيوم(مادَّةٌ مُسَاعِدَةٌ)(ألمنيوم 0.33ملجم)&nbsp;&nbsp; 1.5ملجم</p><p>2-فينوكسي إيثانول&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.6% ح/ح&nbsp;</p><p>متخلفات عملية التصنيع: الفورمالين والجلوتارلدهايد متواجدان بكميات أثارية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            تريباسيل®  معلق للحقن متوفر في صورة قناني أحادية الجرعة
القناني مصنوعة من زجاج من النوع 1-سدادة قنينة هذا المستحضر لا تحوي لاتكس المطاط الطبيعي  
تريباسيل® متاح في صورة عبوة تحوي قنينة أحادية الجرعة 

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>سانوفي باستير المحدودة</p><p>تورونتو-أونتاريو-كندا</p><p>هاتف6672701(416)+1</p><p>فاكس6672912(416)+1</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر 2018م 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TRIPACELP®P suspension for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 0.5 mL dose is formulated to contain:
28BActive Ingredients
Diphtheria Toxoid 15 Lf (≥ 30 IU)
Tetanus Toxoid 5 Lf (≥ 40 IU)
Acellular Pertussis
Pertussis Toxoid (PT) 10 μg
Filamentous Haemagglutinin (FHA) 5 μg
Pertactin (PRN) 3 μg
Fimbriae Types 2 and 3 (FIM) 5 μg
29BOther Ingredients
Excipients:
Aluminium Phosphate (adjuvant) (aluminum 0.33 mg) 1.5 mg
2-phenoxyethanol 0.6% v/v
Manufacturing Process Residuals: formaldehyde and glutaraldehyde are present in trace amounts.
For full excipients see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Suspension for injection in a single dose vial.
TRIPACELP®P is a sterile, uniform, cloudy, white to off-white suspension.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TRIPACELP&reg;P is indicated for the primary immunization of infants from the age of 2 months and in children up to 6 years of age (prior to their 7th birthday) against diphtheria, tetanus and pertussis (whooping cough).<br />Children who have had diphtheria, tetanus or pertussis should still be immunized since these clinical infections do not always confer immunity.<br />Human Immunodeficiency Virus (HIV)-infected persons, both asymptomatic and symptomatic, should be immunized against diphtheria, tetanus and pertussis according to standard schedules.<br />TRIPACELP&reg;P is not to be used for the treatment of disease caused by Corynebacterium diphtheriae, Clostridium tetani or Bordetella pertussis infections.<br />30BPediatrics<br />TRIPACELP&reg;P is not indicated for persons less than 2 months of age or persons 7 years of age or older.<br />31BGeriatrics<br />TRIPACELP&reg;P is not indicated for use in adult and elderly populations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For routine immunization, TRIPACELP&reg;P is recommended as a 4-dose series, with a single dose of 0.5 mL of TRIPACELP&reg;P at 2, 4, 6 and 18 months of age.<br />If for any reason this schedule is delayed, it is recommended that 3 doses be administered with an interval of 2 months between each dose, followed by a fourth dose approximately 6 to 12 months after the third dose.<br />Whenever feasible, TRIPACELP&reg;P should be used for all 4 doses in the vaccination series as there are no clinical data to support the use of TRIPACELP&reg;P with any other licensed acellular pertussis combination vaccine in a mixed sequence.<br />Premature infants whose clinical condition is satisfactory should be immunized with full doses of vaccine at the same chronological age and according to the same schedule as full-term infants, regardless of birth weight. Fractional doses (doses &lt;0.5 mL) should not be given. The effect of fractional doses on the safety and efficacy has not been determined.<br />The childhood immunization series may be completed with a single 0.5 mL dose of DTaP such as TRIPACELP&reg;P between 4 and 6 years of age.<br />TRIPACELP&reg;P should not be administered to persons less than 2 months or to persons 7 years of age or older.</p><p>32BMethod of Administration<br />Before injection, the skin over the site to be injected should be cleansed with a suitable germicide. Administer the total volume of 0.5 mL intramuscularly (I.M.). In infants younger than 1 year, the anterolateral aspect of the thigh provides the largest muscle and is the preferred site of injection. In older children the deltoid muscle is usually large enough for injection.<br />For instructions for preparation of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity
Known systemic hypersensitivity reaction or a life threatening reaction to any component of TRIPACELP®P after previous administration of the vaccine or a vaccine containing one or more of the same components are contraindications to vaccination. Because of uncertainty as to which component of the vaccine may be responsible, none of the components should be administered. Alternatively, such persons may be referred to an allergist for evaluation if further immunizations are considered.
Neurological Disorders
The following events are contraindications to administration of any pertussis-containing vaccine, including TRIPACELP®P:
Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause.
Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy. Pertussis vaccine should not be administered to persons with such conditions until a treatment regimen has been established and the condition has stabilized.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General<br />Before administration of TRIPACELP&reg;P health-care providers should inform the parent or guardian of the recipient to be immunized of the benefits and risks of immunization, inquire about the recent health status of the recipient, review the recipient&rsquo;s history concerning possible hypersensitivity to the vaccine or similar vaccine, previous immunization history, the presence of any contraindication to immunization and comply with any local requirements with respect to information to be provided to the parent or guardian before immunization and the importance of completing the immunization series.<br />It is extremely important that the parent or guardian be questioned concerning any symptoms and/or signs of an adverse reaction after a previous dose of vaccine.<br />The rates and severity of adverse events in recipients of tetanus toxoid are influenced by the number of prior doses and level of pre-existing antitoxins.</p><p>Syncope (fainting) has been reported following vaccination with TRIPACEL&reg;. Procedures should be in place to prevent falling injury and manage syncopal reactions.<br />As with any vaccine, TRIPACELP&reg;P may not protect 100% of vaccinated individuals.<br />Administration Route Related Precautions: Do not administer TRIPACELP&reg;P by intravascular injection: ensure that the needle does not penetrate a blood vessel.<br />Intradermal or subcutaneous routes of administration are not to be utilized.<br />TRIPACELP&reg;P should not be administered into the buttocks.<br />Febrile and Acute Disease: Vaccination should be postponed in cases of an acute or febrile disease. However, a disease with low-grade fever should not usually be a reason to postpone vaccination.<br />If any of the following events occur within the specified period after administration of a whole-cell pertussis vaccine or a vaccine containing an acellular pertussis component, the decision to administer TRIPACELP&reg;P should be based on careful consideration of potential benefits and possible risks.<br />&bull; Temperature of &ge;40.5&deg;C (105&deg;F) within 48 hours, not attributable to another identifiable cause;<br />&bull; Collapse or shock-like state (hypotonic-hyporesponsive episode - HHE) within 48 hours;<br />&bull; Persistent crying lasting &ge;3 hours within 48 hours;<br />&bull; Convulsions with or without fever within 3 days.<br />Hematologic<br />Because any intramuscular injection can cause an injection site hematoma in persons with any bleeding disorders, such as hemophilia or thrombocytopenia, or in persons on anticoagulant therapy, intramuscular injections with TRIPACELP&reg;P should not be administered to such persons unless the potential benefits outweigh the risk of administration. If the decision is made to administer any product by intramuscular injection to such persons, it should be given with caution, with steps taken to avoid the risk of hematoma formation following injection.<br />Immune<br />The possibility of allergic reactions in persons sensitive to components of the vaccine should be evaluated. Hypersensitivity reactions may occur following the use of TRIPACELP&reg;P even in persons with no prior history of hypersensitivity to the product components. Cases of allergic or anaphylactic reactions have been reported after receiving some preparations containing diphtheria and tetanus toxoids and/or pertussis antigens.<br />Epinephrine hydrochloride solution (1:1,000) and other appropriate agents should be available for immediate use in case an anaphylactic or acute hypersensitivity reaction occurs (see section 4.8). Health-care providers should be familiar with current recommendations for the initial management of anaphylaxis in non-hospital settings, including proper airway management.<br />Immunocompromised persons (whether from disease or treatment) may not obtain the expected immune response. If possible, consideration should be given to delaying vaccination until after the completion of any immunosuppressive treatment. Nevertheless, vaccination of persons with&nbsp;chronic immunodeficiency such as HIV infection is recommended even if the immune response might be limited.<br />Neurologic<br />A review by the US Institute of Medicine (IOM) found evidence for a causal relationship between tetanus toxoid and both brachial neuritis and Guillain-Barr&eacute; syndrome (GBS). ACIP recommends that if GBS occurred within 6 weeks of receipt of prior vaccine containing tetanus toxoid, the decision to give TRIPACELP&reg;P or any vaccine containing tetanus toxoid should be based on careful consideration of the potential benefits and possible risks.<br />For infants or children at higher risk for seizures than the general population that an appropriate antipyretic may be administered (in the dosage recommended in its prescribing information) at the time of vaccination with a vaccine containing an acellular pertussis component (including TRIPACELP&reg;P) and for the following 24 hours, to reduce the possibility of post-vaccination fever.<br />Hypotonic-hyporesponsive episodes (HHEs) rarely follow vaccination with whole-cell pertussis-containing DTP vaccines and occur even less commonly after acellular pertussis-containing DTP and DT vaccines. A history of HHE is not a contraindication to the use of acellular pertussis vaccines, but recommends precaution in these cases.<br />Pregnant Women<br />The vaccine should not be administered to pregnant women.<br />Nursing Women<br />The vaccine should not be administered to nursing women.<br />Pediatrics<br />The potential risk of apnea and the need for respiratory monitoring for 48 &ndash; 72 hours should be considered when administering the primary immunization series to very premature infants (born &le; 28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>33BVaccine-Drug Interactions<br />Immunosuppressive treatments may interfere with the development of the expected immune response. (see section 4.4)<br />34BConcomitant Vaccine Administration<br />Administering the most widely used live and inactivated vaccines during the same patient visit has produced seroconversion rates and rates of adverse reactions similar to those observed when the vaccines are administered separately.<br />Vaccines administered simultaneously should be given using separate syringes at separate sites. Simultaneous administration is suggested, particularly when there is concern that a person may not return for subsequent vaccination. Simultaneous administration of childhood vaccines such as&nbsp;TRIPACELP&reg;P, MMR, varicella, pneumococcal conjugate and hepatitis B vaccines, is encouraged for children who are at the recommended age to receive these vaccines and for whom no contraindications exist.<br />TRIPACELP&reg;P may be used to reconstitute Act-HIBP&reg;P [Haemophilus b Conjugate Vaccine (Tetanus Protein-Conjugate)] permitting the administration of these vaccines in a single dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable. TripacelP&reg; Pis not intended for administration to women of child-bearing age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant. TripacelP&reg; Pis not indicated for persons 7 years of age and older.4.8</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical Trial Adverse Reactions<br />Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to vaccine use and for approximating rates of those events.<br />TRIPACELP&reg;P has been safely administered to over 4,000 children in clinical trials. In these trials, recipients of TRIPACELP&reg;P consistently experienced lower rates of injection site and systemic solicited reactions than those receiving whole-cell pertussis vaccines. The size and frequency of injection site reactions increase with the number of doses administered. Although these injection site reactions may produce large injection site swelling, pain is generally limited.<br />In a clinical study conducted in Canada, 324 children received TRIPACELP&reg;P at 2, 4, 6 and 18 months of age. In another Canadian study, 21 children received TRIPACELP&reg;P at 4-6 years of age. The following rates of reactions were observed:</p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RESRXhpZgAATU0AKgAAAAgABAE7AAIAAAAYAAAISodpAAQAAAABAAAIYpydAAEAAAAwAAAQ2uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE11aGFtbWVkLCBVc21hbiAvU0EvRVhUAAAFkAMAAgAAABQAABCwkAQAAgAAABQAABDEkpEAAgAAAAMzNgAAkpIAAgAAAAMzNgAA6hwABwAACAwAAAikAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMDowMjoxMCAxMDo1NDo0OAAyMDIwOjAyOjEwIDEwOjU0OjQ4AAAATQB1AGgAYQBtAG0AZQBkACwAIABVAHMAbQBhAG4AIAAvAFMAQQAvAEUAWABUAAAA/+ELKmh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjAtMDItMTBUMTA6NTQ6NDguMzU4PC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPk11aGFtbWVkLCBVc21hbiAvU0EvRVhUPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAlQCTgMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APpGiiigAoqC9hmuLGaG1uWtJpEKpcIis0RP8QDAgke4IrzHwzd+J9S+KfijQLjxjqT2ehm1eANa2eZhIu5lkIgBI4x8u0j1prV2Dpc9Vorj5vHlnc63c+HRBqWl6hJbTyWk88MaiXy+GZFJYjB5G9AGHI3Cua8JfES81b4d2MOr3F3b69faRcXlvqHkwhJ2jzuKAZAZfl4ZAD2zzUt2i5f11/yY7e8o/wBdP8z1WivOfDnxMt4fBnh6bxDLPeajd6Yl9eywxoogiyFM0gyoC7iBhQT1wMA40vivqmqaJ8N9R1nQdUm0+7sUWVHijikWTLAbWEiNxznjB4HNVJOLs+9v0FH3rJdTtKKy/wC2GguNKtXsr24a/Qk3MMO6KAqm7MjZ+XPQccmuG+K2vaz4e1/wv/ZmvajYWep3v2W6hs7KG4bYATuRTC7l+2BkcdKT0dvOwk7q/lc9NoriLfxfHoLaHYahLrWtSa+ZHsria1gjddse/wAuRU8vBwDj5O+CRirq/ELSv7Wg0+W3vIZWEAuGljVVs5JxmKKXLZDt0woYA4yRkZdmF+p1VFcjafEjR73VrWxt7e9P2+WaKwnMa+XeGIHzNh3ZAUrjLhQcjGRzVfSPipour3OlRLZ6hajVILmaKS4WILGLdisgfa5weMjGRg9aQ3odtRXDTfFjRIvDd7rX2LUXt7SGK68tUj8yW3lYqk6AuPlJB4JDcfd6VbHxJ0YW2pvNDeQzabdxWb2siJ5sssoUxBMMR824YyRjnOMGnZ/1/XmB11FciPiFCuraZp9z4e1q0m1JZvJN1HDEqvFu3RkmX72FyMZDAggkZIt654rOkeCDrrWE0U8qxrBZ3BXf5sjBI1bYWA+ZhnBPFLUOtjo6K808QeJ/Eui+NNN0pLgTBltSI/LjX7eZJmW4IGMgRJhvlIxnLEiuksfF1jdeIGs5r/ymulUWUAiJDL8xDl9u0M+1iqk5KpkDrh2urrz/AADZ2fl+J09FYHhrXJNQvNW0q+YNfaPciGWQLtEqMgeN8diVOD7g9qpWvxF0q91D7JaW15L5rTx2U2IxHfSQZ8yOMl85BB++FB7Ejml/w4HWUV5/8MPEHiDxV4bvPEmpTSNHdSSLZ6fJDEixbHcfK6EsQQFB38hlYjgioPAvjcavM9vquuyxatao02qaRqNqkElrhefKwozEDzklzjHzdi2rOz/r+uof8Mej0V5X4x+JrXPgl9R8K3V1pt3FPZzRmaGJvtNrNLsDgHf8jfN12uCBkDv10Pj7Rptcn03dKiwyyQG8cKIWmjTfJEDu3blXk/Ljg4JIIot3/rb/AD+8Otv6/rT7jpqK4DVfivbWnhC51200LVZIAITaSSxIkd0Jm2xurb8Yz1BwwBGQM5rWPj/TItZj0y6tru3nHkpdM/llLOSbPlRSMrn5mxj5NwHGSMjJZhex1NFeayePLjVvH/hVdCuLyPRdRuLu3kEsMPk3gijY+YjYMgw4xyVzjgEcm9468WyeGvEGmrql/eaPocsZZ9Rt7VZo/P3ACKYsrbEIPUYJ/vDFLt5h3O8orkL7x/p+g2dql+76rcfYPt9zNpqIY47cYDXHzMPkyeAu5j2Bwa47U/iHqOnah45lfVrqXS9PXT5LGW2tLeVrZZxkkBtm9TkD5iSM07O9v63t/XzD+v6+9feewUVzT+NrQ65JpVlp2o6hJAyx3M9rEjR28jJvVHJYEEjvjaMjJGa5fRPik02neFI4rPUdXn1+e5QTPFBbuixM27KiTaCMDoeQCevBS1Dpc9NorkLf4neHZrS9vJJJoLO1t5LlLmVV23UUb7HeMAliA/y8gE5GAQQao+E/Euq6t8Stbsbt72KwTT7W7t7G9ihV7dpC4I3R5yCFB5ZsZPPYNJsHov6/rqjvaK8X8UeMNV0f4h69pFx4x1WxgjtoH0xItPtpENxMWCxO5gIVcgAF2XvljXat43fw5o2lw+MIC2tyWRur6KwCslvGmPMlO5h8qlhwMk84BxSWqv8A1/S69gejt/X9anZ0Vy114/02y8T2WjXdpfRC/mEFrevEogmkKbwq/NvIx/EF2543ZyKqXXxN0+HTNV1G20rVLqx06GeX7bHEnkTmFtsiq27gg/3gucEruxQ9Fca1dkdpRXnun/EJrnxBpI1eO90eG40OXUZbeeKBoWClSZPNSRmXAzhcchucEYqe4+Lei2ui3moz6fqai1tor3yDHF5sttK21J0HmY2k9iQ47qKfK1p/W7X6P+rkp32/rb/NHd0VyI+I+k/Y9Wme2vI5dKuorWa2kEauzy7fLwS+wBt45Zlx3xVrxB4u/sL4eX/iebTriJrW2ab7HcACQMOArbSw645BIxzmpbsuZjXvOyOkoryjWPFHiTwj4E0rxtqmsPfrcNbNfaWbaJIUSbGREyqJAy56s7A88eljTPiFc6X4u8VQeIZru70mz1K2t7e4EUIWyWZAQHxtYruYDOGI4z3NXyu9v66f5onmVk+//B/yPT6K5ZvH+mRHV5ri2vIdP0gS/aNQdYzFujIDIAHMgbJ4DIN2MjIqpN8T9Kt/sK3GnalHNd6gmnNDsiL28zoHTeBIeGUggru98HipWu39XKem/wDVtztKK4+H4hxy63caS3hzW4L2Gxa+SKZIEM6BtmEzLy27jBwPfkZtRePdJk8QHSWS4idZfsz3DhPKS48vzTASGJ3hMnIBXjG7PFAHTUV5tbeObrWviV4aXSJ72LQtUtrs+VPDD5dyIgNs0bAFwCSeGIzgHaM5Orq3jQaR47vNPmF/LFZ6I+om0ighKShXwXWQyBtwGRtIA75o2tfz/C/+Qb3t5fjb/M7SiuX8MePtM8VX/wBjs7a8tpmsIdQjW6RV8yGXO1htY9CMEHHtkc1lpr+p+KviNrPhzStRk0ix0KKH7TcW8UbzzzSDcFBkVlVAo5+Ukk9RTs72FdWv/Wp3lFee+J9e17w34y8MwPfS3lrey3YntLe3iBnRId6csPlYEdQyqfYcBH+IEOt6poKaLeahaW2s6VdXUBFrCysyqOWZmLI6EdNrKd3U4qW/dv8A11/yKtrb+t7HodFeWeHPiDd3/wAMtFF9dXlz4i1TTp7oz2UEO+JYyQZirAJgHaMBSTnhTzVvwt8S3fw/4cttYstS1LV9T0Y6iJbWCIrOUHzqFDLhuRgbQvPWr5Xdrt/wf8mSndJ9/wDgf5npFFcl/wALG0lr+6tYba8la3MsQdVjCzTxx+Y8C7nB8wLzyAvUbsg4Xwv8RdJ8V39vZ2dtfW0t1pyalALqNF8yFm28bWPIPBzjqCMilZv+v67D/r+vvOsorlPiPrer6D4Kvb7w4iSX9tH9o2uMjyoyGk4x3Xj/AIFWN458e3lp4P8AD994Yinc+Ibq3giuoBCxhWXB4EjAFyM4yCuR82O6Wu3dL79h2/X8Nz0SivPtI+I4todZg1+3u3TQJIrOfUTHEn2u5IUbVjWQkMxcYAG31I6VoN8S9MW/0uyOm6kbnUp57ZY1SJjBPCMvFJiT73HBXcpyDnHNP0/r+v8ALuL+v6/ro+x2NFQWVz9tsILowTW/nRrJ5M67ZI8jO1h2I6EVPSegBRRRQAUUUUAFFFFABRRRQAUUUUAFcZ4d8D6jonxB17xNc6za3S60IxJax2DRGPyxtTDmVu3XK8npjpXV38E11p88FrdyWU8iFY7iJVZom7MAwKnHoQa888D6rrviLwbdadqXiO8i8R2WqyWV1dR29uGQo2cKhiK7TGMjIJyetC3du39foD28v6ZPp3wrmsvElnrFz4hkvJ7Y3uTLbfNKtwe7b+q8DOMEADAo0/4Uf2dZ2tsmrpMml6dPY6WZbPLQecPnkkIceYewC7MAkHPWtyTx1YWXiy08O31rqEE90zxW95PEixXDou5gMNu6c7tgQ4IB7VXj+JejPp17qb22oRaTaxtImpPADBc7X8siMhid2/gBgpPUZHNFrxt0t/n/AJsf2r9f6/yMCx+C9nbvoMt/cadqkul2A06Zb7SVminhDFlZUZz5cgz97LA5Py11PjzwrdeMPB1x4fstQg02K6ASaWS0M5CA5woDpg5A5ORjtWZd+OJW13w5avY6zo5vr6a3kt7m0gImKRFgpbzDhTkMHj3A7cEjmpdD+KGka5qVhZJYalZy6hJcwwm5jjCmW3OJE+V257gjIOOueKp3lv6/qJe67r+v6sblvpusxnSfN1mHZaIy3kUNltS7+XC43OzR7evBOawvG3gjVfFWu6HqFjrlppyaLci6hjl05py8nQ7mEyfLjHAAPvQPihpYn1W2m03U7a703T21E21xEiPPApILKN/ynj7r7W5HFZmn/Eo3mo+G5tUhvdGt9R0u4v3iligkhkVFVt5kWQum0cgbed3OCMUr683bX83+j+4OWy5fl+X+a+86HX/CVzrfizw3rK6lFbrocskrQG1Lmcumw4beNvGex5qhN8MtMm+IV14nlisLn7YsZmhvdPSeRJIxhXhlJzHwBkYOcAjBpr/FXR4tF1DUZNP1JfsNkmoG3KRCWa1c4WZB5mNvB4JDDuuSAdnw94wsPEmoajY2sF1b3On+U0sdyiqSsqb0YbWPBHY4II5FFmvl/X9f8AL6f16/r+J53/wiN34V+IXgbTbQXd/pOnz3zRyw6bLttI5lO1ZZV3KfmJAPy4GMjvWtYfB97PUdNaTXUn0/T0voFtjZFXeG6JLAyCT7wJPzBcYx8o61oap8W9N0i91K2vNC1oPpt5DaTkLbgZmz5cgzMCUOPve/PfEtz43kTxzpunSWuqWUctveOIHhtnS78nHzBxKWTGDgYGd3OMUr6a+f5X/Jje/3fn/mZUfwchtvh5feGLG70y1lukWD+0otHVJnhVgwEu2QGR+PvZA77c065+ElxfSa5Nea+guNSvLW/t5bexKfZJ4FAVsGRg6nHKnH1rPh+J2q6te+DtWtLO/s9N1WS9Elhtt3N3HHGzRsrZJU8Y5ZOQeMYNehaVrEHi/whBqmhXU1rFqFvvgnMamSEnjO05XcD2ORkd6p8y1/r+tCdNF/XYyNe0n+3LnR9I1ZbqW9tZ4tQXUrW1MdupjbDpuy2wspI2kkkN1ODi/448Py+JPCk1laFVu45Yrq238KZInDqCewJXGfeuK8M3XifU/il4o0C48Y6k1noZtXg3WlnmUSLuZZCIBkcY+XaR61gS+MvEsev6/otr4u1GbW7fVPsmjWdxYWwt7vCK5SSUQKAcFujq2MYBPVK+iXr+X/AAPuKas3fpp+Df8AmexzwtrukRI/m2kUxH2iGSPDlP4ozzxnoSM5GcdQawNQ+H1teeNYtf8AtbRwpNDcy2ixZLywo6RkNn5VAc5XackDkcg4mpap4j/4XTo/h/8A4SC6tLG90p7ye2t4bdlWVDtIVniLbSeeST7jpXJeGviD4ql8S21iniB9du/+Ejn0250ySC3DR2SHH2g+VGrKR/eJ2npiiKvJW/qzt+f+ZL0Tv/V1f8v8j1Lwpos1vrGv69eRtDLrVyjxwuuGjhjjCIG9zhmx23Adc1k6f8ME0zULaW21GM22mS3VxpcD2pPkS3GdxkYOPMUbjtUBDg8k9am8Q+LdQ0T4keHbJlQaHqLy2MznGRdFVePnGcYBHXksfQUy48Qan4i+JWoeFNH1B9JtdJtI57y7giR53kkOVRPMVkChRkkqSc4GOtLe1vT7v+Br8yrtX+/79P8AgF/wT4Ou/CPgb/hHZNXS6ZDL5N3DamFk3ktyC7ZIZjzkduO5LvwUdX1iO88QX0d4ltby21t5Vr5M22VNj+ZIGO/jOAqoATnB4xyfxM1rxN4WvvDvkeJb2G21HVVs5Vs7CGWQwFMkhTE7GXIP3Rg9lp3xA1fX/DXweuvEWi+KtTkuUkhmglvLK1WTY7IpjdPJA4yT91WB4J4xQ/eV36f194K/Nyrff+vuEn+DltZfD+TRLfUtI08pLE7amujKkrwxOHVZmWQb2yBl8gEZ+XJzWhoHw20BdZ1m/Q6dfx6lJJK5fT1F3bySqVkCzk7lRssQuMjJ+Yiusk065vfCsFs9411c+Wjma6VR5rDB+YIqgfgBj0rO8D+E5/DFj5E8yybU2KR95uF5btxtAGO3Xkmn1kpf1/Vib6Jr+v6uZbfDO5m+Gv8Awh93r3nQ2zR/Ybn7GFaJY3DxiQb/AN4RtAyNmR2zzU3/AArDTn8eT+JbldPvXu0iNxHe6akzrLGMLJDIT+64AyMN0GMHmuXu9X8Ywat418Pr4ovTqtjBHfaKwtbT99EwIEZXyufnwpOfTpznY0rxVe6j8ObHxTHq2ovHb6LJc3kccNszSS4I3EFEBKFZDgFAdozmk5aOb9fvX/As/Mrl15V6fl/ndeRNpXwuuNI1Dw+1prsZsdAuriW0tnscsYpgQY2cSckbjhsdMZB611eraVqV485sNUhhjniWJre7tPtEIALbmChlO4g45JHA4NcfZfESfVXg0awttQeaTw8upSar5duhjLr8jmMuQOQcgBsEjgjJqt4c+KBuvAUY1X7cdbTw8NWe4S3h/fLyrSIu5VJVhnawUHtmnNNJ36f8H/5F7ii7tW6/8D/5LoX7z4S2hsoLbSNRazUaQdFuWlg85prYnJ24ZQjg5w2Coz908YztT+DU95b+IrWy1+3tLTWorSBYzpzO1sltgIN3nDcSBycCtFfivp2m6XZ/brPVrx20NNYe5SCFRJD8odivmfKwzkr07Amu5j1C2l0tNRSTNtJEJlfHVSMj+dOV03/XV/rf8RKV7f12/wCB+BzWleC7zRfEeqapp+sIserpG13bPaFl89EC+Yh35VSByp3exHWsXQvhNJo9j4aik1xZ59AuLmRJVsigmjnB3oVMhwwLcNk9OlYFx8S/EUnhjW9XkL2NnYeJWsLuWCOOSaxs1VQzIGUq7buTkNjccA4Fd54O1O98SfD9L2XVBI9yJRbaharHvaIOwjkKlSgk2gErtwDkbR0C2i5en5XX5/psh2s+X1/VP+vO+7MHTPgtoun+GdW0NhZNBexyQw3kWnpHeRRu27a82SZNpAxwvQZzW34d8HajpHi6513UNagvnutPhs5Yo7Ew8xE7XU+Y2AQxyCDz3HSvIB8S/FDfC2y1UeJ9aGszaoLeRzosQtfLMpTAlNt5ecDP385J+g9gvfHmlaBf/wBl30l5eGyEEd/qBSPZbtKdsZlwV5Y/3EIGcnaKav8Ap+H/AAfvFLdxfr+P+aM69+GkuseJtfv9c1Kzu9O1y0W0lslsGR40TJjZZPNPzAnJO3kgYAqj/wAKkmvLjRbvxFq2na7d6XCbQtqGjiVLi3OCAyNIcSgg4kB78qa14/ijpT6hDZvp2pRyS6y2i5ZIsLOqhsnEh+Qg8EZPHIFLa/E/S7rTb++OmarDb6dcT2108kUe2KSLGQWDkAEnAOcepFStFdf1/XN+I3vZ/wBf1y/gULn4Vvc+JodWbXXZbfVotRgge1BEaJF5YgBDABe4wBjJ4Oc1asPhubHwrrnhj+12fRdS8/7PF9nxLa+dksPM3HeASSPlB9Sa6rStUbU9KF7Jp93Yk7s29wEaTA7jy2ZWB6ghjnNche/FvS7TTtclk0rU4bvSLRbx7O5SNJJImOFcAOdvPVWw47rSezT/AK/q39ajW6a/r+rjH+GE93qmmzanrMNzaWmiyaPPbrYlGmR1wzB/NO3ouBhu/JzxSvfg9LfaHe2kuuxfa59Og0qC6+wHENrE+8Ap5nzSEgZbIHAworuLS81HVvC0V1b2/wDZt/cwBkS7VZBCx/iIjchh3ADc8AkdsL4dXniaeDWrPxZeRak+n6i9vbajHbrB9pQKCfkXgbWJXj0I6jNXrzNdVr+P+b/ElW5U1/Wn/AX3EeleAb2w1DxHdXWrWV2NeaJpIH00+WuyPZtYNKdykYyOD15rXsfCFnD4GPhfUHN7ZyQPBLuyoKuSSqgklVGcKMkgAcnGaf408QP4Z8IalqlvCJ7m3tpJYYicBiqFsn2AGT/9eneDNRutX8C6JqOoSebdXdhDNM+0LudkBJwOBye1Tbmi16L87DtytP1/Q58/Die80nTdB1zWlv8AQNMeJobUWflzTeV9xZpd5V1GBwqJnAyeuU1H4XxajquqSvqWLDWb2C71C1a2DM/k7fLRH3AKp2jdlWz221Q8VfESS08WXelRT3WnaVpbW0eo6nbQRytFLOfkXEhwqYxlgjn5hwMZrtfEGvr4e05btrC+1AE42WaKSAASWZnZUUYB5Zhk4AySBT5nbn/rp/wA5deX+v61Od1/4Z23iS71STUr0JHqFi1m/wBlg8qRgXDK0jbiJNmAF+UEfNknPFJ/hVjTtAt7O70jT5NK1GLUJ3sdFEC3bRghcqsnykgnJJbnoB0q1L8XNEW3tLi2sNTvILzS5dUhlgjjw0Uf+sU7nBDD3AB7EmneJvHtq3h8p4fmvTfXekPqkE1pFGxtoQuVlcSZGCcLgKxOTgcZCbcFft+jb/R/d5DXv2Xf9Ul+TRuap4Wg1PxZo2vfaHhn0wSoUUcTo4HysfQMqt+FYtj8MNLsvGmqa40VhcpqMpuCtxp6vcQSldrGO4JyqEfw7epOCK0vDt5f658MdLvbi/lhv7zTIppLuFI94kaMEsFZSnXttx7Vw1r448SH4A6X4nlumlunlH9pX0cMfmQ24mZXkSPbsLBQMArjvg05R5W0+mn3v/gCi+ZJrr+iN3Q/hld6Jq3hy4j16Oa08PpcQW1u1jhnhlxhWcSfeXH3tuCP4c8m1r/gG91jxhea5b6zb2wudGk0kQPYtJsVyTv3CVcnPbA4/OrfgTWLnxR4Ja9Oq/ao55Zks9QhWMSvEGISR127Fk7lduOmVHIrmPB/jLXIrzxNoXiHUDf6lZxx3emzSxRxtLBKoC5EaqDtfgnHelPqpdE/x3+er/Ece67pfjp8r2Nfwh8Orzwx4jt9Un1uC8SHRodJ8lLExFliOVfcZWwfUYrRu/Blxb+L7rxL4Y1KHTb6/iSG+jubQ3ENwEztbarowcA4zuxjtXI/DT4gX8/w40rWPE99e63q2s3UsFrZww28bMyF8hABGoG1cku3bg84ro5vinoy/wBmm0stRvk1K0uLm3a3jjx+4/1iNucFWHvx71U7qWvS/wCN2/1JitLL+raL8iXxB4K1DWtZ0TUYtbiik0o3DET2Rl81pUKHG2RdoAPAwfc9c4OkfCbU9I/4R3yvElpJ/YNjc2cW7S2/eibPzH9/xjjgdcH142F+I8Gpa7oGm6Lp95cxa5YNfJdJ5S+TFwNxDsOQWGRg+wbtk/D34kG80XTrPxPLdT6lcxXk6XjQRqkyQSsrABMfMF2/wAHsSam1k0/P9b/qPez9Px1RJo/wnuNF0/Ro7XXo/tmm2M+myXH2D5Z7eVt2NvmfK6nkNkjr8tWPDvw0vtC1fwxdy67b3MegadJYCNdPaMzq5+9u807SML2PQ+ox1XhzxCniTTvt0FhdWkDEGJrgxMJ0IBDoY3cEHPcgjuBWMnxJ0qe5eGztLyff9oWylAjCX0kGfNjjJcHIwfvhQcHBIpuTi3f+t/8AN/eJRUlp/X9W/Ao2XwrstN1rW9RsTppl1KSWeCa50tZbi0mkUhsTbgxj5J2cHk/Ng1H4Q+Gd74X8QaVqMuuwXiado/8AZPlLp7RGRA+8Pu81sHp2Pfpni18Kda1vxP4TXxDrl1Iy6id8Fq8ESLbgEg7GQ5ZTxjf8wwfUUtx4uv7L4u2OiXYjXRtUs5Us3x8xuojl+cd1OMf7NNXjJR/rRP8ARtBfmTl/W6/yuX9W8HJr+sXNxr8ejapZ+R5djbXukiVrR+772k+bJ6gKp4XkY55O3+Emu2/hfRdC/wCEts5LfRdRS/tWfSHLDYxZYz/pH3AWPvjAzxW/f/FDSrPxANKg07Ub0/2gumNdQeSsK3LLu8smSRTkLySAR2BJ4rS0bxxpOu6w+n2QnGfN+zzyKojuvKcJL5eGJ+ViAdwGc5GRzSjfRr+ra/8ABKl5/wBX0/zMHVvhRbavaeJbWfUiINcu475UNsG8idAvJycOhKD5SBwSMnjEq/DXytW8M3tjcaXpyaJPJcS21hpIgjuXkTYxAWT5OPXcc98cVq6v480/Q/ElnpOpWV/Ct5cpaw3rRKIGmcZVBlt7em5VKg8Eg1StfihpNzrS6bLYalayNqr6T5syR+WLhU3gZVySGHQgfXFEb6cv9Wsv8vwFLrf+r3/4P4naUV5rqPjy41Dxl4ZTw/cXkWl3OqzafcM8MJgvNkblijYMg2umM/KDzjI5q38TdX1rw1caFrVjq89ro41CK21W3jihIMbtgSbnRiMHAODyDxg80JXt5u39feD0v5K/5/5Hf0V5Xo2ueIR418W+GtQ8Q31xJHbxzaNcNBbKdjtsLfLEASsny/MCCO3eprv4kv4dtPFUlwNS1WbR7u2s0hmgt4sPIqqrbkcB1ZjuJIUjdjAxwlrbz/zt+YPRvy/yv+R6dRXmFz8Rbrw9431tvEC6h/Y9vYWVx9kMUBaxaV2RizKfmAIXIDOeuMirl78TLXRNc8THUU1S5ttKls4jbxW0GIvOyA6N5m5wxIyCAR2B5p2/r8APQ6KxvD3iez8SNqMdrDcW8+m3bWlzDcKoZXABB+UkEEEEc/XB4rZpAFFFFABRRRQAVz2l+D7TSvGmseIreV9+qpEJLfGEV0BBfryWG0dP4fet2fzvs8n2XZ520+X5mdu7HGcc4rzCLWfiFpem+N4Jrm01260pY30+8W2W3BZk3vHsBIOxSCMkk5GSc0r2u/Idr6Gi3wull8Wwa5deIJLloNWl1BIpbbJ2SRCPydwYcAAbSAMeh606H4Vxr4Bv/BtxrEkmjyOz2O2DbNaZfzAC+4iTa3I4Xjg5qb4X+KZPFuk393DrDatp8cyx211PHHHc58sF1kRFVRhjgfKMj1GCeQh8R+L7bSvHOrL4ouLtvC19JHBa3dpbeVcRIgYhzHEr7iCcFWA6cGqfu+6+iv8Al/wAV5Wku/46/wDBO11LwVrOq6h4YvrzxBatcaFOZ5CNNIFySmzgeb8nBP8Ae5PoMVjaV8J9S07U9GvH8S27nS7y9ugI9MZC/wBp+8MmY425ODg9sg451X+KmlW2j6Pqd7p+oxWWpw28huxEvkwGbhVJLAsc8HYGxwTgEVeg8dxXGs6ppcWhar9r02eGKSNvs6mRZSQsqZlyUwM5OPpkEBtNNr1/S/6Eprl+X4a/8E5/Sfg+LG7ee+16W+abRp9JnZrfa8qySM/mbtx+bLHPXPXinN8J5bh/D8eoa3DcWekaVNpckAsSrXEciBGIbzfkOFXs3OfUAdb4f8UQeI5bn7FY3cdtCxRLuXy/LmIYqwXa5YEFeQ4U+1U5/HlhaeL7bw9d2OoW8147xWtxLEqxTui7iq/Nv6dGKhTggNmp30/rr/m/vH/X5f5L7jnJ/hJJcaHqNpLrkbXl1pMejQXX2E4gtUOeU8z55DnlsqOBhR0O14U8E3vh3xRq2s3erQXv9p29tE8MVk0OwwpsDAmRsg8nGPTn1teCPGDeM7C8vU0u5sbeG7kt4XmaM+aEYqcbXJBBBzkDqMZ61mweML28+NH/AAjUQCaZFo73e7AJnk84JuzjIAww685J9KpNuXr/AJN/15isrPy/zS/REnib4bWPiXUNZu5LuS3bVtLGnyKq5CsrFkmxkZZc4x+tPvPAc1z4t0DVk1SNLfR7KWzNs9qWecSKFZvM3jaeB/Ce/XPFXx/44utA1K20jSoJnne0lv7uaCJJZLe2jIDMiMyhmJPcngHhjgHVuhqOvfDuObwl4hmS9ntFms9SeCFjMduVLoU2YbvhRjtio+xfov8Ag/8AB/pFbys/62/4H9M5y0+FV9p9p4atrTxDB5Xh77SsIl04sZFlVlAJEo5Abr3Pp0rqfAvhmXwd4LsNAmvkv/sSlFnWAw7lLEjK7m559a5nwT4g1Dxf4Q0kvr15aarYTMutkw2+4PGSHjcGPCgnGNoU4ycnBrc0z4haVq9vczWNrfyiO3F1AiQhnvISxQSRKrEkbgR82098YINW7ptf16/n+JOjt5fh5FXw74H1HRPiBr3ia51m1ul1oRiS1jsGiMfljamHMrZ468cnpjpWPJ8Jbm+tPEMOra7bSyaveLqFvPbae0MljdKAEkQmZsgBRxwTk81pN8WdGTQ5tTfT9SAttSTTLq3CxNJbysQFLYkKspyOUZuvTrjU/wCE2iOtwaUui6qbqQkuhjiUwx+YYxKQ0gLISCcoGIHJAzSSelvT8n/k7lN7t/10/wCBYxE8A+Jn8cab4ovfFOm3F5YWbWYUaM6LKjHJZv8AST82e449q0fAngzUfBtrq0NxrFrqA1C8lvlMdg0PlSyHLdZW3L0wOD15PbW8QeKLTw/LZ28lvc3t7fM621nahPMkCLuc/OyqAo5OSPQZJAri77x1qPiXxr4b0nwhc3Fnp2o2bag2oLBDIJUVlBQq7bgv3lbADBiuMgGhXbsuun6v8riaW79f0/4BLr/wmPiDQgs13o9v4jN2ty+vwaKFnJVty4/e7geAMliMDGB22ZPBeoReIE8R6ZrFva67LaLaX0j2Be2uwpyGMQkDKw7ESdODmtPxpe6pZeEdQfw6FOrGB/sm4AgOFLZwQQcAHg9TgVlWXxG06TwBofiKeOWWTWPKhgtLYKZJbh+PLXcQoIIbkkAY5NC8un66fiD8+t/w1K/i7wFq/ie80O5j8Q29u+kXov187Tml8yUcAcTJtTHG3r33GovFvgLxD4z8JX2iat4nsU+2yRlpINJdVjRDuAVDcH5iw5Yk8cYHWpLX4taPdact1/ZmpxyNJcL9lYQNKEg/10hCykBU787j/CDkZ7e3uIru2iuLdxJDMgeN16MpGQR+FHT8f6+78AvZ36/1/mYOkaN4gt9UguNa1yyvLe3t2ijtrPTWtwWO352ZppCSApAAx9410VFFF7iSsc/e+Eba88ead4oMzRz2dpLatEo4mVmUruOf4SCQMdTntWbZ/D2LTPA+ueHdMvvKGrSXTiaSEusAmJ+UJuHChsDkc8967KipavHl6f0yrtO/9aHn+k/DO50iWG4t9cia4TQV0aRmsTscIT5cm3zMjGeVzz2K1lWnwd1G0gjjHia1by/Dz6CD/ZbDMbMT5n+v+8MjjpXqtFU3zXv1/W/+b+8S93b+rW/yR5dc/CHUbmxitT4ktVWPw8dBJ/stslCQfM/1/XgcfWu3g8NxP4RstC1W4knW2hijaa0kltGYx4wwKPuXlQcBq2qKG29/61b/ADbEkl/Xov0R5ppfweTRoblrPWmmuW1iTVIDfRSXEK7kKbJI2lzIQGJ37lYnBJ4rqPDfhP8A4RTwi+kaTdp9od5ZvtE0BMYlkYsSIgwwgJ4UMOO/eujopbqw+t/6/rU8mPwb1f8A4V5beER4psvstvffbFn/ALIfeT5nmBT/AKRjG4n8MfWtvVPhgusahdzXepRCDVjayavDHaEfaJLcgqYyZD5QOACDv4HBB5rvqKd2nf8Ar+tED1/r5nnN18Krh/ECahZa9HDAmujW1t5bEyHzNmxkLiRflI6cDHfdWx4V8F3XhvTNZtZdVhu21TUZb4utlsVPMILIVZ23DjHbrXXUUtlb+un+SDd3/rr/AJswNA8MHQfC8ukQXmwyGRlkto/LS3L9okZm2KvZcnFcbB8FlFnfQXuvyXDX2iLpMsn2XaxKuXE2d5ySTyD1Oeea9Roo/r81+of1+N/zMv8As/UY/C40+01GOK/W3ESXrW25UbGN3l7hwOw3fUmuV0vwt420LSre1HjH+1Z/tsTGU6VDBHHbrkyIyhud398ZbOO2SO+op3d7isrWOc8Z+C7Pxlo9xaXFzd2s8ltLbxTwXU0apvHJaNHVZBkA7WyDiqvhnw5q/hqfSdLg1Np9E0/S1t5UmiBM04PEisXZ14B+Q/KAQAT262iktNv63/zG9d/62/yOI8QfDS317XL26N8YbLVTbHUrQw7jOYG3RlH3DZno2Q2R0wea1fFfhWbxLJpfl6pJZQ2Nw0ssCx70uAUKgEZGCM5B5AI6Ht0VFG6sO7vc8rh+Dl7a6bp1jbeJLcRWOjXOkgyaYzM6znJfImGCPlwMdj68aCfC2eCzsVttcjiuodDbQ7mf7DlZ4MfKyqZPkcHvlgeeOmPRKKHrv/W/+b+8S02/rb/JfcYOj6DfaN4Es9Ct9Qt3u7SzW1ju5LRvLO0bQxiEmeg6b+v5Vzej/DK70zwNpvh+fWrW6fSbv7VZTNpxEZOWOJojKfMGXJ4ZcYHcZr0Kim22231EkkrL+uhzfhXwl/wiXh26sbC6je7uria7knaAiITSHJKxBuEBx8u7OB1zzWG3w1vJdZsNcn1i0Or2OnzWCyx6e6RSK5GwvH5xJ2/Pxu5LA8Yr0Cik9f68rfkPb+vmeY+HfhHd+HvDmj2Eev2093oV1Jc6ddtprAL5gYSLKnnfODv4wUxgdamPwme1/sdNH1qK3j0y0vICJ7EytM9znfISJFxzyFx+Pp6RRTk+bf8AroNO39fM4LQfhrPoc3hy4TWkludD06TTi/2Mqs8bEFTt8w7SNozyc89OMUNA+FOpaHqGhXQ8SW8p0dLxEC6YVMn2hixOTMQCpPHB969Moo5ne/8AWt/82TZWt/WhheGvDK+HpNSdJYmF9cGcw28Jhij4xkJubDHqxGATzgVzdt8LFsrmE2mpxC3097ubS4ZLQt9nluM7zIRIPMUbjtA2YB5J616DRSKu0cx4O8LX/hHwDb+HotVt7me0jaO2uzZlFXJJUtH5h3YJ5wwz7VzurfCb7dbaRc6fd6PpfiCxu1u59ZttF2y3TjP3sSg4bJ3As2favSaKbbb5upKVlboeLz2HieD4uNdQaJpd5D9rjdmlsL+Esdio0yMu61343EOx34+XPQV2ngz4bad4N1K7uLVLCYSTSSW839not3ErklkefJLrk8cAgcEmu0ooTskhvU8+1z4XS634nbV5tfk+XU7TUIIZLbf5PkAjygdw+U7iegwSTzVU/CrUTrCXx8RWuE8QnXBH/ZjfeK7PLz53THfHXt2r0uiktNv62/yQPXf+t/8ANnnlr8LriwvdJ+w65GlhpOrS6jbWz2O5gsu7fGziQZ++21sDHcNXV+LPDsHizwnqOh3T+VHewmMShdxjbqrgdyCAfwrYoo3Vh3alzdf6ZzH/AAg9mPFGh62LiTztIspLQA5zcBtuGc55wVJwc8tntWBqPwqm1RvFX2nXIwNfure7iCWRH2V4SNmf3h3jCjP3e/Tt6NRTu73/AK3v+ZNla39djzXxV8K9R8T3muSt4jt7dNYs7a1ZTppdoxC+8NnzgDkluw4I9OYtX+E2p6tc6/M3iS0iOtNZtIBpbHyjbEFcfv8AnJHNen0UJ22H/X9fccv4S8J3fhvVdfvbvU4b3+2bwXeyK0MPkttCkZMjbhgD07+vHUUUUgCiiigAoorktN8cXur6Vaalp/gnxBNaXkKTwSebYLvR1DKcG5BGQRwRmgDqbhZntpFtZFimZSI5HTeqtjglcjP0yK4Kx+HWuyaHqWl+KPGTaxBdlXhVNMjtlhcSeYSwVj5oYgAhjyMjPNbv/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVR1uA3wn4P/AOEbutWv5bmGfUNWmWW4a2tjbwLsXaoSLe2OOpLEk1zVv8LNXMHiCzv/ABPbPYeIrprnUI7XS2ilO4AFEdpnCqQMHKk8nBFdP/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUdb/L5f0g/wCHOd8SfCRNdkmjt9aeysfs9pBa2n2YOtqIJN42/MOGwAR14Bzxityx0y31Hx/Nry219aXNlbNp03nQmOO5+YMki9nABbB7byOoNTf8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVO7/AD/EVl+X4EmjeFzpfiPUNXe5ieW9jRHSC38kSFf+WkgDEO/bcAvy4HOM1z//AArCdvGFvr1x4gkuHttXk1GOOW2yQjxCPyd27ouBggcdMHrW5/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUloN638/8rDvCHhMeFNJu9NS9N1bTXc1xEPL2NGJHLFSQTkgseeOMcdziWvwm0m08dHXftNzc2TaYdPbTb2ea6VgWydzSyNuTHHlkbe/Wtn/hKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5Ko2d/62sHf+utzN1f4ZabPNBN4aFpoDx209nJHbWS+VJDNjzBsUrh/lBDZ4PUHpXU6RpVvoeh2elaeCtvZwJBDu5wqjAz69KyP+Eo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqjpb+v61YGb4R8B3/h7U/ENxqWsWuoQ69M1xPFDYNAUcjHysZn+XGeMZ96y9P+D1vpXgvUdB0u/tbGe5jMEOqWmmJFdCIsG2TOGzL0wSNmR78103/CUav/ANCJ4g/7/wCn/wDyVR/wlGr/APQieIP+/wDp/wD8lUbfl9wdb+dzlrz4RXE2marZ2uvxQjUtXh1RmfTy/ltGFOwASrwWUHPYcc9a6vxD4VbxBfadPJdxQixuI51YW+ZkKnJ8uQMCm7hWyGBXIxzmm/8ACUav/wBCJ4g/7/6f/wDJVH/CUav/ANCJ4g/7/wCn/wDyVTu9PL/gL9EH9f194vifwm2ualpmq2F5HZappZlFvNLAZoyki7XVkDKTxgghhggdRkHD0P4Yv4d8SaFfaZq0QsdH097FbWWzLSSh23O5kEgAYsM/cwORz1G3/wAJRq//AEIniD/v/p//AMlUf8JRq/8A0IniD/v/AKf/APJVC02/rf8AzYPXcfrHhZfEGtRya2mlajpEUREen3umiYrKf+Wgdnx04xs6Z55rzrVfAWveEfAF1pun3VjrEMmpi7tbddIuVSwLMWOzyJXmVQcbTGNyk9cEkehf8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVT6f1rcd+/9aWOD0L4dXHibS9Gv/EGl6LY3WlSyolu+myz2t5BJtZmaG5KyrJuz8zfNkEnINet21vFaWsVtbxpHFCgRERQqqAMAADgD2FYH/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVVNk2Okorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKpDOkorm/+Eo1f/oRPEH/f/T//AJKqtf8Aji90y2Se+8E+IIonmigVvNsGy8sixoOLnu7qM9BnJwKAOtorm/8AhKNX/wChE8Qf9/8AT/8A5Ko/4SjV/wDoRPEH/f8A0/8A+SqAOkorm/8AhKNX/wChE8Qf9/8AT/8A5Ko/4SjV/wDoRPEH/f8A0/8A+SqAOkorm/8AhKNX/wChE8Qf9/8AT/8A5Ko/4SjV/wDoRPEH/f8A0/8A+SqAOkorm/8AhKNX/wChE8Qf9/8AT/8A5Ko/4SjV/wDoRPEH/f8A0/8A+SqAOkorkpPHF7FqsGmv4J8QC7uIZJ4o/NsPmSNkVzn7TgYMqcE5O7jocWf+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqgDpKK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqAOkorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoA6Siub/4SjV/+hE8Qf8Af/T/AP5KqtH44vZdVn01PBPiA3dvDHPLH5th8qSM6oc/acHJifgHI289RkA62iub/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KoA6Siub/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KoA6Siub/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KoA6Siub/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KoA6SiuSsPHF7qds89j4J8QSxJNLAzebYLh4pGjcc3PZ0YZ6HGRkVZ/4SjV/+hE8Qf8Af/T/AP5KoA6Siub/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqgDpKK5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+SqAOkorm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KoA6Siub/AOEo1f8A6ETxB/3/ANP/APkqq1144vbK5soLnwT4gSW+mMFuvm2B3uI3kI4uePkjc5OBxjqRQB1tFc3/AMJRq/8A0IniD/v/AKf/APJVH/CUav8A9CJ4g/7/AOn/APyVQB0lFc3/AMJRq/8A0IniD/v/AKf/APJVH/CUav8A9CJ4g/7/AOn/APyVQB0lFc3/AMJRq/8A0IniD/v/AKf/APJVH/CUav8A9CJ4g/7/AOn/APyVQB0lFc3/AMJRq/8A0IniD/v/AKf/APJVH/CUav8A9CJ4g/7/AOn/APyVQB0lFc3D4un/ALX06w1LwxrGmf2jM0EE9y9o8e9YnlwfKndhlYm5xjNdJQAVzfw4/wCSWeFP+wLZ/wDohK6SuW8Azra/CHw1cOGZYtCtXIQZJAgU8DuaTaSuxrV2OpormvCviyTxLYw3wtLVbG4jaWO5tL4XCIoxhZPlXZJycqMgbT8xqDxB49s9M0nT9T0U2etWl3qUNhJLb3oxGZH2bgVVgxB6rkfWqs72/rsLdXOsorn7LxnpE+nXV/e6lpdpZw3jWqXH9oxPHIRjHzA4Vjn7h5FVrr4g6Fp02pnU9R0+3tbCaKDzlv4nLO/8LIDmMg/3uwJ6Cl/X9feB1NFUotZ0ue/+wwalaSXfkif7Ok6mTyz0faDnafXpXPaN49g1v4gX/hyyjtLi2tbNbuPULW9EyyZcoUKhcKwYNn5j0/AHWwdLnXUV53q3xJ1jS9W8S2//AAjtjLa+HYY7m5m/tZleSJwWBRDBjfhT8pYDOBuPWuxtfEOm3K6ckl1Fa3WowCe3s7iRUnddoJwhOSRnnHShaq4PR2f9f1c06KoWuvaPez3cNnqtjcS2X/H0kVyjNB/vgH5eh646VmXnj/wnYWdnd3HiLTBa3spiguBdxmNmGd3z5xgY5OeuB1NAHRUVgab4x0q60KDVL/UNMsoLm4eCBxqMUkcpDlV2yA7WLAZ2jkZx1FXJPEuhQ37WMutacl2kiRNbtdoJFdxlFK5zlhyB37U7dANOiqUWs6ZcatNpcGo2kuoQKHltEnUyxrxyyA5A5HJHertIAooooAKKKKACiiigAooooAKKKKACub8ef8i7a/8AYa0r/wBOFvXSVzfjz/kXbX/sNaV/6cLegDpK5DT9d8VD4kS6PrGmaeukT2r3NncWsrtLEFZVxNkBctuyAvTB5PWuvrldN8OeJbfxpdavqXixLvTZgRHpcWmJCI+MLmXcXYDJODwSScChfF94P4TI8R+N9Z8L/E3R9NvksJPDmqSLB9oEDrNbzOGEalt5VgzIedo6+2TDp3xC1G6+J3iHS7+TTbHw/otqtyZnhczSIQRuL7wqjIJ+6cjFafi7wHdeMft9tf6rbw2M6wm2ENkwuLaWJ9yuJTLg8lhgIOCOeDnGuPhFNfa5rtzfa5btY6zZJYvbRWDI8Ucf+qKyGY5YEKSSuGweBmiPS/n+Wn4jdn+H56/gdQ/xC8NR2tvPLfSxrcXa2SJJZzrIszDcqOhTchI5G4DIIx1qu/xI0B59EisZbi7OtyyRWzQ2czbTHkOXULldrAAg4xnJwATWPP8AC26ubmK/l1yD+0m1e31O6mWwYRy+QmxI1TzcoMdSWbJPbpTtD+F9zo02hznXIp59HvLy4U/YSqypc5LIR5hIIJ4bOMfw96en9ei/W/3C/r8/+B95L4L+JdpquhhvE15aWmor9rkcRwyRxNFBKUZwWLDgAEjcSM+ldhpGsWmt2P2uw8/ytxUi4tpIHB68pIqsOCD05zXB6H8KL3SL7TLiTxBbXC2K3yOn9mY80XT726ysBg+oYEdRXZeGtDk8P6bJaSXYuFaZpI0jjMccCHGI41LMVUY6ZxknGBgB6W/rv/kD307/AIFO+/5KnoX/AGBdS/8AR9jXSdOtc3ff8lT0L/sC6l/6Psa37u2ivbOa1uAximQxuEcoSpGDhlII+oOakDnPD3i19f8AF/iDS0t1jttKW3EUp+9MZFZi3X7uAuPz78YWh+PtXi+IWs+G/FiWIjgtWu9NubSB4vtEaMVkDBnf5gR2PbPfjZ8L+Abbwt4o1rV7W/u7hdUWFVhubiaYxBFxy8kjFyexPIHA4qhefDq71XWNN1bVNWtWvtMu5p7d7aweJWSRTmKQGZiy7tp4IyARjnIOq9A6P1/r/Iz/AAH8Sb7VtD1LVvGLWdokOqSadb2lhZzSSs6dRwztISOyoMbSenTpr74h+F9OFubnUjtubWS8haK2llDxR/fYFVPK9x1HpXK6L8JL/R7bJ8Q2k13Dq0mrWk39mOqxzSKVkV08870IPABUgjqelSXHwhItrC203Wkt4bTTb2yYS2ZlaRrrJeTIkXGG5C4PcZ9B7fL9P8wW+vf9f8jT8QfEiytU1Gz0Mtcahb6M+qwytaSyW5XaWTcy4GGCnncPTrxU+i/EjRrzQLe51G62X4t7Z7m1gtZmffMm5RHGFLSA/Njbu+6eeDWanwvuorWeOPXIfMufDy6HMzWJIwgIWVR5vHDHKknPHIqPTvhZdWU1y8+s2N2k+nWtkI5tLJVWt1IST/XZ6ndwVIIGGGOa0V7f1q/0t/VxK7tf+vh/4J6FaXUV7Zw3VsWaGZBIhZCpIIyMggEfQjNYFj/yVPXf+wLpv/o++rZ0qyk07SLSymupbyS3hWNriY5eUgY3MfU1jWP/ACVPXf8AsC6b/wCj76k7X0BXtqaHiTXrbwx4cvNYvVd4rWPd5cYy0jE4VR7kkAfWsvwvr1/4j0W/nF3YRXscjQi3W1m/0GUKMpKHZGcgkHgR5BGPWtHxT4et/FXhu60i7kaJJwpWVACY3VgysAeDhgDjvVPQfDFzolrq0wv4JtX1WY3E919lKwiTYEUiLfnaAoyN+Sc8jsuj/r+uv4eZXaxxvh/4o6zeeEvFDaxZ2KeItDOY7eFHWKVHTdC5BYnB5JwegrZ8KfEFZvAej634wu7aK61aIzxw2FlNiNB1JUNI21erSHCjIziqs3wsuZrmXUf7atk1SbSf7MlkTT2EDjlVlMXnZLiNmX7+MnPbFRWXwnu7Pw/pdiNet2utOsptNW5/s9gslrKBuUp53EgIyHzj1U0+/wAvwv8Anow0v5a/p+Wp0tx8Q/C9pqUlhcamUniaAP8A6NKUHnf6pt4XbtY8bs4zwTmsDxP8UVs7LVD4fi3XGk6lbWV015Zy+UwkdFYK3yjcN47npnGCDVS/+DksxvI9O12G1tpodPggiksGlaJbRgyZbzRu3HOeBV7Vfhhc39nrlvba5DAmrarBqZMliZDE8ewleJVypMa+hAz16hrluvX9V+lydbfL9H+tjeHxA8NsqmO+llZp5LcxRWczyI8ZAk3oELIqkrlmAUbhzyK6SvPrb4Z3cEWoqdcg8y71WXUYp47ApLamQjcI383IbC4DdOTuVhxXoI4FLou4+r/rr/kc34D/AORduv8AsNar/wCnC4qv498Q6r4atdJu9LNm0VxqdvZ3EVzAzsyyyBcoyuu0jnqGzx0qx4D/AORduv8AsNar/wCnC4qLxz4V1DxbZ2FtYara6dHa3kV4xmsmuC7xsGQDEqYGRz1J7EUl8S9V919fwDo/RmNrfj7U9O+I8fh2K3tow7QfZre4icSagjnErxS7gi+UMkqVYnHbNS/E7xhr3giGw1XTYbK50pZV/tKKWB2ljh3qGkR1cDjcOCp9c9qsav8AD6TWtYW5vNVVrVry3v5YvsxMqzQgBRFIX/dodvK7WPzNgjNaniXw3c+I5BbS3doulS20tvdW0tm0kkiyDBKyCQBSMDGVajaKtun/AF/X/DJ6OWu1jnNY8e6svxW0Dwzov9nrpuowPNNd3ELyudihyqYdQMqV5OeT04wd2T4i+F4tMvNQk1Jxa2SCSaT7JMcxltvmINmZEzxvTK+9cvbfCK8tNX8OXUXiGCSDQrN7MRz6e7vcLIu2Us/nDBI+7gfLx97FFx8GzP4fudNGtorf2YNIspjZE+RbeYHO8eZ+8c4A3DaP9mq0Wi8/zf8AwP63SvfXy/S/6nRaj8S/Dlhpc97HPcXQgvIrJ4orSUyCWTG0bduSCGBBAOR0zVLRfiJFL4r1jSdemhtlh1KKy05ltpUMhkhEirITkK3JHO3OMYzxVKX4V3c7ao8uvQ+Ze6hZ6jGVsCBFLbhRgjzfmVgo4ypHqaW9+F1/d+ILnVF1+3j8/WrfVxGdOY7TDHsEefO5yMc4HfjngVr6/wBfD/8AbCd+X+vO36HZaP4j0zXpLhdLlllFuQGdraSNHBJGUZlAkXKn5lJHHWs/xR/yMXgz/sNSf+m+8qbQfDb6JqeoXIvFaG7KlbaGHyo0YZLSFdxBdixJKhQcDIzyYfFH/IxeDP8AsNSf+m+8qR9TpK5d/Fzt8S7XwxBbqYJLCa6luW7ujooVfpuOT68djXUVxB+F+nL41i16HUNSjiSzmtmtf7RuiSZGBLLJ5uUA5+VQBkg8EChfEr7a/k7fiHT+u5P428cx+GLm2sIQgubiJ7iS4mikkhs4UIBlkWMFiMsB2HUllAzUXj3XfE+geCY9d8NNpl8bVFlvhJaO4kiwN0kQWUYwMttJOR345Zrvwzg1FkbTNTuLRmsptOuXvWkvmmtpSCyh5ZNwYEZViWAz90iunm0t4vDZ0rSZY7cpbC3gkniMyoAu0ZUMpbj/AGhSekbrf/h/+B+PkNW5l2/4b/g/h5mRZ+JZLknWxqVg3hhbNJPOFs4keVuflfzCCMEfLsJycZJzT7v4g+GbDTor27v5I4pfM+X7JMZIxGQJDJGE3xhcjcXAAyM4zWLafDA/8KkPgXVtVju4UULBdQ2fllQrh13IzuH+Yc8gEcY70mq/DA6j4dj0e21Gz0u0a0uIbm207TFht5ZZFAEwjD/Ky4J5LdTyOCKla7sKOyv8zem8feGrfUp7CbUdk9ukUkubeXYqSfcfft2lT/eBwO5FaWja5Y6/Ztdaa05iVth8+1lgbOAQQsiqSCCCDjBzxWBongq80nxDfalNq0E6XemW9gIlsihTyQQH3GRgclm42+noc6vhnw+3h20ubf7UssUs5khhiiMcVsmABGiFm2jjJAIGSSAoOKemotf69P8AMq+KP+Ri8Gf9hqT/ANN95XSVzfij/kYvBn/Yak/9N95XSVIwrlvASzP8IPDS2rrHO2hWojdhkK3kLgkfWuprm/hx/wAks8Kf9gWz/wDRCUAc1efC99Q1DWp4VstB/tLTprKaTS3fF674Imlj2qqlTu4BYnectVDUfhx4mvYnukbTFvJr/T53tTey+QkdoOqt5OS79/lAAxycc+sUU02rW6W/B3B67/1c8j0j4ZeI7DVf7Suho91nVr66k0+S5kaCaC6VVYEmL764/ukEEjin3/wy1+61zXr2A6TDFd6lp17ZxLPIBttcAo2I/kyBxjdjp716zRQm1a3S34Wt+QPW9+v6nmp+GFzca94iubu7LJqbTTWd2t/cb7R5YfKZfI4iYAdH644xwDU/g/wVrui+NY9X1NdMW3XQ4dLK2k7s2+JuHwY1GCPfg8c9a9DooWm39aNfqJq+/wDWqf5pHlGt/C3VfEHjXXdcuU0yznmEEuj38Nw8lxaTQZ2FlMQG18/MoY4x36i/aeA9avvGyeIPE4s5TNFbmWC11W6WO3ngJ2uiBUWVWzna4G05xuyc+kUUlokv6/r/ACHL3tzyGb4UeIdQ+3G+v9NtmvNFl04mz3qsbm4MqFUCgBCuFKjGOfvEk10N74Q1i7uvDWqRWej2l/pl7Jc3lvBM4inLwmMsJPKyW6Hle2M8ZrvaKd9Lf1vcHq7/ANbW/I8f0n4WeJNO8P2ULz6ZJeQw6haSQ/apPJEd0+7zFbysl16bdoB/vCmap8KPEckl+lhPptxG9tpkFvNd3Uiyv9kcMxfETY3exPQV7HRQm07/ANaf8Owet79f1/4ZHM6X4fv7DxfcX8f2aDT7hJHlhjkZzJO7L8wVl/d8LztbDk5KgjJ6aiil0sHW4UUUUAFFFFABRRRQAUUUUAFFFFABXN+PP+Rdtf8AsNaV/wCnC3rpK5vx5/yLtr/2GtK/9OFvQB0lYvirVtU0TQ3vtF0mPV542GbVrowM4PHyHYwLZI4OB71tVm64uqPZxLo1raXMonjZ1u7poFCqwYkFY3yeAMYHXrQNGT4d8YN4q/s+80W2tpNJu7dpJJpLpluIJFOGiMPlkZBIBy478dM2rvx34RsLyW0vvFOi21zC2ySGbUYkdG9CpbINQaT4NttE8aalrmmyGGHU4gbizB+QT5GZVHQFgAG9SoNT3fg3TL28luZrrWlklbcwh129iQH2RJgqj2AAp6aC7kHjfxXdeEvDUmr2Giy6ysQ8yZY7hIVjiHLOWbrx0UAkn86pat47vdM1nRIh4YvpdK1R4oX1EyIpt5ZfuIYvvH/aPAHucirfjHQbzxBZw6YumaTqWmSAi4TUZpEkibjZJGyq2WHP909PmFZl1onja2v9As9Im0S50nTY4kuLvVJJnvJGA2vIoUbQ+3djcTyxzRHfXv8Ah1/r/hhPb5P/AIBuSeLLVfHlv4WjieS4ls5LuSXOFjCsgC+5O/Ptx61vVwlr4C1Kz+J9n4iGvXN3YQWU8Lw3IhEm6SQNtGyFcpxnJbdkDnGa7uj7K7/8F/pYb3f9dDm77/kqehf9gXUv/R9jXSVzd9/yVPQv+wLqX/o+xrpKQHLeNvFt54OtYNQXR/7Q0wNm9liuCs1tGOsgj2EOAMk/MD7GtHSNZuNVuZ5UisjpRiSW0vILxpGnVhnLIYwFH0Zqk1GLUZdWsRbWlnNYjeLp57lkdQRj5UEbB/xZaz/CPg+DwfHqVpYTOdPubkzWtuSf9FUgZjX0XduIx03Y7ULZ/wBf15fPyBktt488IXt5HaWfirRLi5lcJHDFqMLO7HoAobJPtVTxZ4xuvDGqaTCmgXN/ZX11HbTXkUyL5DOdq4Q/NIc8nAwBzntVu28GaZaXkdzFda20kbh1EuvXsiEj1RpirD2IIrM8WeFb7xRq8CT2mmLZ25SS01NZpI76ykDAvsAXBDYA++vuDimrXXrr6A9nYkHjW9i8e/8ACP33hq8t7WaCWay1ASo4ufLxvHljlOoxu5OegqXwh4vvvEOo6tp2seHrjQr3TXTMUs6TCSNwSjB0+XOByoJx6moUtPG7ePJb2aLw6NESJo4NskzXhGMgFiuxQzAFsAnAHXFSeDrPxhb3mpTeMV0FFuJA8I0kzMzHofMaQDOFCgYA6GlHbXt+v+QM6uubsf8Akqeu/wDYF03/ANH31dJXN2P/ACVPXf8AsC6b/wCj76gDpK47WvHUvhzxja6ZrWlpBpV6Vit9WS6LKszZ2JKhQbNxVgCGYcDpnjsa53VNCl8RT6rpmv6dZS6HeWywq63TNMxBJyYzGAmCxIIckFQe/B1Hp1LVlrUsOhz6j4oXT9ISGR1d1vjJEqq23c0jpHjJzxj05pdL8XeG9cuza6J4g0rUbgKXMNpexyuFHU4Uk45HPvUOjeGzY+DbfQdQvrq68qMxvdR3EkM0g3EhvMQhgxGMkH1qbS/DFho92bi0n1WRypTF3q91cpg/7EsjLnjrjNPS/kT08zMn8ZXdt8RLPw3NoFytpexSNBqfnIVd0GWBjGWVeQN5xkkAA5zWdD8SjDoniG91nS47WbRNQXTzFBdmZZpG2bSHKLtBMgByOOTViTwpf6h44g1y/tNMtZbCZjBf2M0guLqAqwEEylQMAkHO5hleAM1laZ4M177L4rt9e0rQ7uDXr4XawDUZmVAQikE+QpyoTcCMEnA+X71Jba9v1X6XKdr/ANdn/wAA6vwv4lHiFNQhnthaX+mXRtLyBZPMRXChgVfC7lIYEEqD7Vu1geEPC8fhbTJojO11d3c5ubq4Ysd7kAYBYs2Aqqo3EnA5JNb9N26f13JVzm/Af/Iu3X/Ya1X/ANOFxXSVzfgP/kXbr/sNar/6cLiukpDOT8a+M7nwYbW8m0j7Zo5P+m3UVwfNtEyAZPK2HcgyMkMD144rV0rV7m+mvZbiGxj02La1tdwXhlMyFd25lMahBgjozd6df2+oXGtWyrZWU+ltDJHdNNcsJBuxwI/LKuOBnLL1PpzR8IeEIvCOl32l21zLLYS3Ly2sbOd1vEyj92D1ABBxjoMULZ/1/X9eQ30/r+v68yay8c+EtSvYrPTvFGi3dzMdscEGoRO7n0ChsmqXiPxldeH/ABLo2n/2Bc3djqVytq9/HMgEMjZ2gR/efgZYgAAdz0q7ZeD9NsL2K6gudaeSI7lWfXb2ZD9UeUq30INZXiPwpf8AiPxHby3VrpkdvZTRTWWqQzSJfW+GBkjwFwVfBGd4GDypxTVroXRjtO8fxanry2NvaR+RdS3VvY3BuP8AXTW5xIrLt+Rc5wwLZAOQOAb3grxRL4s0W4vLmxSxmt72ezkijuDMu6JypIYqpIJHoKwtK+H11pWvQXMf2WW00y5vb2wDTMHlluckq42EIq5I3AsTnOBjB0Ph1oGteG9L1C116KwU3GoT3kbWV083+tcuVO6NMYyBnnPtQtvl+P8AVwlvp3/DX/gHX1zfij/kYvBn/Yak/wDTfeV0lc34o/5GLwZ/2GpP/TfeUgOkooooA4SH4h3o1zUtB1DRbey1eGF59PR79jb6hGhw+2Xysqy45XYT+HNdNd+IbDRdMtrnxTqGm6O8wCnz71Vj34yVV3CbvyB9q57W/Bl34u8Oy22tRWum6lb3b3OnXdjdPM0LE5BLGNCM5KsoyCO/p02qaLbaxaxQ3kt7GsZ3A2d/PasTjHLROpI9jxR9nz/r+v6sD+LyG6d4i0fWrSe50LU7PVY4OJDYXCT4OM7flJ59q5nTPHmsX9n4iS68Kvpmp6Iqy/ZLu+UxzRMCyt5sauA21T8oDYOBnuOm03RodEtJk017ydn+YC/1Ge5y2OBulZyo+n5Vymn6X4+fSfECa5B4Za4v1K2yWU86Biw2kyyNGx+VQoG1ecc460pXs+Xt+I42ur9/wOo8L63/AMJJ4T0vWvs/2b+0LVLjyd+/y9y5xuwM4z1wK1a5/wACaRqOgeB9K0fWFtRc2FuluWtZmkRwoADZZFIz6Y49TXQVpPl5ny7ERvZXOb8Uf8jF4M/7DUn/AKb7yukrm/FH/IxeDP8AsNSf+m+8rpKgoK878A+HNUn+G3hqWLxprlskmk2rLDFDYlIwYVIVd1sWwOgySfUmvRK5XwHbQXnwg8NW15DHPBNoVokkUqBldTAoIIPBB9KTdlcCb/hF9X/6HvxB/wB+NP8A/kWj/hF9X/6HvxB/340//wCRa8t+Huq3XhbwL4ai8PWmmwtreu3VndPLbHcQGlKtlGXO0JjBzxxxW3beOb7WYPh9rF9YWTvfXF2JUjSTdHJHFIN0R34GQpG1g33uuRmqaS/ryuDTTt6/hf8AyO3/AOEX1f8A6HvxB/340/8A+RaP+EX1f/oe/EH/AH40/wD+Ra4mw+KfiK68Kw6zdaNBaW+qXFtDp13LsMcXnSFD5irMzME4+Y+XuJxtXGavapr/AIwh8Y6dpEl7pEMg0W6vbkR2sssUrowUY/eKwGCDjJxyMtwQpXS+/wDBXf3Ia1dv61djqP8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWvOdA+JmpWXgvT5LHSrSG107R7a8ntlilc3AllMYjgYyErt25y2/JOOOtbNr8R9ePjAaddQac1mfETaR8kMiS7DB5qtkuRuHQ8YP+zVcr5uX+t0vzZN1y839bX/I63/hF9X/6HvxB/wB+NP8A/kWj/hF9X/6HvxB/340//wCRaxPH+nX91rljfaVbaVrUmn27yyaNqT+WSCeJ4XwQkgK43EcA9R34q48c3tra+ItR0K3htmt/C1ndWc9zHI1wqMWASTMhViCWIYAZzzmpWqv/AF1/yKtr936f5nqH/CL6v/0PfiD/AL8af/8AItH/AAi+r/8AQ9+IP+/Gn/8AyLXO23jTxL/wmdt4dg02PUFs7e1k1G6VEhDLNn94u+fcoXHQLIWORleM43xV0yGX4m+GLmHwvp3iG6NhfF7O7Cr9pCKhVdxR8kZO0EYyeozQ9Px/AUdfw/E7v/hF9X/6HvxB/wB+NP8A/kWj/hF9X/6HvxB/340//wCRa880LxbeeHvBvhrS/B6Sa3c6u9zJEsyKFtih3G02vMm0rnaMsSApO09K6C8+ImqWvjTTbDytPks7q8jsp7aLc88EjQGXmXcEJGMbVVhjB3jOKbVnb+v6voK+lzo/+EX1f/oe/EH/AH40/wD+RaP+EX1f/oe/EH/fjT//AJFrh9T8f+KLr4U6j4qspNLtYZ0UWaLG5uLZjP5TrIN2GYAg7htweNveo5vGWs6H4416zmt9OudRY6XZpfw2syIDMWAeSMzN8qknAUqTkAnvQk27D6XO8/4RfV/+h78Qf9+NP/8AkWj/AIRfV/8Aoe/EH/fjT/8A5FrkH+I/iCZ9HgtYNPiludSvtNuZJraQo7W6MRLGBIMKSnKknuN3Gau6F491vWLTwzqNxFp9lYanbwtcP5TykzSOVEYIcGIHHysyuGOQSpHIlfby/HYH7u/n+DsdF/wi+r/9D34g/wC/Gn//ACLR/wAIvq//AEPfiD/vxp//AMi10lFIDm/+EX1f/oe/EH/fjT//AJFo/wCEX1f/AKHvxB/340//AORa6SigDm/+EX1f/oe/EH/fjT//AJFo/wCEX1f/AKHvxB/340//AORa6SigDm/+EX1f/oe/EH/fjT//AJFo/wCEX1f/AKHvxB/340//AORa6SigDm/+EX1f/oe/EH/fjT//AJFqtf8Age91O2SC+8beIJYkminVfKsFw8UiyIeLbs6KcdDjByK62igDm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWukooA5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FrpKKAOb/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+Ra6SigDm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWukooA5KTwPey6rBqT+NvEBu7eGSCKTyrD5UkZGcY+zYOTEnJGRt46nNn/hF9X/6HvxB/340//wCRa6SigDm/+EX1f/oe/EH/AH40/wD+RaP+EX1f/oe/EH/fjT//AJFrpKKAOb/4RfV/+h78Qf8AfjT/AP5Fo/4RfV/+h78Qf9+NP/8AkWukooA5v/hF9X/6HvxB/wB+NP8A/kWj/hF9X/6HvxB/340//wCRa6SigDm/+EX1f/oe/EH/AH40/wD+RarR+B72LVZ9STxt4gF3cQxwSyeVYfMkbOyDH2bAwZX5Ayd3PQY62igDm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWukooA5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FrpKKAOb/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+Ra6SigDm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWukooA5Kw8D3umWzwWPjbxBFE80s7L5Vg2XlkaRzzbd3djjoM4GBVn/hF9X/6HvxB/wB+NP8A/kWukooA5v8A4RfV/wDoe/EH/fjT/wD5Fo/4RfV/+h78Qf8AfjT/AP5FrpKKAOb/AOEX1f8A6HvxB/340/8A+RaP+EX1f/oe/EH/AH40/wD+Ra6SigDm/wDhF9X/AOh78Qf9+NP/APkWj/hF9X/6HvxB/wB+NP8A/kWukooA5v8A4RfV/wDoe/EH/fjT/wD5FqtdeB729ubKe58beIHlsZjPbt5VgNjmN4yeLbn5JHGDkc56gV1tFAHN/wDCL6v/AND34g/78af/APItH/CL6v8A9D34g/78af8A/ItdJRQBzf8Awi+r/wDQ9+IP+/Gn/wDyLR/wi+r/APQ9+IP+/Gn/APyLXSUUAc3/AMIvq/8A0PfiD/vxp/8A8i0f8Ivq/wD0PfiD/vxp/wD8i10lFAHN/wDCL6v/AND34g/78af/APItH/CL6v8A9D34g/78af8A/ItdJRQBwmp6Nfad4t8Hy3niXVNVRtWlUQ3kdqqKfsF2dw8qFGzxjk45PHTHd1zfij/kYvBn/Yak/wDTfeV0lABXm3grxXojfCzw9p2o6drFzH/Y1tBNH/wjt7NFIPJUEZEJV1PqCQR6ivSa5v4cf8ks8Kf9gWz/APRCUAYUMnw8tljW38GTRCKTzowngy7XY/8AeGLbhuOvWs9l8OJ4l0i9sLXVtP0vSWeaDTLTwdexKJ2VkZ9ywjgh+Vx1VTkcg+o0HpxTu1qHSxxK6z4NWyu7NfDeoC2vXL3UA8JXuydj1Lr9nwxPqc0T6z4NuoYIbnw3qE0VvE0MKSeEr1lijYYZFBt+FI4IHBFZJ+KmrW0Oo3moeGbVbHTNVGl3BtdUaWdpCVAaOMwKHGXXjcD14r0FdV099UbTVvrY36xiVrQTL5qof4imcge+KVrq/wDW3+TB6P8Arv8A5nIRan4IgWzWDwtexrYMWtAnhC8H2Yk5Jjxb/ISeeMUw3vgM3JuD4SujObj7UZf+EOu9xm/56Z+z53/7XWp1+JmmDx5c6HLNpq6db6e162rLqKmNCsgjaNxtCoQx/vHtxzXSp4i0WSzuruPWLBrazOLmZbpCkHGfnbOF4IPPrR05v63/AM0Ftbf1/Wpgah4l8LatF5Wq6Hq17HlW2XPhW+kGVOVOGgPQ8j0qBtX8FteXN23hm/NzdxeTcTHwjeb5o8AbHb7PllwAMHjgV0x8Q6Ks9lC2r2Al1Bd1nGblN1yPWMZ+cfTNS6frGmasZxpWo2l6baQxTi2nWTyn/uttJwfY0WC5zCa/4RjubW5j8P6mk9nH5VtKvhO9DQJ/dQ/Z8qPYcVHdax4MvtWh1S98Nahc6hBjyrubwlevNHg5G1zb5GCcjBrt6KAOEa/8CvJM7+FLxnnmFxKx8H3hMkoJIkb/AEflhk8nnmp5Nd8IS3hu5fD2pPcmVZjM3hO9Ll1GFfd9nzuA4B6gV2lFAHEjWvByxXsa+HNREeoEm8QeEr3FyT3kH2f5/wAc1EuoeBka6ZfCl4pvIxFckeD7z9+gxhX/ANH+YcDg8cV3dFAHDSap4Jmjs45fC986WKlbRW8IXhFuD1CD7P8AKOO2Kda6v4LsUtVsvDN/bLZszWwh8I3iCAnOSmLf5ScnOPWu3ooA5v8A4TzSP+fPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/wAYrpKKAOb/AOE80j/nz8Qf+E5qH/xij/hPNI/58/EH/hOah/8AGK6SigDm/wDhPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABiukooA5v8A4TzSP+fPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/wAYrpKKAOb/AOE80j/nz8Qf+E5qH/xij/hPNI/58/EH/hOah/8AGK6SigDll+IugtdSWqxa4biNFkeIeHr/AHqrFgrEeTkAlGAPfafQ1L/wnmkf8+fiD/wnNQ/+MUWP/JU9d/7Aum/+j76ukoA5v/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGK6SigDm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYp1trupTeOtW0SS2tVgtbGG6tZFlYtJvZ1w/GF5Q9M8c57VF4S8Q3GtahrFrPqGlaiunzrEJtNyu1iDujdS7HcpGN2QDnoMGjcHo7P+tLj/wDhPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABis+z8ZX9xrFtM8Vr/Y15qk2lQqqt56SR7x5jNu2lWaJl2hQRwcnOB2lHS4PR2Zy0HxF0G6jMlrFrkyK7xlo/D1+wDIxVlyIeoZSCOxBHapf+E80j/nz8Qf+E5qH/xijwH/AMi7df8AYa1X/wBOFxXSUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSVFc+f9mf7J5fnY+TzSdoPqcc/57UAYH/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wnNQ/+MVjnxX4gt7mXRbldPk1STU0sLW+jt3W3bdCZmZojIWyiqQVD8kjkZ4vjxlNF4GvtXuLaJr+xuJLJ4UbbHJOsvlLgnJCsxU9yAe9HS/8AX9ahZ/18/wDJln/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABipvDurahc3+paTrZtXv9PaMtNaRtHHKki5UhGZipBDAjceme+BvUAc3/wnmkf8+fiD/wAJzUP/AIxUUXxF0GeSaOCLXJHt3Ecyp4evyY22htrAQ8HaynB7MD3rqa5vwv8A8jF4z/7DUf8A6b7OgA/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8AxiukooA5v/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGK6Sub1XU9e03xFpgVbGfTb66+ym3SJ/tEfyM3m+Zu2kDbyuzgfxHpR1sHS4f8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFJaanr0PjRNK1RLGe0urSS5je0idGtSjKux2ZiH3b+GAT7p4qhdeMb+DWLiZYrX+xrTVIdKlVlbznkk2DzFbdtChpFG0rk8nI6FpXaS6/52/PT/AIAPS9/60v8AkaH/AAnmkf8APn4g/wDCc1D/AOMUf8J5pH/Pn4g/8JzUP/jFdJRSA5aL4i6DPJNHBFrkj27iOZU8PX5MbbQ21gIeDtZTg9mB71L/AMJ5pH/Pn4g/8JzUP/jFHhf/AJGLxn/2Go//AE32ddJQBzf/AAnmkf8APn4g/wDCc1D/AOMUf8J5pH/Pn4g/8JzUP/jFdJRQBzf/AAnmkf8APn4g/wDCc1D/AOMUf8J5pH/Pn4g/8JzUP/jFReIPEV3pHifR7JL7SI0v7gRLY3BIuJ1/idG3ADb/AHdrbumQTS2Wu6pL44n0zURHYW21zaW8tmS90i7cyLOspTGW+4UDAfnQtf67f1/VmD0/rv8A1/WhJ/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFZmu+M7/AE7WdRFqLMWOjNbC8hmVvPnWYj5o23AKFz3VtxBHy9a7ejpcOpzf/CeaR/z5+IP/AAnNQ/8AjFRL8RdBa6ktVi1w3EaLI8Q8PX+9VYsFYjycgEowB77T6Guprm7H/kqeu/8AYF03/wBH31AB/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xU3inW7nSRplrYGCO61S8FpFPcoXihJR33MoZS33MAbhkkc0eHtfudY8MzXrWqyXttLPbyQwOAsssTsh2FjwGK8ZPGeTxR0bHbb+v62ZD/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFL4O1nUNXtLr+2JYVvYJQktotk1s9qSobY2ZZA/BGHUhT2ro6b0Ec3/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMV0lFIDhNT8S2Os+LfB9vZwapG66tK5N5pN1apj7Bdjh5Y1UnnoDnqccGu7rm/FH/ACMXgz/sNSf+m+8rpKACub+HH/JLPCn/AGBbP/0QldJXnfgHw5qk/wANvDUsXjTXLZJNJtWWGKGxKRgwqQq7rYtgdBkk+pNAHolB6cVzf/CL6v8A9D34g/78af8A/ItH/CL6v/0PfiD/AL8af/8AItAHCW/wt8QRaxqXiOFNGsfEX9qtqNhcxXMkqvG4CvbTEwqdm0HBGcFug76+l/Dm/wD+Ei1fUtZkTzL95Li3mg1O4c2ckkPlugiIWNwO0hAOMDbwK14LB7rUJ7G1+JuqTXlswWe3j/s1pIiRkBlFtkHAPWrv/CL6v/0PfiD/AL8af/8AItH2bdLW+Wn+S/psbet/O/8AX3v+rHnk3wp8UyWrQq2ijHhdtAVhdSjc275ZSPKOAVHK84PGT1qeb4V+I7ldUJn0+1M7abNbpbX06BmtUCtGzLGrIrc4ZckYBxXZ3+j3WlWMl5qnxG1iytYseZPcLp0aJk4GWa2AHJqtFFHP5/kfFPUJPs7ok2x9MPlM/wBwNi24LZGAevaq5m3f+t7/AJsX9fgl+SQ2DwNNp11pkmiQ2tkIiq3Ze7muC0e9pGQ+YG835mO1iUZSSR121qeEtAvdAa8gmNulh8iWdvDI0nlKAc/MyghcnhMsFxw2DgH/AAi+r/8AQ9+IP+/Gn/8AyLR/wi+r/wDQ9+IP+/Gn/wDyLSuxWOkorm/+EX1f/oe/EH/fjT//AJFo/wCEX1f/AKHvxB/340//AORaQzpKK5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FoA6Siub/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+RaAOkorm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWgDpKK5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FoA6Siub/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+RaAOkorm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWgDpKK5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FoA6Siub/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+RaACx/5Knrv/YF03/0ffV0led2fhzVD8SdZiHjTXFddJsGMwhsd7gzXgCn/AEbbgbSRgA/Mck8Y6D/hF9X/AOh78Qf9+NP/APkWgDpKK5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FoAcnh7U4vG+oa/FqlqIrqxS0jtmsmJjKFmVy/m/N8ztkBVyMDIxkmm+Hb6zvrzVp76yl1i9WGKaeKxaOExRsxAEfmlt2HYbi57cYGC3/hF9X/6HvxB/340//wCRaiTw/qElxLBH8QdceaHBkjWLTiyZ6ZH2XjOOKadht33/AK/qwlt4K+z65FOdQ3aZb3suo29iIcMlxIGDEybvmTLswXaCCepGAOqrj4tOln1SXTIfiXq0l/CoeW0QaaZY1PQsn2bIHuRVz/hF9X/6HvxB/wB+NP8A/kWl0F1uw8B/8i7df9hrVf8A04XFdJXnfgvw5qk2g3LR+NNcgA1bUlKRw2JBIvpwW+a2JyxBY9sk4AGAOg/4RfV/+h78Qf8AfjT/AP5FoA6SoL6O6msJ49PuI7a6ZCIppYvNWNuxKbl3fTIrC/4RfV/+h78Qf9+NP/8AkWj/AIRfV/8Aoe/EH/fjT/8A5Fo3AqL4R1eXT4FvNZsDfWVyLqxuLbTXjRJMMHMiNMxk3B2Bwy9eMHmp18GE+G59Flv98F0JZriYQkStcvJ5nmqdxCgNnCkH+Hnjl/8Awi+rjr478Qf9+NP/APkWo4NA1C5tkubb4g65NA67lljj05lYeoItcEUXA0NA0O40ua9vdTvkvtRvnQzzRwGGMKi7VVULMQAMnljkkn2GzXLW+gahdwLNa/EHXJ4mztkji05lODg8i19Ripf+EX1f/oe/EH/fjT//AJFoA6Sub8L/APIxeM/+w1H/AOm+zo/4RfV/+h78Qf8AfjT/AP5Frn/DnhzVJNe8WKnjTXIjHq0as6Q2OZT9htTubNsRnBC/LgYUcZySAeiUVzf/AAi+r/8AQ9+IP+/Gn/8AyLR/wi+r/wDQ9+IP+/Gn/wDyLQB0lc/JpGvv4n/tAaxp32IEKlu+mO00cfG5Vl8/aCxHJ2enpUf/AAi+r/8AQ9+IP+/Gn/8AyLR/wi+r/wDQ9+IP+/Gn/wDyLR1uHSwWGjeJbW/vLm51vS5zcBthXSZEdTz5YZvtB3IufugLnk5BJJgm8FNNrLztqIGnT3sWo3FkIDl7mMKFIfd8qZRWK7SSR94cgu/4R/UPtX2b/hYOueeU8zyvK07dtzjdj7LnGeM1nXDWtprC6TdfFm9h1JmVFs5JdLWYs33QENtuycjHHOaa3VgeqdzuqK5v/hF9X/6HvxB/340//wCRaP8AhF9X/wCh78Qf9+NP/wDkWkAeF/8AkYvGf/Yaj/8ATfZ10led+HPDmqSa94sVPGmuRGPVo1Z0hscyn7Danc2bYjOCF+XAwo4zknoP+EX1f/oe/EH/AH40/wD+RaAOkorm/wDhF9X/AOh78Qf9+NP/APkWj/hF9X/6HvxB/wB+NP8A/kWgCXWfD11r2oQpqF5aNpME8VzHbLZt54ljYOp84yEYyOgQHHGalj0e/m1db/Vb+2uDbGT7DHBaNEIt4xl8yMXYDjI2jk8dMUH0G/iuIreT4ha4k02fLjaPTgz4GTgfZcnAqtBZNc6rPplt8TtUmv7cZmtIzprSxD1ZBbZHXuKOlgLV74MTWtbtNQ8QHTro2ixlfJ04RyO6nd80jO7eXvAYIMYIGS1dRXHz6dLbanBp1z8S9VhvrkEwWsn9mrLKB1KobbLY9hVz/hF9X/6HvxB/340//wCRafQOp0lc3Y/8lT13/sC6b/6PvqP+EX1f/oe/EH/fjT//AJFrn7Pw5qh+JOsxDxpriuuk2DGYQ2O9wZrwBT/o23A2kjAB+Y5J4wgPRKK5v/hF9X/6HvxB/wB+NP8A/kWj/hF9X/6HvxB/340//wCRaAL3iTRX1/ShYZsfJeRTMt9Yi6VlHPyqWChs4IYhgMfdNMsdDk0TSo9O0Ca1tbaGBwgmtjITMxz5jFXUEZLFlwCSeCMc0/8AhF9XHXx34g/78af/APItRRaFfT2i3UHxD1uS3Zd6zJHpxQr67ha4x70bIDX0fSZrGS5u7+5jutQu9nnyxQ+VHhRhVVCzEDqeWY5J56Aadcdpmnya3am50b4marqEAYoZbT+zZVDDqMrbEZq7/wAIvq//AEPfiD/vxp//AMi0AdJRXN/8Ivq//Q9+IP8Avxp//wAi0f8ACL6v/wBD34g/78af/wDItAB4o/5GLwZ/2GpP/TfeV0lcJqejX2neLfB8t54l1TVUbVpVEN5Haqin7BdncPKhRs8Y5OOTx0x3dABXN/Dj/klnhT/sC2f/AKISukrzvwD4j1SD4beGoovBeuXKR6Taqs0U1iEkAhUBl3XIbB6jIB9QKAPRKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA4jThe2Xiey0jSdXt9SsLyWeaCKS3VdS0MyI7ebyCGjyWGXXncBlu8Hh7W/Gl7qWkW2o65f7Lz7Xp07paWylLuCXmVf3P3TGr8HjI9a77/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5Kpp2t/X9f12B6/1/X9erPL9c8VeIdW8K+PRrd5p9vZWtrd2r6fJOBcQMDthYJ5SkB17tI4YkbQvSubn8X2VnNrt5pOu6fl7nQ0xugnSZRGFkGHDD5SCcrgqV6jFe6f8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVEXytfL8Hf8AEJa3+f42/Kx5zB8RdWh8cG1k8SwT2X/CVPpggkWAKIGg3AFlUNkPwDn1B3Vq/DnxNrniPxfIL7xTa3ttDbyGayt7mydWl8wgGNY1MwiC45kKtu9Qa7A+J9XIx/wgniD/AL/6f/8AJVcn4e0BPDmuSata+BPEU10wYJJKNHV0DdcyRyrJIT6yM575zzRHS1+36W/4IS1Tt/Wrf/APUaK5v/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSqQHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAFj/AMlT13/sC6b/AOj76ukrzuz8R6oPiTrMo8F64ztpNgphE1jvQCa8IY/6TtwdxAwSflOQOM9B/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAG7fTT2+n3E1pbNdTxxs0cCsFMrAcLliAMnjJOK878C37WHjDxR/bGn3mmGZrR57nUJ7cAzMu0KdkrcsSNoGRgAcHAPT/8ACUav/wBCJ4g/7/6f/wDJVH/CUav/ANCJ4g/7/wCn/wDyVQtHcHqZCXsd58U7IaPe6PqVnbR3ENxb2YBn06RuWeRlcj5mXbtKqcnvzXd1zf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVHSwdbh4D/AORduv8AsNar/wCnC4rpK878F+I9Uh0G5WPwXrk4OrakxeOaxABN9OSvzXIOVJKntkHBIwT0H/CUav8A9CJ4g/7/AOn/APyVQB0lFc3/AMJRq/8A0IniD/v/AKf/APJVH/CUav8A9CJ4g/7/AOn/APyVQBL4wkvho4gsNMvdQjnfZcrZSwpIsWCTgyyIOcBTg5AJIrD+GuoWMvwp0Sz1SOO0/wCJXlra8kiPmwKoDSbQx/d8jOcYzyBWv/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUdGu//BHfYpfCi5srn4aaZ/Zs0EsEXmxjyGBVMSN8vHA4xx9K7Gub/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KpvVkpWVjpK5vwv/AMjF4z/7DUf/AKb7Oj/hKNX/AOhE8Qf9/wDT/wD5Krn/AA54j1SPXvFjJ4L1yUyatGzIk1jmI/YbUbWzcgZwA3y5GGHOcgIZ6JRXN/8ACUav/wBCJ4g/7/6f/wDJVH/CUav/ANCJ4g/7/wCn/wDyVQB0lBOAcDPtXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHJaLqV1bfFe5vtd0W+0x5tHZ7q4vLi28qCNZSQcrM2IwBtzjOckgZJrtb9YrzW9MsbcJ5O9tQnKAbXC4CZ9y7KwP8AsVX/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqhaJLt/m2D1bff/JI6Siub/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KoAPC/8AyMXjP/sNR/8Apvs66SvO/DniPVI9e8WMngvXJTJq0bMiTWOYj9htRtbNyBnADfLkYYc5yB0H/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQBmeJLnSbX4seETcS2cWoSx3USl2VZXUoNq+pBbOB61zXhi7sYviKluhWWGK81CRLV2C3WmSMxLyTDH+qkwShOMbh97I29x/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlULT8RPVW9DD8VarbX+taJH4f1HRNRk+221zcaYhElxPGWUJOrI+QqKd+SpBAHOOD6BXN/wDCUav/ANCJ4g/7/wCn/wDyVR/wlGr/APQieIP+/wDp/wD8lU+lh9bnSVzdj/yVPXf+wLpv/o++o/4SjV/+hE8Qf9/9P/8Akqufs/EeqD4k6zKPBeuM7aTYKYRNY70AmvCGP+k7cHcQMEn5TkDjKA9Eorm/+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKoAl8YSXw0cQWGmXuoRzvsuVspYUkWLBJwZZEHOApwcgEkVx3hy+srj9n63sNStLlS2hOPsMUkZuJ4VTaXjVWY4+YcnkZGR2rrP+Eo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqjo13/AOCUnZp9jD+GN5HeXOsSCe11GX/R1OqWDAwXKCPCLgDAkQAhhzyQeMhV9Arm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5Kpt3dyIqysdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVIYeKP8AkYvBn/Yak/8ATfeV0lcJqes32o+LfB8V54a1TSkXVpWE15JasjH7BdjaPKmds855GODz0z3dABXN/Dj/AJJZ4U/7Atn/AOiErpK5v4cf8ks8Kf8AYFs//RCUAdJQc4OOvbNFFAHmza/48HxDXwr9v8O+a2lHUfO/sufaCJNnl/8AHx0/2v8Ax2umufHnh2xS/N5qBX+zo2kuWS2lZQEIEhQhSJNpIDbM7e+KqnwfqJ+KS+Ljq9r5C2RsBY/YW3eUW3583zcbt3fZjHGM81if8KftIdL8SWVlcafC2teeIr1tLVrq3WY5dGlDgyLknaPlxxknFH2V6P776fhYrTm+78tfxOng8d+G7iyvruLUh5Wn+X9o3QyKy+YAY8KVBbcCNu0HOcDJrA8MfEf7WfED+IXjSHT9U+x2n2WwnWaZTGHAMPzyFwCcgAfdJIGDVb/hU9xImrfadejZ79bF4misSnkzWoXYxBlO9SVyV469e9Q3fwcOoXF7dajq1ldz3GrJqiJPpXmQB/L8t43iaU70I6cgg9zVaXf9dV/wSFsr/wBaP9bHWf8ACfeGjqS2Cag0lw8MNwix20rh45WCo6sFwQWIGQeO+KbpXxD8L61MkdhqeWkillXzreWEFYm2ycuoGVPUdR1xiotL8GvpPjOTWbS7tIrNtMj0+OwgsfLEQRiwIYPgDLN8oUcY54yeXsvg3NEtpDqGvw3NtFBqEEyR2DRtKl225sN5p2lT0ODxU+nn+tv0K/4H/BOvbx94dFl9qF3OymXyhEljO0zNt35EQTeV2/NuC4xznHNXbTxNpV9rMml2k8stzGuXK20vlg4B2+bt2bsMDt3bsHpXM2Pwxh0/weujWsmlwXC4/wBMtdJWBmKjasp2OG80KT84YcnOMZB27PwvLaeJ01YahkCAxSosOx7lsABpWDbXwAMZXcOfmwcU9L/1/W5OtjoaKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooA5ux/5Knrv/AGBdN/8AR99XSVzdj/yVPXf+wLpv/o++rpKACiiigCrql8NM0e8v2jaUWsDzGNOrbVJwPfiud8LeJdQ1LVBZaq9hMbnT49StpbFWVVjc42MGZskcfOMBsn5RiupmV3gdYWRZCpCs67lBxxkZGR7ZH1rnNB8HR+HUuLjTzp8WpXRQTzQ6eIoQitkokSsNoO5zksx3NklsYojvr/W//A+7zB7af1t/wfv8jN0/xdrV54+l0hoLMW8VzJFNaeU63EEKplLkuW2sjnCgBRyfvHaRXcVx9v4Fmi8WQ6rNqwlgt7ua8hQ2uLjdKpVo2m3fNEM8JtB+VeeBXYU/soH8Tsc34D/5F26/7DWq/wDpwuK6Sub8B/8AIu3X/Ya1X/04XFdJSAKKKKAKOqpqklqq6JcWdtOW+aW8t2mRV/3FdCT0/iGPfpVPw/e6rfeFxd3rWdxeP5hheGNoIpVDERtgs5UMAD1PWtK/t5bvTbi3gn+zyzRMizBd3lkjG7HGcVEtpcW0cVvp8tvDaw25ijjeAsVYYCHIcfKADlcZPHzDHK6MfYo+D9ZuvEHhOy1O/ihhubgMZI4CSikOy4BPJ6df0FbdYnhDQrrw34ag0q9vor54GcrNFbGAEMxbG0u/Iyec1t1T3JV7ahXN+F/+Ri8Z/wDYaj/9N9nXSVzfhf8A5GLxn/2Go/8A032dIZ0lFFFABRRRQBw/hfxbrWteKriyu4LMW8RnWe3jidJ9PKOFj8xmYh/MXLKQq8DjcOakvPHSt42XQbOaG0iguI4Li7urWaRJZWAbyEZcIj7SOWbqcBW5pdM8C3umaz/aC6zDNJbxTpZu9ifM/etuPnuJP3wVuQAE+ueanuPBL3OrSyyaip065vYdQuLM2+WNxEE2lJN3yoTGpK7Scj7wyacbXjf+tf8AL9BPZ2OsooopDOb8L/8AIxeM/wDsNR/+m+zrpK5vwv8A8jF4z/7DUf8A6b7OukoAKKKKAOa8Sanr2kXVpdWSWNxYPeQ20loYnNxIJGCl1fcFXbknaVbIU8jtHYeI7uX4g3OgzX2kXCR2xne2tmIuLQ7lCB8sd+4EnhV24Gc5BNnUdI1668QRXtpq+nRWcQAS3n0x5ZIzyHZXEygMQcAlDgduTkh8P3sviFNY1e9sri4tY5YrL7NYtD5aSYyHJkcuflHTaOvHTAtN/P8AL/PUH/kVvEHiK70jxPo9kl9pEaX9wIlsbgkXE6/xOjbgBt/u7W3dMgmuprm9R8Oajrk1rFrd/YTWFvJBcGGDT2jlM8bBgwkaVgqlh93bnHG7uekp9P6/r+vkHUK5ux/5Knrv/YF03/0ffV0lc3Y/8lT13/sC6b/6PvqQHSVDdi5NnKLBoluSpETTKSit2JAIJA9ARn1HWpqKAOGvvEHijRvD/ia+nk0jVJdHhDxGO2ltELBN8itmSUnClcYxknBx1rsIbtf7LjvLlljXyRLI3QKNuT+FY2q+F57/AMFapodvqEcM+pLMst3LbmQDzSdx2B16KcD5uMDrjFWm0Se70W30vVLqOe2Ft5V0bdJLd5XG3ayOsm6McHjJPI5GOTp56D00+f6W/UqeEfEd14ibWTd2gtBY6gbaGM53mPyo3Bf/AGjv6dunbNdHXN+FfBlt4UvNXntr28uf7SuhOFubqabywEVduZHbcflJ38EggdFFdJTdtLdl+WpKvrcKKKKQzm/FH/IxeDP+w1J/6b7yukrm/FH/ACMXgz/sNSf+m+8rpKACvO/APgrS7r4beGriW61xXm0m1dhFr99GgJhUnaizBVHoAAB0Ar0Sub+HH/JLPCn/AGBbP/0QlAFKfw54VtdQjsLrXdVhvJUMkdtJ4qvlkdR1YKZ8kD1q7/wgekf8/niD/wAKPUP/AI/XH+M5bjSfEGo3+j39rdG7kiiu/DupQ86gyquDav8Ae3hSOAGAIyccmta2k8UR+Jta0y81m98q3C6hZ3TWsBiMLKw8hwsYJ2upPB3EAfMOcnS/9f1b+ugdbf1/V9Da/wCED0j/AJ/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/H689vde1m5svD8Nx4lvUx4jSz1C9jFsYgfK3BUkEQRlEgAG5QwJKsMgVS1jx/4xi0PxhqR1ay0s6U0sSWhkja4t3WUCFvKaDAWRc5LO+7I27elP+vwX+Y0m3b+t2v0PT/8AhA9I/wCfzxB/4Ueof/H6ig8G6BdeZ9m1PXJvKcxyeX4mv22OOqnE/BHpXk158UNZtdevWXxnG9ta6lpkcUBS02TwzqrTZPl7iF5wQRgHkmruj+OtTeymgXX4LKzuPE95Zz67FBbf6OgTMJbCeWd7YG9hz0zkgh8r/r5f5k3Vv67N/oehat4f8JaDbpPrniDU9NhkbYkl54rvYVZsZwC1wATgHijStA8Ja9bvPofiDU9ShRtrSWfiy9mVT6ErcHBrG+M96ln8Hyl/qVqLqWe0VJpAI1mcSoxYIW6YBbAPAB54zXMSeK7rQLvxVqlx9kl8YTW0H2U2rbbW9sQ3y3EK/OWKqXZuXI2+lSuv9dv69Neg+it1/r+vPTqen/8ACB6R/wA/niD/AMKPUP8A4/R/wgekf8/niD/wo9Q/+P15/wCIPGfiTTPBltKviK3bUWtLu9tpdPSO5jvI4lVl3StEqnhsFY41J6gpg1tW3inVtY8bW9g+tx6NEbC1u7SBYI5F1QOpMwUsN2VO0DY3HVgwNO39ff8A5CurX/rp/mjoZfBugQTQxT6nrcck7FYkfxNfhpCASQoM/JwCeOwqX/hA9I/5/PEH/hR6h/8AH68g0TxXrNpH4Kkm1s6pqN7eakZ9PvI7YskyrJtRT5YkjJYgfez82OmBWhcfEXxJH4G12+i1oPJa6Rb3jXvlwf6FfO+Hs9uzbwMDawLjPJyRRbT+v6/rzKtrb+t7Hp//AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9cDB431m8h8R28fii3VdLvoH+0j7Okv2Z4A7BGZDEPmyFLrg427gSGHq+lXBu9Hs7hjKxmgRyZo/Lc5UH5l/hPqO1Fv0/FXJujG/4QPSP+fzxB/4Ueof/AB+j/hA9I/5/PEH/AIUeof8Ax+ukopDOb/4QPSP+fzxB/wCFHqH/AMfo/wCED0j/AJ/PEH/hR6h/8frpKKAOb/4QPSP+fzxB/wCFHqH/AMfo/wCED0j/AJ/PEH/hR6h/8frpKKAOb/4QPSP+fzxB/wCFHqH/AMfo/wCED0j/AJ/PEH/hR6h/8frpKKAOb/4QPSP+fzxB/wCFHqH/AMfo/wCED0j/AJ/PEH/hR6h/8frpKKAOb/4QPSP+fzxB/wCFHqH/AMfo/wCED0j/AJ/PEH/hR6h/8frpKKAOSj+GuiR6rPfi98QebPDHCw/4SC9HCM5HzCXcf9YeCSB2AJYtZ/4QPSP+fzxB/wCFHqH/AMfrpKKAOb/4QPSP+fzxB/4Ueof/AB+j/hA9I/5/PEH/AIUeof8Ax+ukooA5v/hA9I/5/PEH/hR6h/8AH6P+ED0j/n88Qf8AhR6h/wDH66SigDm/+ED0j/n88Qf+FHqH/wAfo/4QPSP+fzxB/wCFHqH/AMfrpKKAOSsPhromn2zww3viAq00sx/4qC9TmSRpDwkoHVjzjJ6sWYkmz/wgekf8/niD/wAKPUP/AI/XSUUAc3/wgekf8/niD/wo9Q/+P0f8IHpH/P54g/8ACj1D/wCP10lFAHN/8IHpH/P54g/8KPUP/j9H/CB6R/z+eIP/AAo9Q/8Aj9dJRQBzf/CB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wAKPUP/AI/XSUUAc3/wgekf8/niD/wo9Q/+P1Wtfhrolpc3s0d74gLXkwmf/ioL1cERpH1WUFuIxyxY9s7QoHW0UAc3/wAIHpH/AD+eIP8Awo9Q/wDj9H/CB6R/z+eIP/Cj1D/4/XSUUAc3/wAIHpH/AD+eIP8Awo9Q/wDj9H/CB6R/z+eIP/Cj1D/4/XSUUAc3/wAIHpH/AD+eIP8Awo9Q/wDj9H/CB6R/z+eIP/Cj1D/4/XSUUAc3/wAIHpH/AD+eIP8Awo9Q/wDj9H/CB6R/z+eIP/Cj1D/4/XSUUAcla/DXRLS5vZo73xAWvJhM/wDxUF6uCI0j6rKC3EY5Yse2doUCz/wgekf8/niD/wAKPUP/AI/XSUUAc3/wgekf8/niD/wo9Q/+P0f8IHpH/P54g/8ACj1D/wCP10lFAHN/8IHpH/P54g/8KPUP/j9H/CB6R/z+eIP/AAo9Q/8Aj9dJRQBzf/CB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wAKPUP/AI/XSUUAc3/wgekf8/niD/wo9Q/+P1Wj+GuiR6rPfi98QebPDHCw/wCEgvRwjOR8wl3H/WHgkgdgCWLdbRQBzf8Awgekf8/niD/wo9Q/+P0f8IHpH/P54g/8KPUP/j9dJRQBzf8Awgekf8/niD/wo9Q/+P0f8IHpH/P54g/8KPUP/j9dJRQBzf8Awgekf8/niD/wo9Q/+P0f8IHpH/P54g/8KPUP/j9dJRQBzf8Awgekf8/niD/wo9Q/+P0f8IHpH/P54g/8KPUP/j9dJRQBwmp+GbHRvFvg+4s59UkdtWlQi81a6ukx9guzwksjKDx1Az1GeTXd1zfij/kYvBn/AGGpP/TfeV0lABXCeE9T17QfBeiaReeB9ce40/T4LWVoriwKMyRqpKk3IOMjjIFd3RQBzf8AwlGr/wDQieIP+/8Ap/8A8lVQ03VNV01rhv8AhD/FV208rSbrm709zGCSQin7SPlBY4ByRnGcAY7OigDm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KrpKKAOb/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqukooA5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+Sq6SigDm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KrpKKAOb/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqukooA5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+Sq6SigDm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KrpKKAOb/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqukooA5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+Sq6SigDm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KrpKKAOb/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqukooA5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+Sq6SigDm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KrpKKAOb/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqukooA5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+Sq6SigDm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KrpKKAOb/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqukooA5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+Sq6SigDm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KrpKKAOb/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqukooA5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+Sq6SigDm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KrpKKAOb/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqukooA5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+Sq6SigDm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KrpKKAOb/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqukooA5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+Sq6SigDm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KrpKKAOb/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqukooA5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+Sq6SigDm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KrpKKAOb/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqukooA5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+Sq6SigDm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KrpKKAONubnWNe8SeG2bwrqmm2+n6hJdT3F5NaFFU2lxEABHO7ElpV7etdlRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGbq+g2mt+T9tm1CLyd237FqVxaZzjO7yXXd04znHOOprN/4QPSP+fzxB/wCFHqH/AMfrpKKAOb/4QPSP+fzxB/4Ueof/AB+j/hA9I/5/PEH/AIUeof8Ax+ukooA5v/hA9I/5/PEH/hR6h/8AH6P+ED0j/n88Qf8AhR6h/wDH66SigDm/+ED0j/n88Qf+FHqH/wAfo/4QPSP+fzxB/wCFHqH/AMfrpKKAOb/4QPSP+fzxB/4Ueof/AB+j/hA9I/5/PEH/AIUeof8Ax+ukooA5v/hA9I/5/PEH/hR6h/8AH6P+ED0j/n88Qf8AhR6h/wDH66SigDm/+ED0j/n88Qf+FHqH/wAfo/4QPSP+fzxB/wCFHqH/AMfrpKKAOb/4QPSP+fzxB/4Ueof/AB+j/hA9I/5/PEH/AIUeof8Ax+ukooA5v/hA9I/5/PEH/hR6h/8AH6P+ED0j/n88Qf8AhR6h/wDH66SigDm/+ED0j/n88Qf+FHqH/wAfo/4QPSP+fzxB/wCFHqH/AMfrpKKAOb/4QPSP+fzxB/4Ueof/AB+k/wCED0gdbzxB/wCFJqH/AMfrpahvYDdWFxbq5jM0TIHHVcjGaTbSuhrfU85RfDs8M95aW3jO60qHeDqcOv3phYqSCFBuhIwyD8wTb33Y5rqP+ED0j/n88Qf+FHqH/wAfrH8C6hd6D4V03wvqGjaimq6dALb5bSQ20wX5RILgAxhSBuwSGH93PFYJ0e7l17Nxpl9H4ih1l5pdWjtpdsmnFydgnUYK+WQgiB3BhkL/ABVTtey27/1/SRPS/wCH3/8ADHaP4G0aONne98QBVBJP/CR6hwP+/wDWBoNho3iG4UWlj41htJIhPFfXGv3iwyxsMoykXRY7v7uNw/iC5GeL0mys9Ps9J+0+G9bkE1lqVvf+bod3M0qvLugWXMZLdyM5xknjNX/DtjNp6eFY9A0XUtOvB4dubeYNpdxBDHeFY9pkBQIrFlf5zyeOSCKOjf8AXX/JfeUtbL+un+Z2Q0Lw6fFR8Pi48UC7Fp9r3nXtRERTcFwHM+CcnoM4744rU/4QPSP+fzxB/wCFHqH/AMfryy50nUWhLeEPDGsaddS6IYb+YWvku04mjaUFpMeZIyq4DgMGJHJHSxH4Y0ay1Lw2bOz8UX2nSajJLc295o8sVvCjW7owNvFAiKC3l5ymDkkEgtTtp/Xd/oSne/8AXRP8z0KXwn4fhvorF9R177XNG8scA8SahudVwGI/f9AWUfjUlt4I0ue1illk8SWzuoZoZfEl8XjJ/hO24K5HsSPevNtM0SGeHRry/wDDep7LTStTtA7aXOlxAfNUwBflEi4jLbSPcA54pNRs7m+8G6CieF9Q/tXT9Is2jvbjTrl5YnjkUSRxrgeU42kljguCMBwOBLT+vP8ARXBvS/8AXT/M7OxsPDGoQ61JDceKkXRbh7e587XdRQsyoHO0GfJGGGDxntxg03xHpmk+HV08tY+MdQN/MLeMWfiS5BSRvuq3mXaYzzyMjjkjjLfDxn1DxN4jt/7P1CC3utcjuDLc2UsCSRR28YypdQGBki28duehFXPic0j2miW9uNXST+1IZmuNLsJLl7dEzufiN1GMjhgc88HBpNfD58v42v8Am/uG/tW6X/Wwzw7o/hzxLZ3EtpP4nt5bWdra6tbnxDfrLBKoBKsBcEdCDkEgg5BNa/8Awgekf8/niD/wo9Q/+P1yGo+BtH0/xj4dgmstS1pLy6urjUZ7u3kuIZWeLaHmCp5KnIUDKrgDsKzJdAublxDJpl/a69DfXTalqaRSxLPYkS7VFwuAy7TGFQNlCOgxmk2kr/15/wBdgWrt/Xl/Xc9C/wCED0j/AJ/PEH/hR6h/8fqFvBOmLeRwhvErRsjMZx4lvdiEEYUg3G7JySMAjg5I4z5KdH/tH4cx3Oh6RrERfwsIL829pcI99dERfZ8bRmbGHywyoU4JxxXReItJuLfVVj8E6VqNjNdeGrhY2trKaGJZmeNwMlQkcrBZMlsNnG7nAq5R5Xb1/C/52EndJrr/AMD/AD/A7a88I+HrCON7zUtehWWVIULeJNQ+Z3OFUfv+pJqx/wAIHpH/AD+eIP8Awo9Q/wDj9edr4M0hvDdvJaaZrOpWzatZXFxZ6poyRCDDYk2QJBH1U/OwUg9cnmo5bBm8Q3t7D4Z1PSre6sNStrtbWzumuJZN6GMvKgy+Rkptyqj5Qx6CHon8/wAEn+eg46u3p+bPSP8AhA9I/wCfzxB/4Ueof/H6y/Efh/RfDfh681iYeKbyGzjMssVr4jvfMCDlmG+5UHA5xnPpmsGHwrZaV4O8N+JdE8N2kWu2kMMUyzWQgmmMiCFg+5Q24MwOTzwR0PPQeJtGt/Dvwa1PRdIsJHA02S2ht7CzaRpJXQjISNSeWOScYGSTRNcqdug6dpuN9n+BNpPhPSdV0m2vifE9n9ojEgguPEl75ig9M7Lll6c8E9az7rTNCg8RLpEMXjC8cNGtxcW2vXzR2pkzs8z/AEgNg4PKqwH8WM1wup20d62uX0Og+IZrn+ydP+xmbSL0tHdROwbygyfIVBTlcDliOrVq3lhHd654tvNA8N3sN5cNaSic6NLbPdQBlN1Gkrxr8zjIK5BY+vWrkkpaERbtb0/I9B/4QPSP+fzxB/4Ueof/AB+j/hA9I/5/PEH/AIUeof8Ax+vOdQ0K2aaOTT9D1SHw7NrNlJbaZHptyiJtz9odrcL8kZG3hlAJBIHOTVm0SxsL/U0sPD2sRiDxRayWbR6VdkR222NZvLYJxHhZVIXjbtHTbSjG7t/X2f8AP8Bt2Tfl/n/l+J6h/wAIHpH/AD+eIP8Awo9Q/wDj9U5PC2gLc3FpBe+ILi9t4BO1rF4lvt5U7gv3rgAZKkDJA4rhn0+C40W90NPCF1LanVr0Wa3Wl3H2a1Vk/dssIUBgTnaeFU87lJGaTaBM2gatfXegakdTuvCFpFHcRWEwuTdKJFdSyrvDbvKBHcAZyoOJWseb0/FX/AuKvK3n+qR6gngXSXjVmufESFgCUbxJf5X2OJyPyp3/AAgekf8AP54g/wDCj1D/AOP1wGoabeanJemTSNQbWbgWsnh3UGsZR9iURoGUuVHkYcOWV9u4HHzdKhsrOKw8SRXsOja4bpfFcji7k027dxatDtY72Qnyy2O+OAe3FW9639bpfrr6Gd9L/wBbN/oei/8ACB6R/wA/niD/AMKPUP8A4/R/wgekf8/niD/wo9Q/+P10lFSUc3/wgekf8/niD/wo9Q/+P0f8IHpH/P54g/8ACj1D/wCP10lFAHN/8IHpH/P54g/8KPUP/j9H/CB6R/z+eIP/AAo9Q/8Aj9dJRQBzf/CB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wAKPUP/AI/XSUUAc3/wgekf8/niD/wo9Q/+P0f8IHpH/P54g/8ACj1D/wCP10lFAHN/8IHpH/P54g/8KPUP/j9H/CB6R/z+eIP/AAo9Q/8Aj9dJRQBzf/CB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wAKPUP/AI/XSUUAc3/wgekf8/niD/wo9Q/+P0f8IHpH/P54g/8ACj1D/wCP10lFAHN/8IHpH/P54g/8KPUP/j9H/CB6R/z+eIP/AAo9Q/8Aj9dJRQBzf/CB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wAKPUP/AI/XSUUAc3/wgekf8/niD/wo9Q/+P1t6fYQ6ZYR2ls9w8UedrXNzJcSHJJ5kkZmPXuTgcdBVmigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiuf8AGXiC/wDDWix3+nadb6gWuYoHjnu2t9vmOI1YERvn5mGRgcZPPQ0tM8fWZk1a38VfY9AutImjiuTNfK1ufMXdGUlYJnI7FQc9qN/6/ruB1tQX1lDqNhPZ3XmeTOhjk8uVo2KkYOGUhh9QQap6j4m0HR7aC51bW9OsYLgZhlubuONZRjPyliAePSlh8R6Jc3ltaW+safLc3UQnt4Y7pGeaMjIdFByy47jii19AvbUl0fSLPQdHt9L0tJI7O1TZCkkzylF7Dc5LYHQc8DgcVdrnvFfjGw8Kx20dzJB9rvGK28dxcpbxnGMs8jcKoJAzgnJAAJOK147sxaWt3qjW9qViEk5WfdFHxk4kYLlR6kD6Cm237zC1tC1RXL+IPiDoOieGotZj1PT7qG6mWC1cX0axSuzBf9ZkgKucsRnABODS3/iu/wBL+H9x4ju9CaSe3haZ7O1vI5FZFJ+dZTgFCo3Zxuwfu54pdLjSu0l1Nu40q0u9QgvbhZXltx+7Uzv5YOc7jHnYWHZiCR2NXKwtX1vU7TS0utI0db9hB9plSS58lVTGSqttbc/oDgccsOM6Wk6lBrOjWep2e77PeQJPHuGDtZQRkfQ07PXyJutH3LdFFFIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAch8TdOv9Y8H/wBnaZpN1qbzXdu0kdtcRwskaSq7Hc8iYOFIG05yR06ipqHhdtKsbJfC2hb5Lu6Ml9cXMqXN5BuiZd/mTudzDIUnc2FJADV3VFLo13HdniUmgawujaRoJ0q4e5h8PfYNWhh+yzOkLPgY33EaoTsYq4L+6cCtrQ/Cv2nxRLqN9oup31pdXsOp6dejVmjhtx5aALLAJgC67TghHDAgE16FqPh7RdXuoLnVtIsL6e3OYZbm2SRojnOVLAkcjtWiBgYHAq+Z3v11/O/5/wBaieun9bW/r/gHH+JtJv8A/hJo9Vs9J/tiCfTZdOmtlkjVo9zBg/7wgFDyGwc9MA1Bf+FdTtvhjo+jWZW/vdJNnI8TuFF35LKzJk8DO3jPGcZrt6KlaKy9fubf5tg9Xd/1ol+SPLNU0LX2ivNRs/Dl2z6jrtlfnTkntg8CQeWXdyZQm99h4Vm/hyRzjsvHFvfaj8PtYtNM0+a7vbyykgitkkjVtzrt5LMFwM5PPY4zXQ0UfZ5f62S/QcW1JS6/0zktTvNYGgafZQ+GdUnS4twl6tvParLAAACmWnUZP95ScD3rpNNLf2Zb77P7CfLAFqWUmEdlJXK5A9CR6E9as0U273JSskuwUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUV5B/wlGt/wDQSm/Oj/hKNb/6CU350Aev0V5B/wAJRrf/AEEpvzo/4SjW/wDoJTfnQB6/RXkH/CUa3/0Epvzo/wCEo1v/AKCU350Aev0V5B/wlGt/9BKb86P+Eo1v/oJTfnQB6/RXkH/CUa3/ANBKb86P+Eo1v/oJTfnQB6/RXkH/AAlGt/8AQSm/Oj/hKNb/AOglN+dAHr9FeQf8JRrf/QSm/Oj/AISjW/8AoJTfnQB6/RXkH/CUa3/0Epvzo/4SjW/+glN+dAHr9FeQf8JRrf8A0Epvzo/4SjW/+glN+dAHr9FeQf8ACUa3/wBBKb86P+Eo1v8A6CU350Aev0V5B/wlGt/9BKb86P8AhKNb/wCglN+dAHr9FeQf8JRrf/QSm/Oj/hKNb/6CU350Aev0V5B/wlGt/wDQSm/Oj/hKNb/6CU350Aev0V5B/wAJRrf/AEEpvzo/4SjW/wDoJTfnQB6/RXkH/CUa3/0Epvzo/wCEo1v/AKCU350Aev0V5B/wlGt/9BKb86P+Eo1v/oJTfnQB6/RXkH/CUa3/ANBKb86P+Eo1v/oJTfnQB6/RXkH/AAlGt/8AQSm/Oj/hKNb/AOglN+dAHr9FeQf8JRrf/QSm/Oj/AISjW/8AoJTfnQB6/RXkH/CUa3/0Epvzo/4SjW/+glN+dAHr9FeQf8JRrf8A0Epvzo/4SjW/+glN+dAHr9FeQf8ACUa3/wBBKb86P+Eo1v8A6CU350Aev0V5B/wlGt/9BKb86P8AhKNb/wCglN+dAHr9FeQf8JRrf/QSm/Oj/hKNb/6CU350Aev0V5B/wlGt/wDQSm/Oj/hKNb/6CU350Aev0V5B/wAJRrf/AEEpvzo/4SjW/wDoJTfnQB6/RXkH/CUa3/0Epvzo/wCEo1v/AKCU350Aev0V5B/wlGt/9BKb86P+Eo1v/oJTfnQB6/RXkH/CUa3/ANBKb86P+Eo1v/oJTfnQB6/RXkH/AAlGt/8AQSm/Oj/hKNb/AOglN+dAHr9FeQf8JRrf/QSm/Oj/AISjW/8AoJTfnQB6/RXkH/CUa3/0Epvzo/4SjW/+glN+dAHr9FeQf8JRrf8A0Epvzo/4SjW/+glN+dAHr9FeQf8ACUa3/wBBKb86P+Eo1v8A6CU350Aev0V5B/wlGt/9BKb86P8AhKNb/wCglN+dAHr9FeQf8JRrf/QSm/Oj/hKNb/6CU350Aev0V5B/wlGt/wDQSm/Oj/hKNb/6CU350AesfYbT/n1h/wC/Yo+w2n/PrD/37FT0UAQfYbT/AJ9Yf+/Yo+w2n/PrD/37FT0UAQfYbT/n1h/79ij7Daf8+sP/AH7FT0UAQfYbT/n1h/79ij7Daf8APrD/AN+xU9FAEH2G0/59Yf8Av2KPsNp/z6w/9+xU9FAEH2G0/wCfWH/v2KPsNp/z6w/9+xU9FAEH2G0/59Yf+/Yo+w2n/PrD/wB+xU9FAEH2G0/59Yf+/Yo+w2n/AD6w/wDfsVPRQBB9htP+fWH/AL9ij7Daf8+sP/fsVPRQBB9htP8An1h/79ij7Daf8+sP/fsVPRQBB9htP+fWH/v2KPsNp/z6w/8AfsVPRQBB9htP+fWH/v2KPsNp/wA+sP8A37FT0UAQfYbT/n1h/wC/Yo+w2n/PrD/37FT0UAQfYbT/AJ9Yf+/Yo+w2n/PrD/37FT0UAQfYbT/n1h/79ij7Daf8+sP/AH7FT0UAQfYbT/n1h/79ij7Daf8APrD/AN+xU9FAEH2G0/59Yf8Av2KPsNp/z6w/9+xU9FAEH2G0/wCfWH/v2KPsNp/z6w/9+xU9FAEH2G0/59Yf+/Yo+w2n/PrD/wB+xU9FAEH2G0/59Yf+/Yo+w2n/AD6w/wDfsVPRQBB9htP+fWH/AL9ij7Daf8+sP/fsVPRQBB9htP8An1h/79ij7Daf8+sP/fsVPRQBB9htP+fWH/v2KPsNp/z6w/8AfsVPRQBB9htP+fWH/v2KPsNp/wA+sP8A37FT0UAQfYbT/n1h/wC/Yo+w2n/PrD/37FT0UAQfYbT/AJ9Yf+/Yo+w2n/PrD/37FT0UAQfYbT/n1h/79ij7Daf8+sP/AH7FT0UAQfYbT/n1h/79ij7Daf8APrD/AN+xU9FAEH2G0/59Yf8Av2KPsNp/z6w/9+xU9FAEH2G0/wCfWH/v2KPsNp/z6w/9+xU9FAEH2G0/59Yf+/Yo+w2n/PrD/wB+xU9FAEH2G0/59Yf+/Yo+w2n/AD6w/wDfsVPRQBB9htP+fWH/AL9ij7Daf8+sP/fsVPRQBB9htP8An1h/79ij7Daf8+sP/fsVPRQBB9htP+fWH/v2KPsNp/z6w/8AfsVPRQBB9htP+fWH/v2KPsNp/wA+sP8A37FT0UAQfYbT/n1h/wC/Yo+w2n/PrD/37FT0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVX1G5kstLurqC3e5khheRIE+9IQCQo9z0rlfC3iy71XS11e91HR7nSxbyTXM1orxNZOu0+VIrOxJA35Y7fu/dFHfyDt5nZUVzCfEfwq0CyvqhgL3KWqw3FtLDK0rAMqiN1DnIIIOMEVOfHGgDSItRW7mkhmkeNI47OZ5yyEhx5IQyArg7srx3xQB0FFef+IfiKy6nY2Hhee1b7VYyagL+7s7iW1MalcAyRgBAdxzISQmACCWFdJFqd1f8Agcanpd/Y3FxJa+dDdi1fyJDjORHvDbT/AL1D0i5P+v6sNK7SNyivNNA+I+oR3Gk/8JZNpj22qaMdVE9jBJEbUDZlHQvIWyXwGBBJGNtdXB440G4sluYbm4ZWna3Mf2KcSo643B4im9AAQSWAABBJwabTjv8A1rb8yU7/ANeV/wAjoKK5dPiBpH9valpsy3cI0+GGVrhrObZKZM4VDswzH5cAcsSQoODU9v468P3U0MVvdXDyzJMyR/YZw+YuZEKlMq4/uHDcjA5FLYZ0NFc3p3xA8Navd29rpd/JeT3EaSrHBaTO0aP91pAE/dg+r7a6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAhvEuJLGdLKRYrlo2EUjDIV8cEjvg1xjeFNcfxLea7aLpOk6gbCW2juLUu/22RsbJJ1KKBsK8DLn5j83Y9zRR5jueXHwP4tXUWutul3DXF/Y307XGqTMytAMMqnyMHPbAUD+6Ksab4Q8Wabqo1qOLR2vo7y9dbU30vlSQ3Lq5Bk8nKurIv8LAjPSvSaKFpt/Wy/JE2/r7/wDNnnWl+DPEOga3p82nxaXdWtrp1zbyNNeSRO0s8omYhREwChlwPmzg57YOz4e0XW9H+F9tok0OnyarbWf2ZQt0/kOQMBi/l7hxzjYfT3rrKKHrFxe3/Dv9WUnZ3Rwnh7wVfeG/hyLDRLDRNI8SfZUgku7NBsnZMDez+UGJYZOSrbSf4u+anw/11LfUv+PNri41Br62uBqtyk9u7RRIT5oTJwUb5SCrDaMKOB6bRTbbbb6/8P8AoSlZJHm/iH4eavrcl80s+m3hmSwlH2xCUuJrctuSSPaR5b7uvOM/d4q9F4Qv7KbRrzRdH8P6RJZzzNPYWbMkG2WMIXDrEu5wQDyi5HGRjNd1RS3v5hZHnvgLwf4k8N6xE+stpU9rDpaWKzWksgkJWRnBKMmMfORnd2zgZwPQqKKdxvV3CiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBFcic2sotDGs5U+WZASobsTjtXI2974k0/UvEFgks2vi1tI57OR44Y5BM+/MORsQgbVYZwcNyTwa6XWri9ttFuZdKtpbq8CYhiiVGYsTjOHkjUgZyQXXIBwc1wmlX/j3T7O4SfQbyed1zHKthZoDISMySg6kS5wMAKyAfQAA7jNXTdRkufCd/KniHXWntZSt2Z9Oha9tWCgmNYo4dpPIIO2QEHgkEEavgjVJ9Z8G2F/eXcd5NKrbpo1C7sMQNyjhXAADAcBsiubjv8Axfa2c8th4Z1NdVu5llurm4t7KSFsIF2pEuoKVGAMZdu+c5qXTmvbDw/LpR8FeKGS4llmnmivbKCRpJHLuVaO7DJyTjB4HFPv8v6/r8Rdv6/r+tjvq53xjb6odHuL3StcutKFlazTMttDC5mcLlcmWN8KMHgYJz1rmP7L/wCpQ+IH/hVf/fGtLXdV8Qal4bu9M07wfrlpLcQGBZ7hrGcIpGCSv21Sxxnkt15OelRO7i7blQspK+xha3ceJNG8F6Zrb+NNXdbuWxEoSwtJHUSuBJtVLcluGG0AE5HfOKkg17xDd/DHxPrNprlw9tbRyXOi6s1vAs9xGke4+ZH5ewDeCv3FbA6A81DqNv4xvvCOjaPHoOpRT6bNBK9ybOyZZvJYNGAn9ojb90bvmOecYqrqekeLZLPW9N0LQ9V0/SdaR/OtJ7Sxn8h5FIkaJhqCbQxO7aQwBJPetJ2tK3d2/C36/wBMino4uXlf8bjNY8Q6roF5FHqPxFu7VptEF/bJd29lie43f6oKIVZgf7qkN6Guq1jXvEs3w70+fTIlsfEl3ZC7eB493l7EEkibW6ZOI/YuD2rD0OPxtp3ia11TUdDv7uKCwFgYILGyhLIDkNuOovhs4zxjHYdatX9tqGueIpr3xN8PrrWLBYRHZWd3ZadI1qerNva9YHd3wq9F9DlPbT+tXb9Ajo7vy/JX/U1tQ8Wz6tceGdN8OXItn8Q273ZvdgcwQIgYlA2VLkuoGQQOSQelVvGS+JPD3hHUL2DxTdlbVIWinFpbtcMfMIcOPKKMCGXG1FOVHXJzy+meHPEun6XYRDQ9aW+0i4ll0q5t7awjW3jkzugeM3zb4+QAAVICjnjNauu/8Jpr3hmbT7jQ9US7uGTzZltbLyQituwkX9oZBJAyxdu+AOxK3QFfZ/1/w5NeanqS+DfE1/pPivxC82n2RmjbVNJhtnjkVWcbVe3QlSBg5Q+xBzXfaMs6aJZi7u5byYwqXuJlRWkJGckIqqPwArzjVpPiDrmg6lpmoaTeKt9atbA2+m2SBA/DMQ2pMSduQMEAE5IPSr2kaj46try1OsaFqV1aWsZVbeytLK2MjY2guzajJkAZ4AHJB7UaW/rzG9l8/wBLfqejUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVSA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqgDpKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqgDpKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqgDpKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqgDpKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqgDpKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqgDpKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqANTX9Xi8P+HNQ1e5VnisbaS4dV6sFUnH6VySalqNhodhr3iLxtZaY+oeVILS8FvFZorYZo42YCQtsyNxc85O300r7W7/AFLT7iyvfh/r01vcxtFLG0+n4ZWGCP8Aj69DXGDSfFY0e00B9G1ufQrSWF4oprewa6CxOronnC+CkAqBkx5x3zzTjvr5f8H9A7fP9LfqdPoOqap42udQ1PTtbk07TLO+ktLSK2hikFz5eAzys6sSpbOAhXjvzwy11DXtd8TXXh0awdOOjWlub+9soIzJcXEgJwglVlVAFyflJ+bGRjnKgi8T6RrF7ceGvDutWVlqNwbm6s7mHT5wsjY3PEwvU2FsZO4OM847Ut1B4jg14634b8Oa/Y381ulvd/bVsLqK6VM7WZReowcZPIYDBxg8ULp/Wtg7/wBdf8juUTWrPQ73zJYdQ1BBI1qdnlq/H7tWA6HPBI+vHQcb4f1y/wBa0y8ij8VXaajb2cjX1ndWcMN3Yz/KV2oY8eWMOAWD5yPmNao1nXjpM9q/hPxKbmZGBulm08FGYYyo+1fKB2Ht1Jya566g8V3uqPqVz4e1V7yGzls7GT7LYDy1k27jLi//AHp+UYwUAyTipd7O3b9Bq1033MHS/irqOnaTBqKa4PFUTaH9svlMcI+w3ZKKkRaFFChmcjawLDaTmvT9P0rxHB9muLrxE15JI6Nd28lrEkKrj5lh2qHXk/xs/AxxnNcvY22qH4cx+Edf8G65qEC2Ys2mgNhBuRRhTg3jYYAA5z1GcDpVzw9d+MYbq1s9b0vWZ7KN0RJzDYwyAZxundLx94HBOyNScdDnFaSceZ2/rUhJ8qv/AFojvqKKKgoKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArifDlz438QeFdK1n+2/D9v/aNlDd+T/Yk7+X5iB9u77WM4zjOBXbVzfw4/5JZ4U/7Atn/6ISgA+w+N/wDoYfD/AP4IZ/8A5Mo+w+N/+hh8P/8Aghn/APkyukoIypB7+hxQBzf2Hxv/ANDD4f8A/BDP/wDJlH2Hxv8A9DD4f/8ABDP/APJledeA4LnUfiB4n0+8n8TXNtp2rmO1u/7cuDDaoq7hGyGYl8kfxKRg4J7V0EfxZur/AErWNQ0Twxc3ltp8Us8MshmhjnSJ9sg8wwbA/BKqpfIByVPFGlk+6v8AIdndrzsdL9h8b/8AQw+H/wDwQz//ACZR9h8b/wDQw+H/APwQz/8AyZWFq/xPl0oWCx6ML+XU082xSxlnnM8axq8hwkBIILhV4wepKVpWfjPUb/xjdaJbaB+7t4LW5aeS72OIpiQd0ZT5XXaflyc46g8U7O9ibq1y39h8b/8AQw+H/wDwQz//ACZR9h8b/wDQw+H/APwQz/8AyZRrms3Ojah/o19bXski7l0l0PnsBgZjMYLY9dyEZIyyiuX1y71m0+JXhfVJbrXNO069Hk3NtL5b2aM6HbCyISRLuwTIx2jGAeopLUb0TZ1H2Hxv/wBDD4f/APBDP/8AJlH2Hxv/ANDD4f8A/BDP/wDJlec+FtT8RXevy6ddajePc3NpLcxyrdvJBrEPnLiS33HFuyx7lwu3JdW54NbFze6xL4y8OeD7qbUdL069t7m7l3Xha6dEwEgM6sWyM5ZlcnoNx5JdtvP/AIP+X+dmD0v5HXfYfG//AEMPh/8A8EM//wAmUfYfG/8A0MPh/wD8EM//AMmVradp39nGSNLy5nh2qscdxKZWiAB/jbLNnrliT7+l6kBzf2Hxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmV0lFAHN/YfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZXSUUAc39h8b/9DD4f/wDBDP8A/JlH2Hxv/wBDD4f/APBDP/8AJldJRQBzf2Hxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmV0lFAHN/YfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZXSUUAc39h8b/9DD4f/wDBDP8A/JlH2Hxv/wBDD4f/APBDP/8AJldJRQBzf2Hxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmV0lFAHEz3PjeHxVY6N/bfh9vtdlc3fnf2JP8nkvAm3b9r5z5+c542988aX2Hxv8A9DD4f/8ABDP/APJlF9/yVPQv+wLqX/o+xrpKAOb+w+N/+hh8P/8Aghn/APkyj7D43/6GHw//AOCGf/5MrpKKAOb+w+N/+hh8P/8Aghn/APkyj7D43/6GHw//AOCGf/5MrpK8ta6vbjx82qaithqMMOuLplvYyxOZrIbMrNGS20Mclidmdp+8AMULWVv63S/Ng9It/wBd/wAkdd9h8b/9DD4f/wDBDP8A/JlH2Hxv/wBDD4f/APBDP/8AJlZ/jzRY5JbPXpVtr42DoiadfW0c0UhaRQTHldyTdlIPoMV2lHS4dbHEwXPjebxVfaN/bfh9fsllbXfnf2JP8/nPOm3b9r4x5Gc553dsc6X2Hxv/ANDD4f8A/BDP/wDJlFj/AMlT13/sC6b/AOj76ukoA5v7D43/AOhh8P8A/ghn/wDkyj7D43/6GHw//wCCGf8A+TK6SigDm/sPjf8A6GHw/wD+CGf/AOTKPsPjf/oYfD//AIIZ/wD5MrY1e/Ol6Pc3iQTXDQoWWKCJ5WY9sKgLH8ATiuK+FuoLd3fiqIy388o1bzHlvLKa3LboIu0irjkH5OoG3jBBLWra7K/4r/MHokzd+w+N/wDoYfD/AP4IZ/8A5Mo+w+N/+hh8P/8Aghn/APkyqun+GNCtPHputK0axtJrO2LTXMNsiyzSTH+KTG5iFRick53g111LoHU5v7D43/6GHw//AOCGf/5MrNgufG83iq+0b+2/D6/ZLK2u/O/sSf5/OedNu37XxjyM5zzu7Y57aubsf+Sp67/2BdN/9H31AB9h8b/9DD4f/wDBDP8A/JlH2Hxv/wBDD4f/APBDP/8AJldJRQBzf2Hxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmV0lFAHN/YfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZXE+JIrP8A4WXLqE5E8Ntf2EUt4gAudNkONsUeTkxSblD4/vHhudvU/EiBH03RZ2aRXh1yxK7ZWVTmdAdwBwwwehz69acVe3m7fl/mEtL+SuXfsPjf/oYfD/8A4IZ//kyj7D43/wChh8P/APghn/8AkyukopAcTPc+N4fFVjo39t+H2+12Vzd+d/Yk/wAnkvAm3b9r5z5+c542988aX2Hxv/0MPh//AMEM/wD8mUX3/JU9C/7Aupf+j7GukoA5v7D43/6GHw//AOCGf/5Mo+w+N/8AoYfD/wD4IZ//AJMrpKKAOb+w+N/+hh8P/wDghn/+TKPsPjf/AKGHw/8A+CGf/wCTKq/FCBJvAF40jSKYZIZFMcrJz5ijnaRkYJ4OR7VznjgLJqvie5ueb7S9Lt5tFJ+9FKzSDdH6MzhFOOowDwaFqwOt+w+N/wDoYfD/AP4IZ/8A5Mo+w+N/+hh8P/8Aghn/APkyqXiy3g1LXvDena5FHLpdyZ2ngmGY5ZliyisDwcDewB7qD2q/4AnmufAmmS3EjykxsI5HYszxByI2JPJygU570CvsN+w+N/8AoYfD/wD4IZ//AJMrN1S58b6bqOjWv9t+H5f7UvWtN39iTjysW8027H2vn/U7ccfez2we2rm/FH/IxeDP+w1J/wCm+8oGH2Hxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmV0lFAHN/YfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZWl4itb++8M6la6PP9nv5rWSO2lJxskKkKc9ue9ch8O43TXdV+x6O2jaeltbxzWokidPtgL+aQY2ZSSpTcc5PGec01qD0V/wCv6/yZu/YfG/8A0MPh/wD8EM//AMmUfYfG/wD0MPh//wAEM/8A8mVnabokeh/EuSQJbX8mqW81w97LbRi8t8Mn7syqoLREHChuRsAye3a0uiYPexzf2Hxv/wBDD4f/APBDP/8AJlH2Hxv/ANDD4f8A/BDP/wDJldJRQByUl74q0jxBoVvqupaPfWmp3r2kiW2ly28iYtppgwZrhx1hAxt6Gutrm/FH/IxeDP8AsNSf+m+8rpKACvO/APj7wfZ/Dbw1a3nizQ4LiHSbWOWKXUoVeNhCoKsC2QQRgg16JXN/Dj/klnhT/sC2f/ohKAD/AIWP4I/6HLw//wCDSD/4qkPxG8DlSD4y0Dn01WEf+zV0tBztO3k9smgDzvw/qHwr8MX95e6N4s0mKe+bdctN4kM4lb+8wkmYFv8Aaxn3q3pniL4ZaM92dN8UaBCt5I0s0X9sxtHub7xVDIVTJ5O0DJ5NO8N/ENtSuNZHiS20zQoNLv8A+zjO+qbxNPgHA3xxjBBGOck54roT4s8OrMYm1/SxIELlDeR5ChthOM9AwK59RjrR0Xp+G4bN/wBanKPqfwpaw0uzXxHoEUWkEGxMOtpG8HGMB1kDYI4IJwe+asWniL4Z2PiK61y28WaIl/dxJDM511WVkT7oEZk2DHOMAdT6mr8PxE0ABDfanptuLjUHsbVo9QilWYr3ypwp/wBk8gkDqRVrWfGGnWOk61Ppd1Y6lf6PbPcT2CXih1CjOH2himQO60OVlzMdm3y/1v8A5nOXvjTShqdxPonxF8CWUMxUss8aTSsQAMs63aBunHy8DinWGt/De11BtSn8XaBLqExEk7LrQEDS7cGRIGmZEJ9Rzz1NaifEHS5vBsWtw3Wm+c6QeZaSalFGIpJAG8tnbADAEnBAJx0qrbfEZZPEl/o11a2VtPa6rHYR+ZqaKZ0dA/mIHVSzAMvyLk88GnZp8vX/AIb/ADRPMmubp/X+RBpWs/C3RL5rzTfE2gRzFDEhfWkkEKE5KRq0hEakgHagA46VY1nxN8NPEEUKar4p8PymB/MglTWI4pYWxjckiOGQ47gitS0+IHhK9upLaHxHpYmjuvsgje8jVnl4+VQTk8nA9SDitqy1Cz1K3M+nXcF3CHZDJBIHUMpwwyDjIPBHaluh9TmdP8a/D/S7UQWnjDQ9vUvLrMcsjnGMs7uWY4HUkmrX/Cx/BH/Q5eH/APwaQf8AxVdJRQBzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVXSUUAc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFV0lFAHN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVdJRQBzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVXSUUAc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFV0lFAHN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVdJRQBzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVXSUUAed3nj7we3xJ0a6XxZoZt49Jv43lGpQ7FZprMqpO7AJCMQO+0+hroP+Fj+CP+hy8P/wDg0g/+Kovv+Sp6F/2BdS/9H2NdJQBzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVXSUUAc3/wsfwR/wBDl4f/APBpB/8AFVTPi/4atq39qN4h8KnUPL8r7Wb2283Z/d37s49s4rU1vW9Q0m+slt9KS7tJ544JJPtWyUF2xmOPad4Xq2WXABIziorrWtdtdetbZtGsfsF1c+RHMdRbzyApYv5QhK4wpOPM6Y6Hiha/1/XcNkZUHiT4WW15BeW2s+D4rm2iEEE8d1aq8UY6IrA5C+w4rS/4WP4I/wChy8P/APg0g/8Aiqj17xmdG1C6ih0/7Vbabbpc6lOZthgicsAUXad7AKzEZXAHUnArpwQygjkEZBp62uHU88s/H3g9fiTrN03izQxbyaTYRpKdSh2MyzXhZQd2CQHUkdtw9RXQf8LH8Ef9Dl4f/wDBpB/8VRY/8lT13/sC6b/6Pvq6SkBzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVXSUUAc3/wsfwR/wBDl4f/APBpB/8AFVU/4TL4bl2c+I/C29pxcs3262yZQABJ977wAA3dcCpL3xlc6RNqjazpAhtbGzN2kkF0JXYZwEkXaBG5PQBmBAPIxV/QdfuNRvb3TtVsY7DUbJY5JIobgzxtHJnYyuVXP3WBGBgjuMGjzE7bFNPiB4DikkePxb4cR5W3SMupQAucAZPzcnAA+gFSf8LH8Ef9Dl4f/wDBpB/8VUWjeMn1XVLaKXTvs9jqHnf2ddefuafyjht6bRsyMsuC2QOdp4rqaBnN/wDCx/BH/Q5eH/8AwaQf/FVz9n4+8Hr8SdZum8WaGLeTSbCNJTqUOxmWa8LKDuwSA6kjtuHqK9Erm7H/AJKnrv8A2BdN/wDR99QAf8LH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFV0lFAHN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVdJWJ4n1rUND043lhpcd+kQ3Sq915LEf3YxtbfIeynaD/eFAGPP4r+GVzqsOp3OveE5tQgGIruS8tmljHork5H4GorvxB8KdQs47S/1fwdc20UrTRwzXNq6JIxJLhScBiSST15NaGoeN7W38V23hyy+ySalIqPLHdXq24jVv4QMMzybQSFVe3JXINWdf8AEdxpd/Bp+l6cNRvZIJLp42n8lUhjKhju2tliWAVeAT1I60bIN2Qj4jeBwMDxj4fA/wCwpB/8VS/8LH8Ef9Dl4f8A/BpB/wDFVtaZqNvq+k2mo2bFre7hSaIkYJVgCP0NWqbTTsxJpq6PO7zx94Pb4k6NdL4s0M28ek38byjUodis01mVUndgEhGIHfafQ10H/Cx/BH/Q5eH/APwaQf8AxVF9/wAlT0L/ALAupf8Ao+xrpKQzm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KrpKKAOP1Pxh8Ntbs/sms+IvCuoWxYN5N3fW0qZHQ7WYjNJL4t+Gk8tnJN4g8KSSWP8Ax6O97bE2/GPkOfl444xW74g1K+0rS5LrTbGC7eNS7i5u/s8aqOT821jk9htx6kVnax4yi0ex0aWWxnNxqs9vELZjtaASuqln642lwMdzx7gWrsu6+/oD8/Mo3Pir4Y3tnNaXmveEri2nl86WGW8tmSR853spOC2QOTzV1fiJ4GRAqeMPDyqowANTgAA/76qfxZ4w07wjZ28l/JEJruTyreOWdIVY4yWZ3ICqBySfYAEkA7FjNNcafBNdJCk0kYZ1t5jLGCR/C5Vdw98DPpQtgML/AIWP4I/6HLw//wCDSD/4quf8R+PvB8+veE5IPFmhyJb6tJJMyalCRGv2G6XcxDcDcyjJ7sB3r0Sub8Uf8jF4M/7DUn/pvvKAD/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOWufH3gG8tZba78WeG54JkKSRS6lAyupGCCC2CCO1Qr4x+G6WMFkviPwqtrbsrQwC+tvLiKnKlV3YBBAIx0qefxtFZah4kh1HT5raDQLSO7eYurfaEYOcqoPH+rI5IOew6mzoPiO41LUbnTtU09LC9ghjuVSK485HhkLBTu2r82UIIxx2JHNPUH/AF/X3Gbp3i74aaR5/wDZPiDwpY/aJDLN9mvbaPzXPVm2sMn3NXf+Fj+CP+hy8P8A/g0g/wDiqi0bxk+q6pbRS6d9nsdQ87+zrrz9zT+UcNvTaNmRllwWyBztPFdTSDqc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VXSUUAcJqfizw5r3i3wfa6Hr+l6lcJq0sjRWd7HM6qLC7BYhSTjJAz7iu7rm/FH/IxeDP8AsNSf+m+8rpKACub+HH/JLPCn/YFs/wD0QldJXnfgHw5qk/w28NSxeNNctkk0m1ZYYobEpGDCpCruti2B0GST6k0AeiUHO07eT2ya5v8A4RfV/wDoe/EH/fjT/wD5Fo/4RfV/+h78Qf8AfjT/AP5FoA4Wb4d+LrrQ/E1jPbaFu1rWY9TUf2hKyoFdGaNs2/PEeM4/i6cc9ZeeEbm5+JGm6x9h0s6Tb6fcW00TOd5klZWJCeXtI+XBJYE7jxxze/4RfV/+h78Qf9+NP/8AkWj/AIRfV/8Aoe/EH/fjT/8A5Fpp2tbp/lb8get79f8AO5xui/DbxFp+sWmo3L6Xut/Ed1qpijuZCDDPGUI3GMfOuc4xg+opx+GniC61S5ub250uNbjTNRsCLbcqp58u6NggQAYH3h1zk5Ymuw/4RfV/+h78Qf8AfjT/AP5Fo/4RfV/+h78Qf9+NP/8AkWl0t5W/C35Du73+f43/ADOB1r4T+IdS8P3dtDNpiXbWVjpsINzII3itpN/muRGSHbgbACFGfmNPvvhx4tvPGTamE0VLRtfttWP+nymQJFF5ezb5GMkc5z7e9d3/AMIvq/8A0PfiD/vxp/8A8i0f8Ivq/wD0PfiD/vxp/wD8i1XM73+f4p/mibK1vl+Fvy0OSuPCraR4VvtC1K/t4L/UNamvdDuYS7P55czICCoCkYIIyQRnnnFem28PkW6R53FRy2PvHufxPNc//wAIvq//AEPfiD/vxp//AMi0f8Ivq/8A0PfiD/vxp/8A8i1PS39bWH1v/Xc6Siub/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+RaAOkorm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWgDpKK5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FoA6Siub/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+RaAOkorm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWgDpKK5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FoA6Siub/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+RaAOkorm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWgAvv+Sp6F/2BdS/9H2NdJXnd54c1QfEnRoj401xnbSb9hMYbHegE1mCo/wBG24O4E5BPyjBHOeg/4RfV/wDoe/EH/fjT/wD5FoA6Siub/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+RaAK/ivwxP4o1Gzin03TRb2ksc8GqNO32u3dXDMI0EeADtAz5n1BxitySwmm8QRXzlDDb27JCm45MjkbiRjsFAB/wBpvxy/+EX1f/oe/EH/AH40/wD+RaP+EX1f/oe/EH/fjT//AJFo2Ay9b8Jaxq8uobDYwRa9ZRWmpoZmc24Tdloj5Y8wlXK/NsxgH2rt0UIiovAUYFc5/wAIvq//AEPfiD/vxp//AMi0f8Ivq/8A0PfiD/vxp/8A8i076WDqFj/yVPXf+wLpv/o++rpK87s/DmqH4k6zEPGmuK66TYMZhDY73BmvAFP+jbcDaSMAH5jknjHQf8Ivq/8A0PfiD/vxp/8A8i0gOkorm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWgDJfwZPfa3qWtX2haNDc3VjLZy2kF47R6iGK4aeTyVIIC4GFcgMee1aPhjwrL4bjmnRUuLy9eJLjzLuVxBCikKiPJud9uT94jJY/dGBUv/CL6v8A9D34g/78af8A/ItH/CL6v/0PfiD/AL8af/8AItHS39dwepQ0HwhqOn6npsd7LaHTdE8/7AYmYyy+ZwN6lQE2KSvBbdnPy9K7Oub/AOEX1f8A6HvxB/340/8A+RaP+EX1f/oe/EH/AH40/wD+RaA6nSVzdj/yVPXf+wLpv/o++o/4RfV/+h78Qf8AfjT/AP5Frn7Pw5qh+JOsxDxpriuuk2DGYQ2O9wZrwBT/AKNtwNpIwAfmOSeMAHolFc3/AMIvq/8A0PfiD/vxp/8A8i0f8Ivq/wD0PfiD/vxp/wD8i0AdJXMeNvD8/inTRpLaVpd7ZzK2+4vZ2WS0fGFkiQRncwyed6H35p//AAi+r/8AQ9+IP+/Gn/8AyLR/wi+r/wDQ9+IP+/Gn/wDyLQNNrYxr3wHey39zbwyWsunX9zaXdxczMwuYZLcRgbAFIbcIxyWXbluGzWlrGi67dalBq+mrYRX4tZ7GSGadzH5TuCsgYR5LLtB2YAOSN3G6p/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWh67/ANaW/LQWxq6FpUWheH7DSbdi8VjbxwKxHLBVAz+lX65v/hF9X/6HvxB/340//wCRaP8AhF9X/wCh78Qf9+NP/wDkWm227sSVlYL7/kqehf8AYF1L/wBH2NdJXnd54c1QfEnRoj401xnbSb9hMYbHegE1mCo/0bbg7gTkE/KMEc56D/hF9X/6HvxB/wB+NP8A/kWkM6Siub/4RfV/+h78Qf8AfjT/AP5Fo/4RfV/+h78Qf9+NP/8AkWgCfxZpc+t6V/Zo0fS9Wtbg4uI9SnZFQdmVRG+5geeq9BzXMap8M9Qm0fSrXTvFGoRvZNYrIJBAUZbdlO8FoXffwSAW27uoxmug/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+Raadndd0/uB6qxDreh6veapY6tZwafNd2Kz2qwXc7BJ4ZQmXLCM7H+QHaFIIyM85Gt4a0YeHfDGnaQsvnCyt1h34xnA7DsPQelZ/wDwi+r/APQ9+IP+/Gn/APyLR/wi+r/9D34g/wC/Gn//ACLR0t/X9asDpK5vxR/yMXgz/sNSf+m+8o/4RfV/+h78Qf8AfjT/AP5Frn/EfhzVI9e8Jq/jTXJTJq0iq7w2OYj9hujuXFsBnAK/NkYY8ZwQgPRKK5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FoAq/wBg6u3i7xHfXNjpdzp2pafFawwyXb7pDHv4kHlEKreYQSC2MdDng8MeEZfDaS3cUUUt9ciGB4nvppEtrdCfkSSQM77dzkZCg5A+UDi1/wAIvq//AEPfiD/vxp//AMi0f8Ivq/8A0PfiD/vxp/8A8i0wKGg+ENR0/U9NjvZbQ6bonn/YDEzGWXzOBvUqAmxSV4Lbs5+XpXZ1zf8Awi+r/wDQ9+IP+/Gn/wDyLUUugahBJEk3xB1yN5n2RK8WnAyNgnCj7LycAnA7A0g63Oporm/+EX1f/oe/EH/fjT//AJFo/wCEX1f/AKHvxB/340//AORaADxR/wAjF4M/7DUn/pvvK6SuE1PRr7TvFvg+W88S6pqqNq0qiG8jtVRT9guzuHlQo2eMcnHJ46Y7ugArm/hx/wAks8Kf9gWz/wDRCV0led+AfGml2vw28NW8trrjPDpNqjGLQL6RCRCoO11hKsPQgkHqDQB6JRXN/wDCeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wnNQ/+MUAcj8PbWy1+HXtX8YpFLr1rqlzDLJcNiTT4wcIsTHmJdmCCuM5zk1r6NrHifUPEGvaNp8ukR2ujTx28E01vKzsjW+9dwEgBIYpkjGRu4BxU9xrvg+71SHU7vw7qU9/B/qruXwnetLH/ALrm3yPwNNXX/DNo9/caRpGq6df3ynzryDwleiR3wcM58j5yCc80dPlb+vx+8e7v5nIeJvGPiO4+GN1qd9HpDtY3C2eqafLYTrunFwF+SRZwQoBRh1zx64GpafEbXv8AhMBpt1Dpr2f/AAkTaP8Au4ZEk2eR5qvkuRkdDxz/ALNao1jw1e6Klh4j0nU9ZLN5s5uPCF6Y5Ze7iNoGA9uTgd6atz4ASUSJ4QuVkE4uA48G3YIlHSTP2f73+11qlZPX+tv8nb1Jeq0/re36DPDHijxjrfjE215p9vbaTH9o+0H7BKDEySFI0W4MnlylgCxKKduNpAPNeg14z4Z0Dwv4b8bS+JIbbVxcu0jBrbwrqsLyb85EmQ0bDnPyxpyAa9C/4TzSP+fPxB/4Tmof/GKX2UP7TOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKQHSUVzf/AAnmkf8APn4g/wDCc1D/AOMUf8J5pH/Pn4g/8JzUP/jFAHSUVzf/AAnmkf8APn4g/wDCc1D/AOMUf8J5pH/Pn4g/8JzUP/jFAHSUVzf/AAnmkf8APn4g/wDCc1D/AOMUf8J5pH/Pn4g/8JzUP/jFAHSUVzf/AAnmkf8APn4g/wDCc1D/AOMUf8J5pH/Pn4g/8JzUP/jFAHSUVzf/AAnmkf8APn4g/wDCc1D/AOMUf8J5pH/Pn4g/8JzUP/jFAHSUVzf/AAnmkf8APn4g/wDCc1D/AOMUf8J5pH/Pn4g/8JzUP/jFAHSUVzf/AAnmkf8APn4g/wDCc1D/AOMUf8J5pH/Pn4g/8JzUP/jFAHSUVzf/AAnmkf8APn4g/wDCc1D/AOMUf8J5pH/Pn4g/8JzUP/jFABff8lT0L/sC6l/6Psa6SvO7zxppbfEnRrgWuubI9Jv0IOgXwclprMjCeTuI+U5IGBwCRuGeg/4TzSP+fPxB/wCE5qH/AMYoA6Siub/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8AxigDpK5G88PafN4607U9Mijtryzld7+9T78yuhC27t1bLOrBTkKFGMZFWv8AhPNI/wCfPxB/4Tmof/GKyF1DwKusHVl8KXg1IsXN6PB955xYjBO/7PuzjvmhaO4dLF7xh4e0/WLi2McMa6wk0UsV/wD8tLKNHBd1Y/cBAK4HDE85GcdbXn883w+uZoJbnwbcTSW6KkLyeDLtjEq/dVSbfgDsB0rc/wCE80j/AJ8/EH/hOah/8Yo6WB7hY/8AJU9d/wCwLpv/AKPvq6SvO7Pxppa/EnWbg2uubJNJsEAGgXxcFZrwnKeTuA+YYJGDyATtOOg/4TzSP+fPxB/4Tmof/GKAOkorm/8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xigDoLiBLm2kglBZJFKsAxXI9MjkVx3w6t3sG1/TpNJttJa31Dd9nsZvMtVDRoR5Xyrt45YbR8xJ71bu/GHh/ULOW0v9L1q6tplKSwzeGL90dT1BUwYI+tV7fxD4TtLO3tLXQdUgtrZxJBBH4UvVSJh0ZVFvhTz1FC0bB7WJPDMCW3xA8XpG0hDSWshEkrPgtGScbicDPYYA7CuurjLXxB4SsdSudQstA1O3vbr/j4uYfCl6kk3+8wt8t+NX/+E80j/nz8Qf8AhOah/wDGKOiEdJXN2P8AyVPXf+wLpv8A6PvqP+E80j/nz8Qf+E5qH/xiufs/Gmlr8SdZuDa65sk0mwQAaBfFwVmvCcp5O4D5hgkYPIBO04BnolFc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFAHSUVzf/CeaR/z5+IP/AAnNQ/8AjFH/AAnmkf8APn4g/wDCc1D/AOMUAUtThSP4xaBMryBptLvFZTKxQ7WhxhM7QfmbkDJ79BVrxvoWna7o72t1ZRXd/LG0dj5nJhkI4lX+4VzkuOQB9BVOfxB4SudXh1W58P6nLqNuu2G8k8KXrTRjnhXNvuA5PQ9zVW9u/AWpJGmo+Ebq7WIuY1n8HXbhCzbmIzb8ZJyfU80dEv63ZV9bo7ayjMWn28bTm4KRKpmPWQgY3fj1qeuYh8baJbwpDBp+uxRRqFRE8NX4VQOAABBwKf8A8J5pH/Pn4g/8JzUP/jFNu7uQlZWC+/5KnoX/AGBdS/8AR9jXSV53eeNNLb4k6NcC11zZHpN+hB0C+DktNZkYTydxHynJAwOASNwz0H/CeaR/z5+IP/Cc1D/4xSGdJRXN/wDCeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wnNQ/+MUAdJXl3jkLJqvie5ueb7S9Lt5tFJ+9FKzSDdH6MzhFOOowDwa63/hPNI/58/EH/AITmof8Axiql14n8MX11bXV7our3FxasWt5pfC187wk9SpMGVP0oW9wLni3TNKvvD7XWuaRZapLbxn7PBeQrKnnPhVAVgRksQM4zzWtoumQ6LodlplsqrFaQJCoUYGFGOlc+vizw2iuqaRrKq83nsB4XvgGkyDvP7jlsgHPXirP/AAnmkf8APn4g/wDCc1D/AOMUCOkrm/FH/IxeDP8AsNSf+m+8o/4TzSP+fPxB/wCE5qH/AMYrn/EfjTS5te8JulrrgEOrSOwfQL5SR9hul+UGEFjlhwuTjJxgEgGeiUVzf/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxQB0lefeK/D0z+PbTWvDCQ2+u29hLMcKEF+oeNfJlI5YFchSfunB7Vu/8ACeaR/wA+fiD/AMJzUP8A4xVFvEPhN9ZTV30DVG1NE8tL0+FL0zKvPyh/s+4Dk8Z70LRp/wBbA9mv63OLsNN03xDbx6h4c0rS1nm1K6uJNC1O38hLsoEVw2FOJY2JwSrAEse+4dXpnhrQvGmh6FqskN7B9gkd4oZXVmDiU7ldsHzFyHXqQQxPJwRYvNf8JajbyQah4f1O6hlJMkc/hO9dXJIJJBt8HJUfkPSrcHjTQrWFYrbTtchjUAKkfhm/UAAYAAEHpTWiXlb8BW/X8WdRRXN/8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFIYeKP+Ri8Gf9hqT/033ldJXCan4lsdZ8W+D7ezg1SN11aVybzSbq1TH2C7HDyxqpPPQHPU44Nd3QAVzfw4/wCSWeFP+wLZ/wDohK6Sub+HH/JLPCn/AGBbP/0QlAHSUHO07eT2yaKDnadvJ7ZNAHmi/FTU7Wz1fUtZ8NW8Ol6LqBsL6e01MzyRsNuZBG0KbkG8Z+bPXiu4tfEmh3t19mtNYsJrjzPL8mO5QuH2ltu0HO7aCcdcAmvOW+HnivU9H8R6Jqf9j2Vh4h1M3txcW15LPLFGSmY1RoUBJ2feLcZ+6a3tF8CXFpq3ilryOzittU8tbGeCVpJ4FSDyQTuQbWxyMMfvEe5Ps+dvxsr/AI3G7c3zf3dDon8YeGYrd55PEWkpCk/2ZpGvowqy/wDPMndgNwfl606Hxd4buGIt/EGlykO8ZCXsbYZF3OvB6qOSOw5Nefw/CnVZ9Cv7a/urOK5XRoNLsPJld0LwMXjuHyilW3EfKN23n5jmug0/wFJbXOvi8kt7u01dEZoH3AGYoqzucYxu2KRg5zmm0lez/r+vu0Qv6/r+tbM1T420WXUNPisNU0q7tryOaVriPUofkSMHLKucuMhgSOFwc1o2XiLRdSDnTtYsLsRxCZ/IukfbGc4c4PCnB56cVwMvgXxVN4j0DU5pdNmXTI75XEt25kPnrtRdwhG/bgZcgE9wSMnDsfg94kXSE064utNtF/4Rw6S09rcyswl84yh8eWuVPAPIPJ69zp/Xn/kvvDr/AF3X/BZ6t/wlXh77PZ3H9u6Z5N9J5dpJ9sj23D5xtQ5wxzxgZqxaazpl/fXNnYajaXN1ZkC5ghnV3gJ6B1ByvQ9a4m28AXtla2c+nw2tlqnmhrqdtSuLvglPM+aZWMqsI1+RguOoYEZO/wCHvD97o2t38mbeLTZVzDbxOXxIzF3YblBjBLfcDMM8jbkijS4tbHSUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzd9/yVPQv+wLqX/o+xrpK5u+/5KnoX/YF1L/0fY10lABRRRQBg+JvFUHhttOja3e5mv7yG2VEONivIqGRjg4ALD6kge4Zd+I7+w8TafYXukKlhqMz29vdJdb5BIqM/zxbcKpVGwQ5PTIFZnjLwNf8AiG6iutN8QXlk/wBrtZXg2wGNVikDZUtCz7hyQC20t1GM1fW38SN4pW4ubDS5bGHMcFwdQk81EIG5vK8gKXYjGd+AOnfLja2vd/dZf8H+tAe/y/HUZr3jM6NqF1FDp/2q2023S51KczbDBE5YAou072AVmIyuAOpOBXTghlBHIIyDXEa34S1jV5dQ2Gxgi16yitNTQzM5twm7LRHyx5hKuV+bZjAPtXbooRFReAowKNLB1Ocsf+Sp67/2BdN/9H31dJXN2P8AyVPXf+wLpv8A6Pvq6SkAUUUfSgDnLfxJqC+KBo+p6MLc3FrJdWckN0JS6xlQySDaoRvnXGGZT/eq14U8QHxN4ej1N7J7Fmlmia3kkDshjkaM5K8Z+Xtke561U0qDxINdubvV9O0lFdWSOeDUZZHCAkogQwKFznLNuJz2IxiLwZpOuaF4bWx1O308zm+nlb7PeO6iKWVpCQTEpLDfjGADjORnFP7Pn/wQe/8AXYNG8ZPquqW0UunfZ7HUPO/s668/c0/lHDb02jZkZZcFsgc7TxXU1xmg+ENR0/U9NjvZbQ6bonn/AGAxMxll8zgb1KgJsUleC27Ofl6V2dHQOrCubsf+Sp67/wBgXTf/AEffV0lc3Y/8lT13/sC6b/6PvqQHSUUUUAFYniXxC/h2LT5Bp8l2l5fQ2bOkioIPMcKHbPJGT0AP4Dmtuua8b6Rq2s6ZYwaHFZSSwahb3cn2y4eJdsUgfAKxvknbjoMZz7U18SvtdfdfUHs7eZY1nxVBpHiDR9I8h559TuPKJU4EC7HYM312EAd8H0puv+I7jS7+DT9L04ajeyQSXTxtP5KpDGVDHdtbLEsAq8AnqR1rI17wLqOp+JdO1Wx8RXsCQ6it3NbsICsYELR/uyYSxPIGGYjDMRg4q3rGi67dalBq+mrYRX4tZ7GSKadzH5TuCsgYR5LLtB2YAOSN3G6p1t9/5afiPS/3fnr+B0Omajb6vpNpqNmxa3u4UmiJGCVYAj9DVqqGhaVFoXh+w0m3YvFY28cCsRywVQM/pV+rlbmfLsTG9lc5u+/5KnoX/YF1L/0fY10lc3ff8lT0L/sC6l/6Psa6SpGFFFFAGN4r19/DOgvqaWEl8I5ERo45FTaGYLuJY9ASOgJ9qr+JPEOoeH/Lul0hbnTFkjjuJxdbZV3sFBSPad4BYZyyn0BpfHGk6lrnhK507RUtWup2TBu5miRQHDE5VGOeOmO/WodYg8TXeo2n2bTNIuLKEJKyz6lLGRMO+0QMHVeoyVyeeMDAt/mH+RP4s8Yad4Rs7eS/kiE13J5VvHLOkKscZLM7kBVA5JPsACSAdixmmuNPgmukhSaSMM628xljBI/hcqu4e+Bn0rndd0TV77VrLV7K202S6sluLZbe6nfy5oJduWLCMlGGwfKAQRkZ5yNXw1ow8O+GNO0hZfOFlbrDvxjOB2HYeg9Ka2/r+u39IH5GpXN+KP8AkYvBn/Yak/8ATfeV0lc34o/5GLwZ/wBhqT/033lIDpKKKKAObPiTUrfxLHpl9oYSO7hllspYLsSO5jwSsilVEZO4YIZh6kVc0DWL3U3v4dS0+Kzms5/KzBcmeKT5Q2QxVTkZwRjg9zWfBD4qGuXN7c6VorjY8dtINUlLBOqpt+z4XcQpZgW6dDgVF4Z8M3Ph+bUb6203TbGbU54nm0+zuG+zxbch5Fbyxucg5I2KCQBn+KhbfL9f6/rUH/X9f1+g3w945m17Xvsf9lLFaSm4ENwlz5jqYJBG4mj2jyiSfl+Zs98V19cP4d8Ja3pvi59UvprMKyyrcXFvK5k1Hc2YzLGVCoYxwCGbjjgcV3FHRB1YUUUUAc34o/5GLwZ/2GpP/TfeV0lc34o/5GLwZ/2GpP8A033ldJQAV534B8OapP8ADbw1LF401y2STSbVlhihsSkYMKkKu62LYHQZJPqTXolc38OP+SWeFP8AsC2f/ohKAD/hF9X/AOh78Qf9+NP/APkWj/hF9X/6HvxB/wB+NP8A/kWukoIDKQwyDwQe9AHN/wDCL6v/AND34g/78af/APItH/CL6v8A9D34g/78af8A/IteNX+kaVovg/x3q2j2Vtp2s2HiNotKuLOMRTI2YtsSFQCVOT8nQ5PFd/pPxE8Q3uuamknh9jp2kh4bsgxiRJkhEmRmXc24/KFEXTB3HkA05b+V/wAE/wBRtNO3m19zOm/4RfV/+h78Qf8AfjT/AP5Fo/4RfV/+h78Qf9+NP/8AkWuUfxz4rTwRpniJToUqapd2QgjSKXKxTsFZG+fhlLD5xkHB+QVcu/Gnii28cweG7fSba+lt4Y7m+liCxo0MkrJuUyTKV2qAThZMnj5eDVcrTt52/C5N1a/z/Q3/APhF9X/6HvxB/wB+NP8A/kWj/hF9X/6HvxB/340//wCRa5FPiRr0/iO703T4tJvxLZ3FxYGHegDRTiLaWdwJMkntGNwwCR81OufiP4g+3aVpej6dDq2oTQz3FyyW4tlYRS+W0YWadTGw/iOZMY4VgchJXt5/8H8rDel/L+v1Os/4RfV/+h78Qf8AfjT/AP5Fo/4RfV/+h78Qf9+NP/8AkWvNvEutz+JfGvhm8mt7SGHT/Fx06BPJP2hdiHezOT91jg7Qo6A5OeLfxm0i2vPHngR00bTdRu7i9lhaO9UKk6hMhHfYx2gknGCMnpSWqT7u34J/qHVrsr/df/I77/hF9X/6HvxB/wB+NP8A/kWj/hF9X/6HvxB/340//wCRa5i48Qah4X8Q6d4T8J+F7eMCzXULu3gWKOJVaTbIIy0qBNpycgP1A2jOaq/8LU10af4j1k+HwdI0z7TFE7Miss0L7ArYlZ2Dcsf3abQOrZzTt28/w0/MPL0/H/ganY/8Ivq//Q9+IP8Avxp//wAi0f8ACL6v/wBD34g/78af/wDIteNX17d6L4q8YXEkOlXckuoaKbpUtpI4pWc53qFlBVgxDZLNnByDmu4g+I2vr4xOm3MOnSWn/CRvo48uGRJCnkear5LkZHQ8YP8As0JX/r0/zQOy/ryb/RnW/wDCL6v/AND34g/78af/APItH/CL6v8A9D34g/78af8A/ItYfg3xP4w1/wASFNV0+3tdKWB3lxp8qGKXeVWJZ2k2S/KNxdFK9uDXoFLpcOrRzf8Awi+r/wDQ9+IP+/Gn/wDyLR/wi+r/APQ9+IP+/Gn/APyLXSUUAc3/AMIvq/8A0PfiD/vxp/8A8i0f8Ivq/wD0PfiD/vxp/wD8i10lFAHN/wDCL6v/AND34g/78af/APItH/CL6v8A9D34g/78af8A/ItdJRQBzf8Awi+r/wDQ9+IP+/Gn/wDyLR/wi+r/APQ9+IP+/Gn/APyLXSUUAc3/AMIvq/8A0PfiD/vxp/8A8i0f8Ivq/wD0PfiD/vxp/wD8i10lFAHnd54c1QfEnRoj401xnbSb9hMYbHegE1mCo/0bbg7gTkE/KMEc56D/AIRfV/8Aoe/EH/fjT/8A5Fovv+Sp6F/2BdS/9H2NdJQBzf8Awi+r/wDQ9+IP+/Gn/wDyLR/wi+r/APQ9+IP+/Gn/APyLXSUUAcrLoN/DNDDN8QtbjlnJWJHj04NIQMkKPsvPAJ49KrTWZt9Yh0m4+J+pxalOu6Kzc6Ys0i88qhttxHB6Dsag8aXOlWnxF8DSXk1nDetezxxtKyrIUa3kG0E84LlBjpkr3xU8stnF4/jbw5q/n3ctxt1rT0uvOWNBEdsjISfJYFUAxtDZ6HqH2DuSXWlz2N1bWt78SdXt7i6YrbwyjTUeYjqFBtssfpVv/hF9X/6HvxB/340//wCRa43xfd21xd+I/LnjuJtZ0m2j0KSNw4uJA0hxEQeSHKOcdBg9BXqkYYRIJDlgo3H3otpcOtjz2z8OaofiTrMQ8aa4rrpNgxmENjvcGa8AU/6NtwNpIwAfmOSeMdB/wi+r/wDQ9+IP+/Gn/wDyLRY/8lT13/sC6b/6Pvq6SkBzf/CL6v8A9D34g/78af8A/ItH/CL6v/0PfiD/AL8af/8AItdJRQBzL+GtVjRnfx7r6qoyWMOngAev/HrVTTNPk1u1Nzo3xM1XUIAxQy2n9myqGHUZW2IzWt4zSCTwPrUd5b3NzbtYyrJDaj966lTkL71yvw41aze51SS4v7C8llktoU1S0kAgu/3ZEcajgCVQCGUZOSDxwqta3CWiTNyPQb+aeWGL4ha48sOPMjWPTiyZ6ZH2XjODUv8Awi+r/wDQ9+IP+/Gn/wDyLWZ4TudJHxK8Z2mmy2Yn8y2lmhgZd27yyHZgO+epPfrXb0uiYjm/+EX1f/oe/EH/AH40/wD+Ra5+z8OaofiTrMQ8aa4rrpNgxmENjvcGa8AU/wCjbcDaSMAH5jknjHolc3Y/8lT13/sC6b/6PvqBh/wi+r/9D34g/wC/Gn//ACLR/wAIvq//AEPfiD/vxp//AMi10lFAHN/8Ivq//Q9+IP8Avxp//wAi0f8ACL6v/wBD34g/78af/wDItdJRQBx8umzQ6pFps3xK1aO+mUvFauNNEsijqVT7Nkj3AqHV4Y9AWI698U9Q0wTZERvX0yHfjrjdbDOMj86xNasL258aahpek3Gn3z3up2V9KyzsbnTfK8vcHUKQqlIyVJZSS5GCDmu11q/gm0KabSZ4Zbi6b7DDPAwfa7PsPI/uncSO200a8qa/r+noPROz/r+tylb+H9Qu7aK4tPiDrk8EyB45YotOZXUjIIItcEEd6l/4RfV/+h78Qf8AfjT/AP5FroLa3jtLWK2gUJFCgjRR2UDAFSU3a+hKvbU87vPDmqD4k6NEfGmuM7aTfsJjDY70AmswVH+jbcHcCcgn5RgjnPQf8Ivq/wD0PfiD/vxp/wD8i0X3/JU9C/7Aupf+j7GukpDOb/4RfV/+h78Qf9+NP/8AkWj/AIRfV/8Aoe/EH/fjT/8A5FrpKKAOWudBv7OBprv4ha5BEvWSWPTlUfibWq2pWR0doF1f4napYNcvsgF0dNiMrf3V3WwyeRwKZ8WpNNh+Hd3LqzWqLHNC0L3JUBZBIuCpb+LGenPWjxRc6e2p2l3omtKviMRRm1s4bvf9qgaQEgw5IKHn94Bx13YFC1fzE9PuNH/hF9X/AOh78Qf9+NP/APkWqsek3MupSafF8SNYe9iQSSWyrppkRScBiv2bIBPetnUdWhawu4tLvbaTUfLmS3iWVWZpkXJXGeSMjI7Z5rivhdO8VwbKw1Q6tYGxSe8klhjSW2vS3zxuUUEseSVfLKRycEUR1dv66/5fkN6K/wDXT/P8+x03/CL6v/0PfiD/AL8af/8AItc/4j8OapHr3hNX8aa5KZNWkVXeGxzEfsN0dy4tgM4BX5sjDHjOCPRK5vxR/wAjF4M/7DUn/pvvKAD/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FrpKKAOVTQb+S6kto/iFrbzxANJEsenFkBzgkfZcjODj6Glj8P6hNLLFF8QdceSEhZUWLTiYyRkAj7LxwQefWsSxv7Oz+KPjWPQo7W61T+zrSU2VvJGsk0q+aDuyQN3zRgliOCuTyKg+HV99g17xZHqlld6b5mowbptRnt8vM8EQ2HZK3zsTkAcYYAHPAaV/uuHc27XTpb69ubOx+Jeq3N1aEC4gh/s13hJ6B1Ftlfxq5/wi+r/9D34g/wC/Gn//ACLWPod6l98TZZtJu9I1XSksHhSbTlG7T2V0JhdlZlYuSW6KRs6dz3lHRPuHVo5v/hF9X/6HvxB/340//wCRaP8AhF9X/wCh78Qf9+NP/wDkWukopAcJqejX2neLfB8t54l1TVUbVpVEN5Haqin7BdncPKhRs8Y5OOTx0x3dc34o/wCRi8Gf9hqT/wBN95XSUAFef+CvFllpHgHw/puoaf4ghu7PTLaCeP8A4R2/bY6RKrDIhIOCDyDivQKKAOb/AOE80j/nz8Qf+E5qH/xikPjvR2UhrPXyDwQfDeoc/wDkCulooA4CwuPh/pV6t5pfg+4srpfuz2/g27jcfRltwa0F8T+F01STUk0TVlv5UEb3Q8LXwldB0Uv5GSPbNdfRQBwb3vgOS0NrJ4Su2tzP9pMLeDrwoZf+em37Pjdz97rV2fxN4Xur+3vrnRNWmu7XP2e4k8K3zSQ567WMGVz7V19FAHEx6z4MhmEsXhrUEkBch18JXoI3nL8/Z/4iAT696P7a8HeTZw/8I5qPlWDbrRP+ESvdtsfWMfZ/kP0xXbUUAcPc6r4KvL/7dd+GL6e78xJftEvhG8aTen3W3G3zkZ4Pam6nqPgfWrxLzWfCt7qFzGoVJ7rwheSuoByAGa3JAySa7qigDkLnxP4Yvbq2ubzRNWuJ7Rt1vLL4WvmaE+qEwZU/SmJ4i8KRXV3cx6DqiT3oC3Uq+FL0NcDGMOfs+W49c12VFAHnj/8ACuZABJ4JlYAKAD4Lujwowv8Ay7dh09KlN34CMxm/4RG680z/AGnzP+EOu93nf89M/Z/v/wC11rvqKAPGPBegeGPB3iefWre31fz5FZM2vhXVYTIGOT5gIeM9j8iIAegxwPQ/+E80j/nz8Qf+E5qH/wAYrpKKfSwbtvuc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRSA5v/hPNI/58/EH/AITmof8Axij/AITzSP8Anz8Qf+E5qH/xiukooA5v/hPNI/58/EH/AITmof8Axij/AITzSP8Anz8Qf+E5qH/xiukooA5v/hPNI/58/EH/AITmof8Axij/AITzSP8Anz8Qf+E5qH/xiukooA5v/hPNI/58/EH/AITmof8Axij/AITzSP8Anz8Qf+E5qH/xiukooA8/u/FllL4+0rUk0/xAbS30y9glk/4R2/8AleSW1ZBjycnIifkDA289Rnc/4TzSP+fPxB/4Tmof/GK6SigDm/8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xiukooA5v/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YrpKKAOb/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GK6SigDz+08WWUXj7VdSfT/ABALS40yygik/wCEdv8A5njlumcY8nIwJU5Iwd3HQ43P+E80j/nz8Qf+E5qH/wAYrpKKAOb/AOE80j/nz8Qf+E5qH/xij/hPNI/58/EH/hOah/8AGK6SigDm/wDhPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABiukooA5v8A4TzSP+fPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/wAYrpKKAOb/AOE80j/nz8Qf+E5qH/xisO08WWUXj7VdSfT/ABALS40yygik/wCEdv8A5njlumcY8nIwJU5Iwd3HQ49AooA5v/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGK6SigDm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYrpKKAOb/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8AxiukooA5v/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGK6SigDz+78WWUvj7StSTT/EBtLfTL2CWT/hHb/5XkltWQY8nJyIn5AwNvPUZ3P8AhPNI/wCfPxB/4Tmof/GK6SigDm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GK6SigDm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GK6SigDm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GK6SigDm/+E80j/nz8Qf8AhOah/wDGKw9e8WWV7rXhme20/wAQPFY6m89w3/CO342IbO5jB5h5+eRBgZPOegNegUUAc3/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMV0lFAHN/8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFdJRQBzf/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxXSUUAc3/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMV0lFAHE32uweIPFHhWPTbHWP9F1OSeeS50a7to40+xXKZLyxqv3nUYznJrtqKKACiiigCtqNpb3+mXNrewRXFvNEySQyoGR1I5BB4IrybwNf6pong/wlpHhqy0m0h1LS57uS5mjZiZowCS0aFd2crzuz+XPrl5aRX9lNazmURTIUcxStE+D6OhDKfcEGuYtvhl4Xs47VLWDUIks4pIbdV1i7xEjjDqv73gH+g9BS11t1/wCD/mik1pcoa74k1TUPgl/wkWlTR6bfXOnxXO7YZBHvClgvzA55OD2rEtdR1fwt4k1+4SW1uo31fTob0SLKTIZ0jRjFukPlAM+4KS4xwMda76Dwno1t4T/4RqO2kOk+UYRBJcyuQn90OzFwB2544xjFZs3w08MXDXBmt79jc3EdzN/xNrsb5I/uN/re3GPoPQVpePPdbX/C60+4hX5bP+vMzvCvjDxN4k15Zl0DZ4dlkniW6JiVojGxUEnzyz7ipBXykK56nrVzxn4btdUkgltk3a81zE1jdH/WWiqylyp6qm0HcOjFsHOQK19P8J6PpeqTahYW8sM08jSuguZTD5jfecRFvLVjzlgoJyeeaZqPg/SdU1R9QuzqIuHRUfyNVuoUZR0UxpIFI5PGOcnNQtLeQ+5N/adhrNxe6MYtSVljdJXayubZCPunZOVVSeeCjZ7jpmvN1tDP8JfC9rAkd9L9uYR6VdPlNTAaXdE7Nn+EF8tkZQZzXrU1uk1q9u25Y3QofLcowBGOGUgqfcEEVgw+BPD8Ggw6NHa3As7ebz4M305lgf8AvRyl96dT91h1PqaVv0Dr9/4/15GR4QvDY/CeS50MefNaLcslreZiFvIrsTbnAJVYz8gxnhRjisibx34ri0i4uymjhl8Px63H+4lIAA+eE/vBnPZ+NueVbrXeR+G9Li8PSaJDbvFYSoySJHPIrvuJLEyBt5Ykkls5OTk1kH4Z+FzbtA1rfGJrL+zyh1W6INvnPl/63p/+qqbvJv8ArZ/rb7gVtP66r9L/AHmTqfjvVoo9W1LT4LP+z9CeFb22mjdprjfGkjGNwwCbRIMAq24g/d61HD4z8TS6n5c8OlW8Da3JpAREklcfufMjl3FlBwRyu3nPBGOekHgXw+Lu3uTZytLBHHGN15MwlEf3PNUviUr2LhiKgPw68OG4E5gvvMF6b8H+1brHnkY348zGccY6Y4xQ7X0/rVfpf0uLW39dn+tjg9Hn8Q3k/g/WJdStrjV7rTb9hNNFL5KqNhG6ISYZskjcCvBH90Cu6TxPqN78MbPxHp1j5l7dWcNx5CRNN5e/buIRSGfaCTtBBbGAcmn/APCuvDYe3aO2vIjaxSxQ+TqdzGI0k++AFkGM5/DAxjAxo2nhfSbHw5BoVtBKunWwUQxm5lZo9rblw5YuMHGOeMDHSjSzX9bu/wChWl0zhZvE/iTVPEGkyaDrulfZ5NLvbh1bTpmR3ikjXDIZUdGw2Np+6dwO7IxMvxF1W2sbK+vorF4bzw/FqKRpG8ZS4d402lyzfu8yD+HIA6muwt/CGh2stpLFZt5tosixyPPI7MJCC+8liZCxUEl88gHrVKH4c+E4Ywn9jRSqtu9qnnyPLshbrGpdjtX0AwB0GKd1/X/b3+a+4l67f1qv8n95x8c3ifQdc8XX0d3p013AtlcXbG1nkjaDbJv8uMzZRguSAGIO3oC3HfeHtRvNW+3Xkk9rNp7XBSwMELKxReGZmLkNlg2CAvA96oJ4PtNCMtz4X0y2fULpFtp7vUbyaRxCAf42Ds+OPkJUHH3hgVoWnh2Gwg0e3sppILfSovKSKJ3RZBs24ZQwUjv8ynB6Ypf1/X3L72K39f18/wADiviO+r3Oranpy6ksWlDw3dXT2yRyJIzqRgiRZBg529iMbhg7siNvHms6BZPpstlbXtyLbThYC3Tbg3JZAr75FDFTGTndGGyB8vWu31zwjo3iNy+r20sjG3a2ZorqWEtExBZD5bLkEqOv9TVD/hW/hdvtPnWVxP8AaraO1l8/ULiXMcZBjA3SHaVIyGGGBJIOSaUdFZ/1q3+TsW9f68o/5Mw7PxP47m1jTNJ1TStO0eW7W4Y3FwnnNIsWwgiGKYhMh8Y81iCD2xmz4K8YeJvFGoxXk+g+R4evIneC6JiVoipwoOJ3Z92Dn93HtIxg9a3bfwVottqtlqUaXr3lkrLDLNqVzIcMMNu3SEPkAD5s8KvoMT6X4U0fRr6a60y2kgaaRpTELmVoVds7mSIsUQnJyVUZyfWmhdDlPFvjHX/Dt1rCpNp5W0Fvc20Z0+SR5Ldy4lziYZZdhbIAAA6HPEuv+LNd0/RrnUrG/wBEEQkuXto5rSeSWaOIcIqI+WJIbMgwFGPlOeOvu9D02/1GO+u7VZbmOCS3Vyx/1b43LjODnHU8jnHU1nzeCPD89pY2z2LCLT7dra3VLiVMRMAGRiGBdTgZDZyQD15qdeXTf+v8l97+daX8v6/4P4GTpvjK+u/E9nZ3qQWFrfQxSWqTW0v+khod7bJwfL3BjjyyA2FLZOcUeOfFmp+GbiKWxm0xoIxE0tpLFLLczBpQjEbCBEoB++wYE8cYydmz8HaJYXNrPbW0wa1A8lZLuaRFIQIGKsxUsFAAYgsB3o1fwboeu3ctzqdpJJLNAtvKY7mWISIrblBCMASpJIJ5GTgjNW7XViNeXXe34md46vNatZvD8ehX0FobrVUgm86BpA67HbHDqQMrz6/mDzaeP/FX9iWly9lYzX2panPpltZ2cBfyXiaXc5eSaNZARFwuY/XPavQtU0Sw1m2gg1GJ5Ut5VmiKzOjI6ggHcpB6EjryCc1hXng/wtovg26tbizum0y2kfUGH2q4mmjkGXMkb7zIrZyflI5JPc1OiTv/AFt/wSt7W3/4f/NHOXHjbx1bxzx6ho2l6Xc22jz6i6zu0zSGKQDG2N9qBl5HzvtJ74wa/jLXL/xLot2bJre3sNLvLBZ4yZBNJJI0T8MrBQgWQDDKwY56YFWtHsPCHirWL6zubLVIbr7ObVPN1G+Vrm1aOKQ7yzLhz5i7lJLcZJIrpLj4a+FLuERXemPPF5UcLxyXczLMsZBTzAXxIRgYLZOOM4qtmrrz/Fv8rKxKt/Xov+CReM73WbXxB4Ug0e/htYbzUmiuUktzJ5iiCR8cOvHydPXB6Ag46+NvEd1b6Ze2SaZ9m1+Sa30+NoJGktpESRkMp8wCQN5ZyAE2k9W61219oenaitkLu2DCwlEttsdk8pgpXjaRxtYjHQg4xVXT/COiaXqsmo2NmY53d5ADPI0cbv8AfZIyxRC3OSoBOTmp0tb+v6/Iq/X+uv8AXmcdY+Ptavr6G1iuNO3X2lwXFox06QKlyzokkb/vvm27wdowQGHJxk29T8Z65p/i+LS4H0e/S5aeGO3iSZWhkjgMqmWb5lUttOY9u4AggtzXTweEtDtntXhsFVrS6ku4DvY7JZM726853Hg8DjAGBipd+APDt5cyTy2tyksk73O6G/uItkjqUdl2ONhYE524z1PPNN6/j/wPuFp/X9en4nO6d4n8Q6/o2h2rz6XFe+IdPa+BFtMqW8Kom9MibczkyDDArtGTg45o+B/Et/p2h+F9Ou2htbO4tIlS4ubeWRbmVpCGQTg7UcAcK4y5YYPBB7MeBfD66Tp2mraTLb6XxZkXkwkhHdRJv37ccbScYwMYGKi074d+FdIWBNL0lbWOGUTCGKaRY3kXG13TdtkYYBBcEgjI5qrx5m1tf8Nf0F9nzE8Qald23i7RLS207T7n7RFdPFNcsRJHKkeQFIU7Q2cFhk4yMVytp8TNat9JtdS1izsHjvNFn1GKC1DqYpIpETazsTuU+YOQoxg9a7rVvC+l63qVpf6gl0bmzV1gkgvZoNgcYbiN1BJHc81mW3w08LWjWxjsbh1tbaS0iin1C4ljEMmd8ZR5CrKc9CD0HoMRHz/rf/gfcPT+vkUdW1jxppEumW0v9gynUtQW1S8SKYCJWjZhmHd8xBUjPmDPHAzxT07xn4t1LX5kstEgn0izupbG6u38uBVeMENLuM5cLuH3PKJCnO89K6AeANAH2PMeoObGcT25k1W6YxuBgcmTlQMgKflGW45OZ5vBWgT6leXslk/mXwxdRi5lEM5xjc8Iby2bAA3Fc8Dmj+vy/wCCPTT+u/8AwPuOQtPH2vSx6vB/oN/JY/ZZRe6dp1xJEsUwfcwi37pgpT7yMAQc4GCKdffEDxFeahFY+DdJt9bmjsor2eSLYIplkd1CK0k0Zj+4cttkweCtdND4A8PW5LQ212kjRJD5o1G48zagYJh/M3AgOwDZyAevAqWTwP4fkks5Fs5IJLKMxRSW13NC5QncVdkYGRSeSHyCSSetVpcnX+v69TjdR1XUfEWv+HdU3QQabB4ieyjtlMgm3IsquzkPsYFk4XbkAAhucV0+r61rsfj/AE/QtNGnW9nc2Mt21zcRvM5MckasmwMgXiThstz24wZpvh94XudQF5PpSSSC4W6EbSyGETKMCQRbtgbnk7cnjPSr9x4b0y68Rwa7PFM2oW8DW8bi6lCCNvvL5YbYc8ZyvYegwlZL7/y/z1G9Xf8Ardv8mec65448SPpev2dvqWlCeHTlvILywtZikYMpjaMOzgSEDH7xcYOflHFa6eMPF1x4ql0zStEj1K20u5htNSuESOFXZo0d5EL3G5AofIXZJuxjcK3o/h34Yitnt0sJfJe1azKG8nIEJbdsGX4AP3cfd/hxVpvBuhtqo1EW0yXOxY5Gju5kWcKML5qBgspGerhjQtF/X9bafiJ3bf8AX9alHwb4lvdclvLfVjDBfW4Uy2P2WWCW3JLcHeSJF4GJF+VsHgdKzB421d7iHUYorM6NLrDaP9n8p/tKOJDEJd+7aRvH3No+U53dq6rSvDumaLNLLp8DpJIixlpJ5JdqL91F3sdij+6uBnnFQJ4Q0SPW5NWS0ZbuRzK2LiQR+YRjzPK3bBJjjeF3e9Gl1/X9aDeqdv60/wAzlPh3o9xcXGreI9VNjeauL68tYrmKCSByqysux2Mj7k+Vdq4+Qep5qonj3xY+h6VMtlY3Go61czW9ta2lvuFuYTJvJaW4jEuQgwMx9zz0rt9D8KaV4ctbq20lbuOK6dpJRLfzzEuxJZgZHYqSSSSMEnnrVVfAPh1NBg0cWlx9jt5zcwE305lhkJJLJLv8xTknow6n1NLy9P8Agg/ibXd/8A4Txlr3iPX/AADr2n3tnb6Nd6dpAutSgaVmkZm37RG8UmFGI93JcHO0jqa15PGviGyvrtJLbTUsdP1OxsSg8x5ZorjYA27KhGHmA42sOCPeujv/AIfeGtTA+3WEkv8Ao5tpD9rmBnjJJKykP+95JOX3EEk9aqt8LvCZhliSxu4oppYpmih1O6jQPEMRlVWQBduBgDAGF9Bi01fXv+v+QdLf1sYmneOvGOrvdX+meFzcaPtuVgfMQZXiLKvInLvuKkbfLQgnqetWX8c340C3v4p7WWJblor26XSrnFrtRTtlt93mQkkn5iWCjBOQa6GLwPoEFxdTRWcqi6cySwi7m8kueriLfsVj3YAE5PPJoPgnQjamD7Pc4Zmd5RfT+dIW27t0u/ewIRRgkjAA6cVHSwdbm1azefZwzB45BJGrb4jlGyM5U+npXBS+MtfbSdbeJrC21PTI2uGsbrT5g6RK3OMyASgqDiRCBkgYFdlpukJptxctBLJ5M2wR2+9zHCqrtARWYheOyhRwOM5JhsfC+kadNNLa2zbpovIPmzyShY/7iB2IRT1IXAJ5PND3ugW1mcraeNNWutf1LTY7mwfybmF7WQWEgEtqyO7/APLY7mHlsm4YAYfd5wOZ1jxL4k8YfDPXrzUtDks9Cu9GkvLS7jmSJ43A3IhKTu0gI5JKR9CCpzXp9h4W0bTJrKWysVjksLY2lu29mKREgleSc8jqcnrzyc58nw68My6beae1ncCyvc+bapqFwsQBOWCIJMRgnqEAB6HIp6J/1/XZ+T7ji7NP+v6/Q4/ULh9EvvGN1bWdvqCvBprTQahI0kZV9ythTngdQvAz6Vq33jXxDZa3qSPa6Yljp+r2diUHmPJNFcFAG3ZUIw8wHG1hwR71sTfDbwzPHepNbXzi+SJLndqt0TIIseWCfMzxjt+NJc/DXw1dm5NxDqDtdTx3ExOr3fzyR/cb/W9VwMfQegp3XNd7f8N+lyIxsrMxtF8ZeINZ8dR6bHNpC2qT3SXtitu73dmkTbYy7+btHmcMCUHB4DdaveMfF2p+HdYtVtJtLktTNbRy2bRyyXLiWXyy+5SFiUZGCwYMcjjHMfhzwdqmmaokty3kLFM0pmttau5UuNxYsPsj4ijyW7Fu/fmt3VfBeha1fS3eoWkrzTLGshjupYg3ltvjJVGA3KejYyOmcUl9krqzlrHx5ry3tpJrNrpsVpNql5p0kNsJHkQwpI4cSEgH/VEEbB1ByOlQaDd6lqvxN0DWtQltvK1PQbieCG2MmIk8yAqrbnKswD8uoXOcY4Bro4fht4Zt5baSO3vy1rdPeRb9WunAmbhnIMp3ZGQc5By3qcz6b4A8M6TqVtf2Wlhbm03i1eSaSUWwf7yxq7ERj2UADJxjJpxaVm+36Nfmxy62/rX/ACMDX/GfiTTNU19ba10v7Jo7WbqshkaS4jmYhhkEBGHUHDDjoc8R3/inVgbqy1Sw0jUPsXiKysXdonVRHL5Tq6oxbMilxg7gMjd7V0Oo/D7w7qt3qFzfQXryal5f2rZqdyiybDlBtWQAAHoABUVx8N/DV1NcSzwX7Pc3Md3KRq12N0sYwj8S8EYGMeg9BSi7NX8vzX+TF0f4HOaNf3Gj3eqaNo8ka3ep+JLiGGa+aSZYgIFkYn5gzHAwF3Dr1AFbPwpilg8DmGdy8kWo30bMXZ87bmQfeclj07kn3q//AMK98N/Z7iL7Jcn7RefbnkOoXBkWfGPMSTfuQ44+UjI46Vp6H4d0nw3ay22h2MdnFNM08oTJMkjdWYnJJ+tNNKNvJL7kv+CLX8W/z/zNKiiipGFFFFABRRRQBn69LdQeHdQm0+ZILqO2keKSSPeqsFJBK5Gfzrzey8beNPsOl6Xo+mR69qUWk21/dy+WkazLLuCpmS4UocIcyASZP8A6V6rNElxA8Myh45FKup7gjBFYH/CB+Hh9hMdpPE9hF5EEkN7PG/lcfu3dXDSJwPlcke1EdG7+X6/5oH/X4f8AB+852z8b+Izqsf8Aalpptvaf24+lSQQ+ZJKB5PmK4kyBkYwRt5zwRjnBvvFd9Fq2j+OL5YZrF9Gv7y2s7YyKyxqqMqvlijOQeWCrjJHIGa7kfDjw0syyrb3wZLz7cv8AxNLrAnxjfjzMdOMdMcYp8fw58Jx3kdydHjleIyGFJpXkjh8wYcJGzFUB9FAHX1NHTz/4FvzGrX1/rV/pY5geMfH8UNub3QbGzivL62ghvLkqAElODiGKeTcV4+YumQfujFSz+NPFOnX99HqMWkPDpuqWVjN5EUu64S42DeuW/dkGQHad/cZP3q6EfDvw4LW2txBfeTaTLPbqdVuv3TL90L+84UdlHyj0pL74deG9RuLya7gvme9uY7qfbqt0gaVPuNhZABt4wBgDA9Birq/z/DT/AIP3kq/Xt+Ov/AOe0Txz4x1u1n1W08L+ZpE1rLNZvmIMHU4RTidmk3YP8EZUjHPWpJvH2oR6Ta3qXNm1sJZI7y9bS7lVtnVUxHNDu32+SzEu25VAGc7s101r4H0CzNz9ms5UjuWLyQfa5jCGY5ZljL7EJyclQCcnPWmnwNoDW7QtbXDB2ZpJDfTmSbdt3CSTfucEIoIYkYUDGOKStcfW4virV77TtJt5tKvdMtpZnwJL2OSYONhbEcUZDSMcdARgZPOMHgtQk1L4iXXhBbptMjsNV0ia8lsrqyknQSDysniVORv+Q9U5PJPHpepeHtM1YWYvbdj9hffbmKZ4jGdu0jKEEggkFTwRwRWbbeAPD1neabdWtveRSaXEYbMLqVztijJyV2+ZtIPGQQcgAHgClprf+tH+tvuGnZHn+g+NfGieH9I0vSLKPXtUOnC/kcxKoaMyFFjJluVIOVOZBvxx8ldv4d1vxDrHijVbbUIdPsLTTZI0a3RWmmk3xBxmTcFUjdyArD0PerI8AeHEFn5NnNA9kX+zywXs8UiKxyyb1cMUzj5CdvA44q/pPhnS9E1C9vdNimjmv2VrjfdSyKxUYXCMxVcDj5QOAB0Ap37+f9fcJ26f1/X/AADmdY8a6ho3jW2s5ZtMuNOmuWt3t7eKV7iDEDS73kzsViVI8vbkgghj0HL3eva7H4htPFqiwuJLjwvd31paLJKkaIrQuFf5mDMAx+ZVXOcHgA16LL4K0GbVW1GSzk+0tdC7yLqUIJgmzeEDbQSpwcD5h1zWdL8K/B00YSTSWZVSSKL/AEyf9wkn30j+f92p6bUwMEjoTlLRef8AwGvzZV1fy/4P+Rg6j468Uafa6rK0ekE2GlW+rDEMvzRvuDQ/f+9lDiTpyPkPWptY8Xaxper6u2n6RpAlj1DTrRp3Z98kU5ChmIUbmBfAXOACTk9K25fhn4XnjuI5ra/kS5tUs5g2rXZ3wocqh/e9B/VvU5S4+GPhe6uHnnh1J5JGidz/AGzeDe0WPLYjzcErgYJ5zz1q7xuu1/wv/kRZ/wBd7f53Zkp4p1SfUtMstVsNLvJI/EEunyXCxsuxlhaSOSNGLbWK5Uktx2znihqfjLxDeeENS8q9tdM1e2mtlltn0+aOW3EkwQqQzjeuCMSocNhsBe3UD4b+GheC6+z35mF4b4E6tdEeeRgvjzcZxx6Y46Vb/wCEI0D7HdWrWcjxXSJG4e6lYqqEFFRi2YwCMgIQAeetSrW18v0uVf8Ar5v9Gc/Z+JfFU/8AwkP2y68PWQ0e6FoGlil2OTHE4lLbxjiQ/u8HJwu/+I5tj4r8Ta3rHh+OK+srcDVby0ulFhKi3QijJDbWkDICvY7sHDfMBg9cngHw7Ha6jbi1uWj1KZLi5339w5MqEFXVi5KMNq4KkH5V9BUsXgnQYJUkitJVdLprtW+1zEiVl2M33u46joTyRnmj/L8dP+D/AFtMtVZd/wAP6scpoHivWNStbPTNHstG0rUrgX11NmF5LceVcmMhVVkJZmOS5x3O05xVJ/ib4iudKu9Ss9P021trXRE1bZOZJXlwzLJHxtC8o2G+bscHOB10Xw58MwWMNpDaXSJBNJNE41K581Gk/wBYBJ5m8K3UrnaTyRS33w58M6g05uLK4Vbi0Wykig1C4hjMC9IwiOFC8dAB1Pqcl1e/9df+B9xStrf+tV+l/vJvEev3Onw6Tb6csKXmsXQtoJbhC8cJMbSFmUFS3CEAAjJI5FcPr2p654nTStHvH0yIpr76ZqEcllJNb3ZWBpFbZ5q/IRjKEn5sfMdvzei3nhvS9Q0OHSb2CSa1g2eUWuJPNQp91hLu3hh/e3Z96oXHgLw/dQ2EclvdqNOlae3aLUbiNhI3WRmWQF3OT8zEnk88mj3b67f8N/wfv8ha287fo/8AgfcZWtW1/pGueEND8P3kVjpTvNDNbtHJIXRYWO0P5gI4zjrg7TzjFct4e8XX3grwna/aIYbvS1s9TuI4wXNwGt5mPzSMxDBg3pkEZyc8eo6nodhq8trLfxO8lm7PA6TPGyEqVPKkZyCRg8VjWnw38MWclq0NndMLRJUhSbUbmVAsufMBV5CrBs85BpXYkkmmxPB2s+KNS+1t4o0UWUAVJbSdBGplDA5XYk83Tj5sjdn7oxXGRatF4j+LllFfx6vCt/o19b/Z59NuYBAjPEBjfGBnAJZ+QCQufu59J0Tw5pvh23MOlRzpHgKqzXUs/lqOip5jNsX/AGVwPap5dIsZtag1eSHN9bwPbxzb2G2NyrMMZxyUXnGeKrTmv01/FNDV0vMxtL8FRaVrCaims6lO6uXeKYQbJCYki52xA9I1PBHOe3Fcr8QNUv8AWbbVLeykt4bDRdRsoZ1PmCaaR3ibIZXChAsgGGVgxz0wK9QIzXPax4E8N6/dzXGraaLh7hUWdPOkWOfYQV3orBXIwMFgTjjpSvqmwVrWMMeN9Wa5h1KOGzfRpdYbSDbCN/tKOJDEJd+7aRvH3Nowpzu7VnS/EnV4LDyHtIpNcnu4rSPTvsbwyWzybz8wllVZVATAdXRXOcba7KHwZoNtq51KCw8uctv2LNIIQ+3bvEO7yw+ON4XdjvUMngLw5NZz201g8scwjB8y6lZoxGcoI2LZiCnkBCuDz1o0tZ/1t/wfv8h33/rv/wAD7i14WvdbvtCSXxPpg03UA7K0SshDqD8rgK7hcjnbubHTJ61w+r3uo+G/GvjPWdHa3dLTTrO9uob0ySeai+fuSM7wIjheOCuf4eSa7qz8Pw2F9bzWlxdLHDEyGOS7mlMpOPmcu53kADDMCw/vYyC3UPCmjapqiajfWZe5VVViszosyqcqJEVgsgBJIDg4zxTvrcXSzOTi8aeIG8wsdNxD4ii0xh9lkBaCVI2U/wCt4ceZyeQcdBV7wVqXiG58G6rfX91a6lfR3t6lspjaBf3czqFY7n+X5eMDgccnk6954G8OahqE15faYs8s80dxIskrmNpUGFfy92zcAAM4yQBnOKt2/hzTLXT72ytYZIYL55HnWO4kUlpCS5Vg2UyWJ+UjkkipfwtLf/gL9U2C312/4f8AzX3HB2XxK1mDRbfUdXttPkF9osOo28dsrx+VI8iRlXZmbK5kU5AGACOetdX4f1vVZPEmpaBr32Sa6s7eG6S6somijkSQuACjMxVgYz/EcjB46VHbfDbwta+UEsbiSOKzawSKe/uJY/s56xlHkKkfUcYGOgxr6N4f07QIXj0yKVfMxvknuJJ5GAGFBeRmYgDoM4Haqbjd28/zdvwsLX+vRf8ABOLj8Va5DLHHY6Xo1rJeeI5tNuJFLkDCZWTAC+YxC8klegHPUS6V4y8Q68ltp2nrpcGrBLxp5p4pGgf7PceThUDhl3HnJZtvo1bI+HXhwTiYQX4db034I1W6AE56vjzMZxxjpyaIPhz4atbWOG2tryLyppJ45k1O6EyNJzJiXzN4DEZK5wTyRmpjsk/60S/PUb8v61b/ACsjA1Dxz4j0v/hIrq/tNNEOiywwLaW4eV7hplTYfNZkVAGcZyvTuOtLL4q8a2mgzy6xaaZo14kr+Q95AZWvEEe4CO2gnkbdkEH94ePmweg6eHwR4fhXVEFk8serqFvYp7mWWOUAbQNjsQuBx8oHAHoKYPAfh8R2ytb3Uhtdwikl1C4kkCsMFC7OWZCP4CSvtSd7aD0ujE0/x7e3V1pMt7HDYWeo2UNxCstrKwnZ497Kk4OwMOQI2GT1B7U/wL4t8T+KLiK+v9B+y6FfWv2i1ucxK0ZJG1DtndpMgk7ikeMYK88bdl4I0DTzZ/ZbSVUsgvkxvdzOgKqFQlGcqxUKACwJGOMVPo/hXSNBuJJdKt5YBIxbyjcyvFGScny42YpHknnaBmrvG7aIs7JehyGo+LtY0y61x9P0jSEng16z0+WUu4MkUoiCyMQoLOBIoxwAB1bGD03hjWdR1Ky1VNSS3lvdNvZbUtbI0aTbQGUhWZiuQwBGTyKgvPh14bvri7nube+L3t0l5Ps1S6QPMn3GwsgAxgYAwBtX0GNHSvC+laKuoCwiuANSlMt0JryabzHIwT87HbkccY6D0FT9m3W346f8H7y5atW2v/n/AMD7jh5PiTrCWNvaw2sVxrt3dLaiyFk0Mlo5SSQ745pUDjEeFYSKHwxGOladt4l8WW1zpT+J7bT9Ht7q3uFnieIySLPGCykMkxQKyAvt5I2ldxzkbUvgPw7PbTQTWMkgldJPMa7mMkZTOzy5N+6MLk4CEAZOOpq5P4X0i60u30+7tmuLe3mSeMTzySOZFOQzOzFmPruJyMg5FPQX9f1+BxWneNPG9/rYsbbQIL0afPDb6o8SpCm541dmVnuN6BQ448uTdg4YZ4hTx/4q/sW1uXsrGa+1LU59MtbOzgL+S8TS7nLyTRrICIuF/d+ue1dxceE9HudcbV3t5UvXVVleG6liWYL93zEVgsmM8bgcVVi8A+HYtBbR1s52szcm7Akvp3kjmJ3GRJS5dGzk5VhySe5ourf18/6+Qf1+D/Wxk65rPieP4N6rql5bpoeu29lM5XCyhducMoVyFLKMgbm2k/xY5oHxh4xbXTpWi6LFq50wW6ajKESFZTIgYspe43RgKc/cl3EEZFdu2g6dJoMujTQvPYzxNFKk0zyNIrDB3OxLMSO5OfeqT+CdCe/jvfs06XCQiBpI7yZPOjGcLLtcebjJ+/u6mi6vcOlvX9DktM+IWuLHa32v22nJaTS6jDLBZrI0kbWpc7g5OGBEZGNgOcHvgZN74j1XQPEjeKNUS2vZbnQFkt7azZ1RfMuIlRTvcqcFxlxsDdwMV29r8NvDFpJaPDa3h+xzSzwrJqd1IoeT/WEq0hDbsnIOQcn1NEXwz8IRcNosc48h7ZBcyyTCOJusab2OxfQLgDtijrf+tn/mJ6/f+qf5I59PFfxAS90rT9S0bT9MfUb57VL26QNuUQNIrC3infGCjA5m54wOeJLbxv4ki1Jf7Vt9LFqmtyaVLFbLI0jAQ+YsisTgcjldp69eOeij8A6BHPp0/l37y6bJ5tq8uqXTlGwRyWkO4YJGGyAGYYwTmM/Drw2bgTmC+MgvTfg/2rdY88jG/HmYzjjHTHGKPT+tV+lx/wBfn+tvuOY0rx5421XRpNZh8Ln+zLq0W4s5hGkjRZdRjy47hnn+Qs2AsRyu3GTkaJ8dXfl6XcC6sf7PuSyyX/2GfyTIHKiN/mzbMOM+YDzleOtbtt4F8P2aTR21pNHFK/mCEXk3lxNu3ZjTftiO7n5AtL/wg+geTHF9klKIQWBu5j53zFv3vz/vcliTv3ZPWjS/9f1/WoPbzDxHrN/a6ppej6M1rDfakZSlxdxNLHGsahm+RWUsTkADcO55xg8zo3jfxHr/AIg03TYbfTLBJYbs3E0iSTlpLa4WKRUUMmFOchiSeeRxz2mteH9N8QQQxapC7+RIJYZIZ3hkifGNySRlWU4JHBGQcVVt/B2iWmsWWp2trLFdWMDW9vsupQioxywMe7YxJ5JIJJAJOQKI2T1/rTT8Qe2hg+LhJa/EDRr6zQTXI0u/CwzzusLlVQrkDIHUgsFzj1wKybfxj4hTSLCPRdP0Wytz4YXVo18tyqsoXMSxqVCrg4HJx17YPa6x4Q0fXtTh1DUorprqCCS3jeG+nh2o4w4wjgcjvjPA54FZyfDLwvHHHGltfqkdmbBFGrXeFtz1j/1vT/AegqdVG39fa/Vob3X9dV+iaOc1TxrrLafqUd5p2kXsB0+yv44JUfasc8hRkfJYSFduQcID6DrV/wDtnxDb+IPFhbWNJitrOe2htRe27qkG9EbPyyfOfmI2gKWbHzKOK0bn4W+FLz/j4ttQYfZ47YgaxeKGij5RSBLyAeRnvz1rRu/BOg3rzvc2szSXBhaSQXkyvuix5bhg4IcYHzjDHAyTVO19P6/pf8OSvPsvv/4f/hjidP8AF3inXdT0F7a5sItx1KO4t2tJY0uXt3CA8vujDA9CG2nOQ3GLui+LNV1LRdItPDtppOm3DaMuqSxSQOYQpYgRRqrLt5By3OOPlOeOmTwL4ejVBFZzR7JZpkZLyZSrTf6wgh8gMecdAeRg81Enw78NR6dY2UdlcJDp6tHbFb+4DojfejL79zIePkJK8Dil0/rz/W33F6f12v8A5aHID4m+ILyzvNSs7HTraxtdMsdTWObzJJZY5iwdMgqEYbTg4YcDrn5e28Sa3eWF1pOm6V9njvdWneGKe6RnjhCxtISUVlLHC4A3DrnPFVr74c+GdRlvHurO6/02CO3nSLUbiJGij+4gRJAqqOwAHU+pzqal4c0zV9MgsNQhllit2V4XFxIssbKMBllDBw3+1uycnJ5qpNPZEa3POdXvtW8ZTeHdNv8A+zY4W1i6sNRtZrR5oLl4Y5Dux5i5QhchTnDYOTtwfU7Gyg03T7eys1ZLe3jWKNWdnIUDAG5iSeO5NYs3gXQJn01zbXMbaW7SWphv54tjtnc52uN7Nk5Zsk5Oc5NdDSvpb+v6/IOv9f1/mFFFFIYUUUUAUdbu7qw0G+u9PiimuYIHkijmcojMATgkAkDj0rz2bx34ri0i4uymjhl8Px63H+4lIAA+eE/vBnPZ+NueVbrXo+oWEGqadPY3gkNvcIY5BHK0bFT1AZSGH4EVzp+Gfhc27QNa3xiay/s8odVuiDb5z5f+t6f/AKqSvd/10f62+4el1/XVfpf7zJ1Px3q0UWralp0Fl/Z+hPCt7bTRu01xvjSRjG4YBNokGAVbcQfu9amh8T+IoY7qK+n0x7ux1F1uEhsZRutFh83KgykhyCvzcgE42nGa2h4F8Pi7t7k2crSwRxxjdeTMJRH9zzVL4lK9i4YitJdE05dbm1cWq/b54BbyTEk7owSQuM479cZPGegqn/d/r+v1EvM85j+IPjk+HzrT+GrRNPuVtpbae4lRFVZZFXZiOaVpDhwQxEfQ5UcCtGTxn4jtNQuobtdLkjsdcttOmMcEimaOcRlWXLnYy+YM53BsdFraf4a+F5NNbTzaXa2bOJFt01O5VIyG3AIBIAi7sHauBkDjgUTfDfw1cNcNNBqDNc3Ud5Kf7Wu8tNHwj/63gjjGPRfQYaceby/4K/S6D7L7nLf8LD8ZXVhqOs6V4Zgl0aGK6aKa5kjiEZhLDLMszO+7Y3y+UhBwMkc0mueL/FLaTqdql1p9pdxwaddxXEFs5CpcylGjIMmSQVPzAjIOMA81183w+8OTrfo1pcpFqBZrmGK/uI4mZvvMEVwqs3OWUAnJyTk0wfDnw0HuHa1vJGuLaO1lMmp3L5jjIMYGZDgqRkMMEEk55OVG3XyG7f18v0uT+JdS1XRdM0+7hnsyi3cEOoPJbOQUdghZAJBswzA8lsD1xXP6H4x13VFuomudJFxY3F0J2ltJIInhRFMThjK2wN5isWO4bc4HFdtfaVZ6lpE2l3sPm2c0RikjLsMrjH3gcg+4OapyeFdElN6ZNPjb7farZ3IJbEkKggLjOBwSMjnp6Cl3/r+v+CCtp/X9b/gji7fx9rxtNRVxaXjWF3AkuoWOl3DxrBJEXMgg3l3AI27lYjB3Y4IrptU8VHT/AAPba1AbW8kuvs8cTwsfIZ5nVA2euwF8+uBT08B6BEZGjgvFkkVFaYajceYdilFO/wAzcG2sRuznHetKTQdLm0E6JLZRNppi8k25Hy7fT1/Hrnmm7fl/wRLpc821vUdavPG2jaXqElqNX0zVYxFeW8cqWssc1tOwLQGQ5ZTH03H2ZdxrSPj7WYLaJtRjsrNLe6ubO91D7LNLamWNgq8q2YFbOSz7gNpXPeuoHgjQBpv2I2szJ5wnE73kzXAkA2hxOX8wELwCG4HA4p03gvQZ7OG0eyZYIlKiOO4kQSKTuZX2sPMDEksHyGPXNNNJ+X9f1/Vglqv68/8AP+tzkI/HvjDUbi/vdD8Nw3Gj28l1AJriSOIK0JYby4lZ2BZMbPJUjOdxq/p/iLxOp8O6hq97oy6XrEO6RYtPlV4HMJkVd5nIIOG5KjpjvmtybwJ4fmuL2X7LcRfbwftMdvfTwxuSMF/LRwocgfeADe9WZPCmjTeHLfQZ7RptNtvL8qGWeRyuwgqN5YsQMdCenHTipW33frf/AIAP4vLX/gHFf8Jt42k1GPTtN0ODVLy0t4Li/wDJiSFHExYhV825DRkKOuJQWyMCmapql/4g8ReHtSWS3j0y38RPYxQL5glLRrKrM537GBZOFKZAAO7kiu41Dwpo+p6vHql1byC8jj8nzYLmWHzI852SBGAkXP8ACwI5PHNVLn4f+GLvUje3OlrLL9pF3saaQxCYAgSCLdsDc8nbk9+lNWun53/FfoHRry/R/qO8falfaP8AD3XdR0jP222spJISFyVYL97Ht1/CuP8AEej6f4Z8GaX4g8MxpHrX2iyVb5eZtQ8yREZZW6yhlYn5icdRjFel29pFbWa2qeZJEq7f38rSsw92ckt+JNY9h4J0DTb2K6tLJw1ud1vE9zLJDbHGMxRMxSM4JHyKOtEdHf0/D/MHqrev4nnskmu6jdabd6hqUNzcweLprW12xyRRxoFlX50EhDgbVIGARg88k1e/4WL4pvYbTTtE0eC91oi7acxRr5Ti3nMPyrJPGVDEZzucrn7rda7C48B+H7m6W5ktrlJEvDfL5N/cRgTnq+1XA9eMY5bjk5gh+HHhm2ggit7W7iNvPJPFMmp3ImR5OZMS+Zvwx5K5wTyRmlHSNn/WiX56+Y5Wbuv61b/VLyIPC+veJdb8QalBq1rp+lwac8aSWaBp5mMkSuP3oYKCC2CArA9j3rn9U1uXwl4u8VXOm20t5d3sumwQxPJvAll3qMB3UADrt3ICeMjOa7rSPDGlaFfXt3pkM0U18VM++6lkViowuFdiq4HHygcADtVS68C+Hr661S4vLKSeTVlQXfmXczK+zlCq78IV7FQCO1HVf16k2Obfxl4r06ztH8TaXBoqtJKkt3PbGWFsY8st5Mzi3DbjlmZwNpHcGtrRPE17e+Lr3SdT8i1aMyNBavayxyPErALIkpJSZSDk7QCuQCO9XJPBGhTWywTwXUyAYYy39w7Sr/dkYvmReBlXJBAAxgVas/DWlWGpnULW3dbghgu6eR0j3NubYjMVQsepUDPfpVXXUDzP4if2qPFmuX7R6VqVvoWkQ6jaWl3BKjRNvkJZJFk+V8x5JCjcMJ8vLHZ1Pxh4zt9a/sbRdJttZv7e1ivbgwwJDG6SMwWMebcqUICHMg8zn+AV0Or/AA78Oa7qF5e6nBfSTXsQgufL1W6iSWMdEKJIF28njGMknuat3Xg7Rby4sriaC4FxZQiCKeO9njkaMY+R3Vw0i8chywPelGySX9f1sVKzd1/W3/B+85648aa4863Nlb2CaedYTSGjnDtMj7wrS5U7SM5ATA/vbv4aypviVrel+HtP1jU4rC4ib+0ku4re3dGdrbzNpQmRtoPl8ghuvWtnxP4D8++s9Q8MafZJeLqUF7c/abyWKNvL7qiq67yBtLbQcdSelap+H3hZ7jz5tIinYTyXCpM7yJHJJ98qjEqu7JJAAGST1NJfB5/8Bfrcn7Xl/wAF/pY5aTxp48s9J+16h4ds4I5b6zhguLh0jDRzyBGAjimmyVLL8xZQQ2doxguj8ReKL/xZo9g1/YW4g1e6s7sRWb7LlY4d6kAy5X5WxglsNg8gYro2+HXht9Lj09re+NrFKk0Uf9qXX7tkOUCnzMqqnBCg7QQDjIFTWngPw/ZX32yC2uTP9ra83yX9xJ++ZSrNhnI5U4I6HA44GKTV/wCvK36/eJ3asv63/wCAQ+JvEl7omtWMOYbXT5hh7u4tZJYzIWwEMiECH13MCD0461k2/jLVLybTruWK0bRdW1KbS0giWRbmBlMiiQyBsHJjOVCqVyPmOK6rU/Del6xcLNqEEkjKFBCzyIsiqSQrqrAOuWJ2sCPbiq8Pg3QrfVpdRgs3juJXeQ7biURpIww0iR7tiOQTl1AY5PPNQttf6/r8Cn5f1/W/mcD4d1o+HfD/AIeWSwt7uzhTVJvtErNJcxmFpDhCe7DgsSSemOc1uaxrHiS28EXWp6tZ6DqNrPHbyRwbJFVVkYBkdW3CTaCpDZXdz8q4517P4d+GrA6f9ltLoDTmla2V9RuXVPM+/kNIQwbuGyOTSv8AD3w5Jo82lPbXZsZiuYP7SudsYUghY/3n7tcgfKmF4HHAqr63ZKVlb+v6/wAzldT8X+JNE8Ta7DE8OoiTULbT9OtEtcGJ5IfM3EtMisMbuCU3HHzDpVyTXvFGr2EegalYWuj6tc2lzPc+cxIaBGVAUEMxKM+8dJG2Y/i4rpbzwR4f1AXX22xeY3YiErNcy7iYwAjg7sq4wPnGG4HPFFz4I0G7itVubaeR7Ut5c7Xs/nEMAGDS797qQACrEg4GRxU29239bf56+exd9U1/X9fhucxp2ualoH7P+kavpcNvc3cGl2zkXbsFwVUEnHLHnOMjPqKH8XeMz4on0jTNIg1caZNCl/LDCkCusgD5UyXO5NqHrtkDEH7tdQ/gjw83hJfDEen/AGfR1AAtraeSHvnlkYMcnk5PPfNPm8H6LcarHqUlvMLtIVgaRLuZPOjXosoDgSgZP3w3U1pKSc3LzISaVvI5DUPiPqWi63fQ3Z0vULVLO6uIUsUlHktC6KEeYkq5O8bgqgoQRg9Tb1+78a2kuiQyanpEJutXih823s5SJIzG7bWQy5GCuOGO7g/LyDuR+AfDUc5lGnF8idfLkuZXj2zcypsLFdrEZ24xnkDNSReCtDis4rbyLqWOGdJ4jPfzyvGyZChXZywUAkbQduCRjk1Ktp5W/O/5FPW/z/LQ5ux8UapPfPpOn2ek6bql7qt5F5/kvLDtgVSXZQUaSRgVHVce+3mlF8QfE+o3EdtZWelWjixv5ZJZxJKDPaTCNgFBXCHPB3E8/wCzhur/AOFe+HPJmj+y3Q867N6ZBqFwJEnIILo/mboyQSDtIyODRcfD/wAOXM0UrWtzG0Nq9mgg1C4hAifl1wjgZY8lupIBJyBS+zbrb8bW/P8AroNWT+f6/wCX9dTOsPGl7d6zpKXSQWFpqVtBLB51tKwnZ0DMqzg7FYdAjDJ6g9qd4p8SeIdO8TppejxaZHDJpNxfLcXQkkYvCyZQopXAIcc7j1z2w2pYeB9A002n2S1nC2ZUwpJezyICoAUlWchioAClgSuOMU/V/Buja5qg1HUYrtroWz2gaK/nhAif7y7UcDnjJxngegw5W+z5/lp9zJhdW5vL/gnJN8RtWutHvNd0+2sl0/SUt2vbSVHaafzYo5GMbhgF2iQYBVtxB+71qr/wmPifS7jU4Q0WrXV7r76fp8UdoF8gLB5hyHnRWG0cLuQ53HJzgdfbfD3w1aSWrwWMo+yokaK17OyuqHKCRS5Eu3+HeG28YxgVPeeCtAv1u1ubFm+2XC3UjLcSKyzKABIhDAxtwOUxTbV9Nv8Agr/J/eJXsr7/APAf6nDeINf8T654R1fSL+yttG1Cz0eS81COR2LOpMgj8popfkz5ZY5Z8ZCkNkmul17UZdL+HukzpY2d9G8ljDLFeAlQrui7guDlgSpAOOmc8Yq/e+AfDmoxxpe2U02yFrdna8m3yxt95ZH37pQevzlueetWL/wfoeo+HbfQp7No9MtmRobe1nktwhQ5XBjZTwcHr1APUUrq/wA1+Df6F6XXz/Jfqjln8b+IYNavRd22mpY2Wux6W8UYkeWSOSNGVw5IAYbwSNpHUZ4yWahf614n+GGrapfmzj0jUNFku7ZLVpYbm3bZuVWYMQ/HJI2Y+7hgc1uyfDfw1LLNJJBfs812t9If7Wu/mnUYV/8AW9QAB+A9BU7eAvDzWN7ZfZblbS+Rkltkv7hY1VjlgiB8Rg99gXOSDmpaTg11/wCAv1uxxlaal0/4L/Sxyy+Ltf03Rb5YW01l0t9NSLdbSZeGcIGU/vPvjdww44+7zUGt6xfazrmhavvgTSrTxDJZxwR+YJmMayqzP82xgWThSmRwd3JFdbcfDrwvdxeVd6a1xEYIrd45rqZ1lSI5j3gvhyvZmycZGcHFOm+Hvha5vxdz6Skji4W6ETSyGETKMCQRbtgbnk7ee/SqbvK/n/kRFJQ5X2/R/r+RyOnfEjxRcaQNbu/DqQ6RfxRHT7iRo0EcssiJGr7ZnZ1O/JbZGRtI288bXgO3vrXxR4vi1S4iuLn7ZAzSQiQRndArfKru5UZJ+XcQO1a0XgLw3Da3dqlgxtbvO+2e5laFMnJMcZYrEc85QLzVrRfCei+H7u5u9KsvLursItxcyyvNLKFGFDO5LHAHrRp/X9fj1Gcy/ivxDY2t8NQm0yS702/k+0RwWMq7rRIfNyoMpw7DA3cgE4wcZrP1j4geJtD0mW4ltdJvZrnRpdXs/KEkaRLHsLRyHLbyFkBDDZuIxhetd+ND00a1Pq32RDfXFuLaWUkndGCTtxnHfk4yeM9BWP8A8K58Mf2TdaaLCYWl1H5Mkf26f5Ys58pDvzHHn+BCFPpSWm/9af8ADP7x3V7/ANb/APDr7jn9R8aeJ9Om1dJF0lhpi2d0cQyfvYZ2KmMfPwylWO/kHj5BVbUtc12UX66V/ZmjXSeKoLGaSK2aX7ShWIq0hDISxBUN7DaD3rppvhr4ZuUuluLe/kF5FFDPu1a7JkSLmME+b2PP4n1NS2vw+8O2lvcQxW9463NzHdytNqVzKzTJja+55CQ3AGQeQADkCqTSlfpp+a/RMj3rW/rZ/rqc2vivXbfWLi2stK0W3luPEZ024uF3ksPs6ukrAAb32jByRjAUZ61Fd/ETWYvD1hNJNo2m3Es97bS317G5tmmt5GRY1TzFYGTaSMscYI+Y10h+Gvhk6kb/AMjUFuGu/tpK6vdhfOxjfsEu3OPl6dOOnFZN/wDDlbGa0Hhm1Z7WNpneKbxBfWsqvKyl3EyF3IJXJTgEkseaneNuv/AX63/XQu6vf+t3/wAD7jrfDdzqV54Z0661xI49Qnt0luI4ojGsbMM7dpZiMZx1PT8K06xdC0KbSXMlxqNzdMYRFsluJZFUBiR992yQDjdgMQPmLHptVUrN3RMbpWYUUUVIwooooAKKKKACiiigAooooAqatbpd6NeW8pkCSwOjGORo2AKnoykEH3BzXmvhDWb+10jwzbWuk2d7MvhBrq1mJJuHkXygYskfKrEr3OSB0xz6feWkV/YzWlzv8mdDG/lyNG20jBwykMD7gg1ztr8OfDNm1qYLO5As7NrGFG1C4dVgbrHtMhBH1B6L/dGHF2vfr/lL9Wh30X9dV/kcw/inXdYu/DUdjrFnEZtWa1vov7NngkGLZ5CkkTyB4z8pwMnPyNkjg5eh+JNY0HQ7Tw94U06TUL+4vdVlRpis22OG7ZcHzJ4ixO8fNvJHXDV6MPBehbU3WsrvHc/almku5ml8zaUyZC24jaSu0nGOMYqpF8OfDMGnw2cNpdRpBcPcwyrqNyJopH++Vl8zeu7qQGwSSSOad1t/X9f11BvT+vP/ADMy38Y6+NajstX06HS7ia3VoLCaJ2+0SeSXZY7pWMRYP8uzGcKWyQcVU/4TrXH0uye1GmzXcmpwWN3HcW09rJaeYccwsSSfQ7sHGR6DqpPBmhSz+bJZu5wco1zKYySmwsU3bS+3jdjd155qCfwF4fuAvnW92zLcrdB/7RuA/mL9zLCTJVcnapO1ewFLS/3fnr+H9ImV7adv0/zOPf4h+K7iddG0fSLe/wBbhe7854YlEUiwTeWMJJcRld2Rk73K/wB1s1tjxfrUfiFbDULGHT5JYFa2sp4XJuZPJ3sqXKsYiwfK7MZwpYEg1ei+G3hiFleG1vI5luHuFnXVLoSq7/fIk8zcA3dc4PcVfl8HaFPcedLZs3BHlm4k8vJTZu8vdt3bRgNjIHQ0ltrv/WxWnM+3Qr+D/EE+u2Nw17NAbq3YLNALSW1kgYjO145CSPZgSGxkelche/EXxDYWuvmMaJqc1hpZ1GBrZJ44FAcq6GQ5E2AM5Xbk8EL1r0HTdB0/SftH2OF9102ZnmmeZn9F3OSdoycKOB2ArFf4Z+FZLFrM2NyLd7Y2jIuo3K5hLbvK4k+5kcL0AyBwcU/tX/r+riWi1/rX/IyX8a65DrEugz/2b/aVxc28VncCGQQxrLFJId678sVETDhl3ZX7tP8AArX+meB9dMYhub611K+2iWaQRuyucAs29wOO+4getarfDjwzJNPNLa3kk06xB5JNTuWYGPhGVjJlWXnDLg8nnk5tQ+F7LQtC1S28Lafbw3F95krebKwE0zA/NJJhm/HB+lTLZtb2/wAv8gj0Uu6/X/M5ew8c+IHtdOl1H+xYRq+iHUraVvMijtHUR71lYsdy/vQQQF6Y96oXGtXPibTrGTVHRrnSfFdvaCa1jmto51yjBjE7E9H/AIiw4yDyK3vC3w40+w8GW+ma/ZRy3hs47W5aK+nlTCYx5TNtMQJUNhAuG9cZrSl+HvhyYfPbXfN4l8Suo3Klp1UKshIk5OFHXqRk881rLlU7rZP8pX/LT8yNZQt1a/S356nLeG9RvdLjbw/oUkSXd9repCK51DzLhY0ifJyN6s7HIAy47nJxg2/DvjXxJ4k8R2+nLBplhCkMzXEjJJO0rwXPkyKg3IEBwSCS3XkcYO8nw88Nx2DWaWlyIzdteiT+0LjzY52+86S+ZvQnJztIzk561bsvB+iadq8Op2VtLDcwW5to9t3LsEZOSPL3bCSeSSMk85zUR0tfp/l/n/XQuet7dX+t/wAibxRZWuoeE9Utr+3iuYHtZN0UyB1OFJHB9CAfwrznRLmex8G3nw/kuJBeW0ey3lBw5sHjLiQf7q7os/3gK9LudEs7zQ30i4N09pInlv8A6ZKJWX0Mobf/AOPcjiqp8I6MbUwfZ5hmzFiZxdSicwA5Cedu39e+7NQ1dSXf/g/16XKTtZ9v+B/XrY4LwrrOoad4L0rSPCdtplqdO8PW2qXC3MDFbjzFYlF2MuxiUYlyG5YfKa14PHOpajfwxx+RpMWoWaT6eL2xlbzt0HmZWUMELKxwYjhsKWzzW0Ph54aWysrUWU4isYjBD/p8+7yicmJm35eP/YYlccYxV9vC2jtqS3xtW85DuVfOk8oNtCbvK3bNwUYDYyB0NaVGpuT73/X/AIHpb5kR91Jf10/4P3nNaJr2vW3wPt/EE8lrqeqrpYvQZQ0KONm7DcsS2M8jAJ7L2zbnxr41/tFNM0fSbXWL6Ozh1CYQQLDGY5SwWLMtypUjY37wBxyPkHftf+EU0ceFn8OLbyppTx+SYEuZVOz+7vDbwMcYz046cVFL4K0OZ7GRre5WWwhFvDNHfTpIYhj5HdXDSLx0csDQ2nNvp/w//AH9lLr/AMN/wTm9W8f6honilILs6fc2Di4DWtpFI89uYoDMN82fL3HaR5e0EZBBIzUPiLVfG0XhS2vlv9ItReXlh5MlvbSsyLLMqtGwL/MBuX5wV3DcNq8GuoHgbw8uoLerYsJluGulAuZfLWRkKMRHu2gMpIIAwepBNJF4E8Pw6c9glrObVnR0ie+nYQlGDKIsufKAZQQE2jgccUo2Vr+X/B+8Nfz/AOAc/wD8JXf2eo6xaLYaZBqT6zBpkVyiMUkLwq6yyjgsQpxtz2C7u9V4/GviqbxLF4dSDSEuUvJ7O4v2SUxsy24mRkh3ZAIYZBkOMEZ710zeAvDrjUhJZTONUkSW6D3kzZdMbHTL/u2XAwU2kYGOgobwD4faS0k8i8WW0MjRSpqVyrlnG13ZhJl2I43MScd6XT+uy/4P3+QS8v63/wCB93mc/YePtTuo/D9zexWun2mp28TPPJbSyQyTs+1oxKpxCQBld4O4sACMc73ijWNT0fUdM+zXNjb2F2ZYJZLm1eVo5fKZ42yJFG3KHIxk8DIzkFj8PvDenW9tb2tncCG2KmOJ7+eRTtYsoYM5DqCxIVsgHkCtnVNJsdZtFttTgE8KypKFLEYZGDKcgjuOnQ9Dwabs9v6Q9LnnKfEjXj4Zs9QFtaz3cpS0mtEs2jZLuSdolA3zBQBsbKswycfMuavw+JvHT3ejadqGladpFzqE9xE1xdL5uRHHvRxDFMQoIyCDKSCPfNdTc+ENCvLPUrW409Hh1SYT3a72BeQAAMCDlSNoIK4weevNRx+CtFjvtPvNl69xpzM9vLLqVy7BmGCW3SHfxx8+eOOlCt/X9dHf5Eyv0MDwp4w8T+I9cSb+wdvh6WSeIXf7pWiMbFQ2fPZn3FSNvlIVz1brWZ8QNUv9ZttUt7KS3hsNF1GyhnU+YJppHeJshlcKECyAYZWDHPTAruLDwpo+l6rPqFhbyQzTyNM8a3Mvk+Y33nEJby1Y85YKCcn1qtrHgTw3r93NcatpouHuFRZ086RY59hBXeisFcjAwWBOOOlJdPIel2czZ+OfF+q6leXGjeFzd6PBLd2yszRI3mQllVt3nlm3OmNnlLjdnccc2bLxrqOpW1jZWVzYNql7dvbGSawmgFqUhMjCW3dw4bjAXeAQQ2a3k8DeHo7q6misXjF2D58EdzKsDkjBbyQ3l7sDG7bn3p0ngnQZrJ7aW1mbdcC5883k3nrKBgMs2/zFIHyjDDA4HHFPS1g6mLHrfjKTxPLo80WhwPa6dHeuV86UXBLMpUHK+UMr1xJgdjXM6TcX9/rnh3V9Ai0/Tb288LzTfZ5Eke0jAlhO1Y1dQvUjcMepBwBXoFv4L0W11Ca+hjvRcz2v2OSRtRuGLRenMn3sknd97JJzkk1Anw98NRabZWEdlOsFirR2+L6fesbHLRl9+5ozgZRiV4HHFC019f8A25fqvuG7ben4W/VM5PTfiV4m8S3ls/hnw0bi2ijtZL5HaIcTIrna7TIV2qcgiN92MfLTrbUdQ8QeOPCGvTyW62F1LeLaQQ+YHRBE4Bky+xmOM8IpXpk8mu0n8H6HPq0epGzaG5SFYCbe4khSSNfupIiMFkUZOAwIFV4fAHhiDVItQTS1M8Nw1zCHmkeOCVvvPHGWKISeTtA55607q90RJNq3oZnjHxdqXh3WbVbWbS5LUzW0ctm0csly4lm8svlSFiUZGCwYMcjjHNzw74lvdR8R32maoYbWeAyMlk9rJFKIw4VXV2JWZSOSyYwWUEZ63dU8GaFrN9LeahaSPPMsayGO6ljD+W2+MlUYDcp6NjI6ZxViw8NaVpmoNfWcEguGQxhpLiSQRqTkhFZiEyQCdoGSATmlG1tfP/gFPXY5HVvGviSx1LWBHaaWLXS9TtLTYxkZ5459gDbsgIwMgP3WHBHvSR+KtUn12y07VrHSrww+IX09rlY2QoRbeckkaMW2tglSd3068bl78OvDeoXF7NdQXzPfzpc3G3VbpA8ifcbCyADbxgDAGB6Cmj4beGRq39peRqH2r7X9t3f2td7fPxjft83bnb8vTpx04ojZJc39bf5P7xyt08/yf/AOZ8O3t3YWsnh3RZYkur/W9RRJ79pZhHFG5LdHV3bkAfOD1OeMHW8CTT6b8Io5UltknthdESXs7CEMs0nLyHLbeOScmtSP4eeGorM2yWdyF+1terJ/aFwZUmb7zrJ5m9d3OQCAcnPWrlt4O0Cz8OXOg2umQw6ZdbzNAhI3lvvEtnOffOeB6Uvs28l+CE9Z83S7/FnF2nj/AMSXF1HYxx6Tcv8A20umyX3kTwIVeASq6wsxJ7j7+DgEcHiWLxXrHifSl0WM2FvqM0N99smKyqjJbzGA+UFkDqWPOd52f7XFdC3w58Ntex3Zt74TxzJcBxqt0MyqgRXbEnzNtGMnJIznqabD8NvC9vbxQxWVyBFNJMjnUblnDSf6wbzJuKseWQnax5IJodnFr+trfnqUnZpr+tX/AMBGHp2ualoH7P8ApGr6XDb3N3Bpds5F27BcFVBJxyx5zjIz6ilv/F3jODxHLo2j6Rb61caekMt68MKQJIsrNhV8y5Bjwq/exIGOeFrp38EeHm8JL4Yj0/7Po6gAW1tPJD3zyyMGOTycnnvmn3fhDRb7UYL+eCf7XBCIBNHeTRtLGOiSbXHmr7Pu6n1NXKSlNy87maTtbyOXuPiFf6e+oRahFbw3kc6wwWE1tLC6h50ijk8wkrNH8+5mTGMhcZ5rN8U6lqN9BJpOvGF77R9Z0qZLqwEkEM6TXCgboy7cjDAqWYdDwenbt4J8PyfaRNYectzCYXSaeSRVQkEhFZiI8kAnaBkgE8gVDP8AD/w7c6Uunz2128C3CXRY6jcea8qfcZpfM3ttwMBmIGBjoKUWk030a/Blf1+BkR+JvEUC3UN/Ppj3ljqLrcJDYygNaLD5uVBlJDkEfNyATjacZrM034geLJtNj1DUNAhtbPVBbrpl1K0aokkzqqq4SeRnUBt27EecY2gkV366Hpqa1Nq4tV+3TQC2kmJJ3RgkhcE478nGTxnoKyovh94ah02fTlsJDZTf8u73czJD82790C5EPzAEeXtwQPQVK8/L/g/f+DB6/wBf1t+KMr4cwXdrqfi+DUJ0nuE1nLvHv2Etbwt8odmKjJ+7uIHQcVnXvxA120tbnEGni/hvIYZLG6gmt5IY5ZliDAncJh8w+ddo59Rg9novhXRvD093PpNkIri9Km5uHkeWWYqMAs7ks3Hqe5PUmub8XfD9b3QJLXw1Z2zXM01vvOoX86okMciyFIzh9gJQDChRk7jkjl3TlHtovyGtbkX/AAmWvJr8nhiZdNXVnvhbwXwhf7P5ZgMwYxeZuLAKV27xnrkdKq2/jnxRf6hbabb2mlW05+3Qz3MolkTzrZgMrGCp2NuU8vkZI7ZPUjwRoT6QLCazlKmcXJl+2zNOJgMbxcFvN3AcBt2ccdOKbL4B8PSyWsn2a6ia0hkhhMGoXEWFkz5hO2QbmYnJY5YnBzkCk/6+7/P+ugK3U5DQ/GHiHVtSvNUOoaXa2TeHrK/jtruN1igeXzMlpA/QFTn5eRtA24JL7Hx94lvr2z0+GPSneXWZ9Llvmt54lO2385HWBm3YI65fnHHDZHTwfDfwtb6ebKLT5fI+zLa7WvZ2IjViyAMXJBUsdpzlc4BAoPw58NnUI74W98tzHcfaVdNUul/e7AhkIEmCxUYJPJGc9TVtx5nZaf8AB/yFr/Xpb89TlB8RvFWpRWVn4e0KG+1YWj3N0qKnlPtmeHavmTxlATGTu/eFcjKmtGXxzrflvqiWtnFpsOqR6VNZujPcpIzrGZN4faQHcfJt5Azu5xW1bfDjwzZxWiWtpdwtZu7QSpqVyJU3nLr5nmbihIyUJKk84q4ng3QYtZ/tOKx2XG5XKrNIImdRhXMW7yy4AADldwwOalWvr/Wv+Wn4i1tp/Wn+ev4HL6X408R3MOhvNFp1w99NqFtNFDA8ZeS3MmwoTIdobyxkHd161R1DV5fEWm6NPfXC/bbLX7NZII4J7RoWZ+VlhdjnjoSSDjcMV1zfD7wvJcGaXSUlbzpJ1EksjLHJJneyKWwmcknaBySevNE/gHw9chPPtrp2S6S7V/7QuA/mJ9w7vMyQuTtUnaueAKE/eTfdP7nf+vkKSbTS63/FWM2x1/xHLrh0O6utK/tKHUD5oSxkCmy8sMHAMxIYkhd2SAcjacZMfjHxR4g0G+1KGwk05v8AiXfa9MhkspJHlkV1R42xKucl0wQBjfznHPRabptydaudY1W3tIbuSJbaNbaQy4iVmYEuVUkndnGMDHU9auXek2N9fWd7d26yXFizNbuSRsLDa3AODkdjnseopdF/XT+mXfV/15/8D0OMn8TahfHS7sQ6TqGlXuqWkEDSW7q8W6MOZBlmDNuOB93bj+I1zW/X9Q8RaNeXmqW893F4nvrO1PkypFEiwTD5oxKQ4GxSB8pHI3fMTXokngfw/Jpdhpws5YbTTrj7Tax293NF5cmSd2UcE8k8HI5qOfwB4duNSS/a2ukuI7p7tGh1C4jVZnGGcKsgUEgntj5m9TlppO/9dP8AJk9P6/vf5r7jnLDxhq2p3ejSPpGky3k2m38qTMzKVnhkWNlU4YpG3ynqx7Y4yb3grxfrOuXemprEdiI9T0ZNTiFrG6mE7lVkYsx3A7gQQBjkc9auwfDPwxa/Z/s9vqEZto5YoSur3eUWU5kAPm/xHk++D2FWtI8CaBoV/Z3mmQXcc1lbG0t9+o3EipDnOza8hUjPqOMD0FNNdf6+L/NfcDvy2X9bf8H7zoqKKKkYUUUUAFFFFAEVzALq1lgZ5IxIpUtG21gD6HsfeuFit4vCd9r2qeHrKRNMmWGCK1sbSSZWugzCScRxAkgBlDEDJKHvzXdXVtHeWkttNvEcqFG8uRo2wRg4ZSCD7gg1maL4W0zw++7TvtpPliJRdajcXIjUdlErsFHA+7jOB6UdQ6HLfCe+iuYfEscb38rJrUrtLe2ssLvlU671Xng5Ufd44AxXYaVrlprDTC0iv4zCQG+16fPa5zn7vmou7p/Dn9al0/SrLS2ujYQ+Uby4a5n+dm3yMAC3JOOg4HFXKfReiX3ISVr+rf3s4GTwjoM3xGt00zSrOyuLC2kvLm+toFW4aWbdGmZcbmOPNY5J5CmtHw9oFppnjLU7vQYEtNMkt0imjiGEnugzFpMdCwGFZupPBJK10K6VZpLfSpG6SX+PtDrKwZsLtGDnK4A/hx3PU5qjovhPStAlEmnfbiVj8tFutSuLlY19FWWRgvQdAKFpYctTiDqd/wCGPGHiS5sPJls5NbsIbiO5aSSRhOkaHy2LYTaX3YwRjIAWr/8Awm2uzpZ6hbLp66dqd/PptvG0EjzW8iGRVlchwHUmI5QBSAfvGtu9+HfhzULm7nu4L5pLy5jup9uqXShpU+42BIANvGAMAYHoMXbXwhodnrD6pb2RW5eRpcGeRolkYYaRYi2xXIJBYKCcnJ5NJfCl1/4C/wCCNvW6/rf/AIHqcBe/ErxPa+G9P1WC20mdrvw5NqrwukseyWJo92G3NldshwuAcr97njornxNrmk6zptrrE9hHa3YQi8GnTLDI7vjyvMEjCJguMF+HLADbjFWLr4V+Dr22WC50hnjRJI4/9MnBiRzl0Rg+UQ9NqkDBIxgkVrTeE9HuJLZ54JpDbLGqh7uUhxHnZ5g3YkwST8+7nnrzV3jpp/V2J+X9bf8ABNS6XfZzL53kZjYeaD/q+Pvfh1ryawvYfhxZsde0FItQs7Ge4t9R06QGHWSkeWaT+ITEDJLA98MRmvVorGGK0kth5skUhcsJpnkJ3EkjcxJA5OBnAHAwAKzLfwdoVtcSTJZNJvhMAjnnkljjjIwUjjdisakcEIBnvUdx6aHGz+KfFv8AYEs/iTwvY/ZHvLJYXuvLCuksqqf3aTTZZCUIYsoOc4BGDdu9c8Zt4ovtP0y90KS3soZJ7l20yZhbAgmGIv54DyEYLABcDnuM7L/Dvw3Jo39lPb3rWQkSRYzqdzmMocoFbzMqoIBCghQQDjIFO0/4f+H9LvWubOPUA7zNO6SatdSRSSN1Zo2kKMfcg0PXb+tEJbanJX3xE8SWvh5NTt7bSpzJ4YXWRC6SR7JAU3jdubcuGJC4B4wW71auvGHjRNfk0nSNIt9Znso4Z7swQpArpKSQgMtyChCqfnCyBj/Ctbcvwu8Hz2YtZdKZoxAbZT9snDpCTkxq+/cqdtoIGOMY4rQn8GaJcXltdyW9wLm2gFssqXsyNJEOiSkOPNHs+7qfU1d43vbr+r/4CJs7W/rZf8H7yjonia+vfF17pOqeTZvGZGhtJLWSOR41YBZElJKTKQcnbgqSAR3rO1Txtq1rPqd/Zw2b6VpGpRafc2zo5uJS/lgyI4bauPNGFKndjqM11Fp4b0ux1RtQtrdxcEMAWnkdY9zbm2IzFULHklQCe/SoZ/CGiXOuHV5rNjdsyO+J5FjkZPuO8QbY7LxhmUkYGDwKlbr+uv8AkU9blHwbrGu679vudY/s+CG3u57NbW1jdmDRvt3GVmAYEDpsH17V5++iSQ2fxGttJ8KeHrjTpLyQTPcXBgcbbeNwBGtu4bazFhlh8xPTrXquh+HtO8OW88OkpOiXE7XEomupZyZG+82ZGYjJ5471Qj8B6DFZ6rapHf8Alau++9B1S6JlbucmTK5AAO0jIAByBipavFr+7b56f5FJpSv53+WpwNhoUWneMPCE/hrw3ok12PDbuftD/ZQvMI3h0ikJb52HQcM3PY48/hfTh4LvWbwvoa348XxRi2Cgw8zxr5fmeVnYQSPudCflr1aw8C6Fpup2eoWkd8tzZW5trdn1S5kVIj/BtaQqRwOoPQHsMVT8MvDDWzwGLUvLe6F4w/tq8yZwciTPm53ZAOfUA9q0clzJ/wBfFzfkYqLUOX+vha/Mn8H6CNGt74jw7pHh+aaUAQ6S26F1VRtY/JHlsswPyqeAOcA1za+O9bsr/T4NXuNNx9ru7TUDDYSARGMM0ThjMdoYeXwQc7uo7drpHhzT9ElmlsjeSSzAK8l5fz3TYGcAGV2KjnoMVFd+EtDvmvmu9PSQ6hLFNc5Zh5jxY2Hg8Y2jp175qd2adDj08Z+NJtdGmadoUOpSad9nXVGijSFGaVQ7bDJcBowqnj5JNxBGVqOXx54og0uS6ls7CS5n1eTR7SytYS5SVWb940kksauMIfl/d5OPmHSu0vPCej32tjVp7aRb3yxE8kNzLEJkGcLIqMFkAycBwcZqsngPw8mi3WlGzmktLq5N1Is17PIwmzu8xXZyyNkZypHPPWl/X4r9L+gdP67P9bepSOv+J7T4bahrGqaLb2utWUMsgtppQscipkh/3bSbcqM7dzYPG7vWQfH2s2c89nfw6fJdTR6c1pJEjpHGbt2TEmWJbaUJyNu7IGB1rsJvDWmXHh6fRJ0uZLK4TZMGvJjLIDgHdLv8w5AAOW5HHSs1fhz4ZD3DSWdzMbm2jtJRPqFxKGjTBQYaQgFSMhh8wJJByTTVru/l/wAH7w6eev6W+7U5nUfEvimXVrXRhe2Fre2muQWlzcRWchiuo5ITKpCGXKdMFdx7c44rqvEGtalFrun6DobWkF9fQTXAuL2FpY0WIoCuxWUkkuP4hgAnnpVhPBuhpYxWn2WRkiuVuxI91K0rTAYDtKW3scfL8xORx04qzrXh3TNfjgXU4ZGa3cvDLBcSQSxEjB2yRsrDI4IB570un9dl+uoaXv5fqzy7TfEWr3Wua34l0pLW2uk0WK4vLa9eWWJmhmuEdYzuHlhvK4bBHcqSSa37/wCJVzpZvrvUbZLa2isjeWtnNbSLJdIIPMOyfJjZs8FMAqFY89unuPBPh66a3MmnKot4hAqRSvGrxA5EciqwEiZJO1wRkk4qWXwnotxqDXlxZ+dIwfMckztFlgVZvKLbNxUld2M4OM4p/wDB/r+tvmN6tP0/Jf5HFy+NPHlppP2q/wDD9nbJNfWcMF1clFBjnkCH91FPLuKll5LoCDnAxg6kus+LbDUNS0y+vtFlu/s8EmmyR6bLGsrPJsYOpnYkA7RwRjcD7Vot8OvDb6ZHp7W98bWGVJoo/wC1Lr92yHKBT5mVVSAQoO0EA4yK2rrRdPvdUstSurZZLywDi2lLHMe8ANxnBzgdc07r+u1l+pOtv63PP4/iP4jMmoat/wAI8ZfDentdxz3A8tGQwbgXB88u25kxs8oYznccc3vDC6ofijfT6zPbSzXWi28wFp5gjQGVxtCu7DIAA3LtDYztFdIvg3Ql1G7vVsm33pZrmH7RJ5ErMMFjDu8ssR/Ftz70zSPBHh7Q9STUNO0/beRwfZ455p5JnjiyTsUuxKrz0HbjpSVtG/60Y5appf1qn+SOX1HxdrGmXWuPp+kaQk8GvWenyyl3BkilEQWRiFBZwJFGOAAOrYweh0LxFeTaPrU2srBJcaPdTQSPaRsizKihwQrMxBwwGMnkU28+HXhu+uLue5t74ve3SXk+zVLpA8yfcbCyADGBgDAG1fQY09H8M6XoLXzabHODqExnufPu5Zw7kYJxIzYyOOMdB6Cl9m3W346f8H7xytdW2v8A5/8AA+489Pjbxbf+E7rVNT8K2T6Rc28M8D3Zj8srI6jYVSaUy/KwYMRHnBBAqHxfJrN8fFiXmoRy2mm6jp4s7eNJIShZojhmDkMuHYEFTk4PGAK7Vvhx4YbSZtM+x3S2MxybddRuVSP5t2IwJP3a5AO1MDgccVNqPgPw/qon+221y32kxGYpf3EZkMQwhJVxkjA56nAznAp6X0/rYlb6/wBf8Ocle/EHxLDq0/h2x063vtaW+mgjlt4B5ZjSGKXPlyTx/NiYL/rOxbHatjRvEPi3U/FUOl6nYadowj0+G9uYW3XMjFmZHQMrqqcqcH5+MfQXm+HHhl5biZrW7M9xci7af+0rnzVmC7d6P5m5Dt+U7SMgAHgCtGy8KaTp+uNrFrFcLevALdna8mdSgOcbGcrnOTnGcknOSaFbT+un+Y3rf+uv+Rmaz4kv9O8XW2ms1vZWdwsawXF1aSuk8rNgoJVYKjADhWHzlhgjFcv4V8TeLn+xWl/qWmXZ1C11GeKZrCRXikhmCru/fYZPm+6ApAAGe9d/eeG9Lv8AUo7+7t3knjdZAPPkEbMv3S0YbaxU8jcDg8jBqkfAvh3bAosXUQSyyx7bqUFTKSZFyG5Rs8ofl9qXTz1/4A18V3sed+JPFWr+MfhZqIhaztWh8PQ6lf7RKrO8qMwWIq4KAbCctvB+6R1NdTLr/iKz1OfRhdaWt1cC2bSN1jIQ0bMRLv8A3w3lFBJxt7HvgaUnwy8ISWcVoujJDbx2xtfJgnkiWSIknY4RgJBkkjdnBJI5q5Y6CYtYtppLCwtLPSoXttNjtmLsEYKMnKqI8BcbRuHfParco82m17/1+AtbL+u3/BN0Z2jcQTjkgYpahtbWO0hMcTSspdnzLM8pyxJPLEnGTwOgHAwBipqgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==" alt="" width="590" height="596" vspace="0" hspace="0" border="0" style="width:590px;height:596px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>In a clinical trial in Sweden comparing 2 acellular pertussis vaccines, DT and a whole-cell DTP vaccine, 2,587 infants received TRIPACELP&reg;P at 2, 4 and 6 months of age. Rates of adverse events following TRIPACELP&reg;P administration were similar to those following DT and significantly lower than following whole-cell DTP. There were 2 reports of fever &gt;40&deg;C and 1 report of an HHE following TRIPACELP&reg;P administration. There were 7 reports of convulsions, but none were within 7 days of vaccination.<br />In another clinical trial conducted in Sweden comparing 3 acellular pertussis vaccines and 1 whole-cell DTP vaccine, 20,745 infants received a different formulation (20 &mu;g PT, 20 &mu;g FHA, 3 &mu;g PRN, 5 &mu;g FIM) of TRIPACELP&reg;P at 2, 4 and 6 or 2, 5 and 12 months of age. Rates of adverse events were less than or comparable to the rates in the other acellular pertussis vaccine and whole-cell DTP groups in this study. The rates of reports of fever &gt;40.5&deg;C and seizures or suspected seizures were significantly higher following whole-cell DTP than following acellular pertussis vaccines. Rates of HHE were comparable, with 29 reports following administration of TRIPACELP&reg;P. No deaths or cases of encephalitis or acute encephalopathy, invasive bacterial infection, infantile spasms or anaphylactic reactions were reported within 48 hours of vaccination.<br />Data from Post-Marketing Experience<br />The following additional adverse events have been spontaneously reported during the post-marketing use of TRIPACELP&reg;P worldwide. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure. Decisions to include these events in labelling were based on one or more of the following factors: 1) severity of the event, 2) frequency of reporting or 3) strength of causal connection to TRIPACELP&reg;P.<br />Blood and Lymphatic Disorders<br />Lymphadenopathy<br />Cardiac Disorders<br />Cyanosis<br />Gastro-intestinal Disorders<br />Nausea, diarrhea</p><p>General Disorders and Administration Site Conditions<br />Injection site reactions: pain, rash, nodule, mass<br />Large injection site reactions (&gt;50 mm), including extensive limb swelling which may extend from the injection site beyond one or both joints have been reported in children following TRIPACELP&reg;P administration. These reactions usually start within 24 - 72 hours after vaccination, may be associated with erythema, warmth, tenderness or pain at the injection site and resolve spontaneously within 3 - 5 days. The risk appears to be dependent on the number of prior doses of acellular pertussis containing vaccine, with a greater risk following the 4PthP and 5PthP doses.<br />Infections and Infestations<br />Injection site cellulitis, cellulitis, injection site abscess<br />Immune System Disorders<br />Hypersensitivity, allergic reaction, anaphylactic reaction (edema, face edema)<br />Pruritus, generalized rash and other types of rash (erythematous, macular, maculo-papular)<br />Nervous System Disorders<br />Convulsions: febrile convulsion, grand mal convulsion, partial seizures<br />Hypotonic-hyporesponsive episode, hypotonia, somnolence and Syncope (fainting).<br />Psychiatric Disorders<br />Screaming<br />To report any side effect(s):<br />&bull;Saudi Arabia:<br />- National Pharmacovigilance Center (NPC):<br />o Fax: +966-11-205-7662<br />o Call NPC at :<br />+966-11-2038222 Exts: 2317-2356-2353-2354-2334-2340<br />o Toll free: 8002490000<br />o E-mail: Unpc.drug@sfda.gov.saU<br />o Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Vaccine against diphtheria, tetanus and pertussis.<br />ATC Code J07AJ52<br />Mechanism of Action<br />Diphtheria and Tetanus: Strains of C. diphtheriae that produce diphtheria toxin can cause severe or fatal illness characterized by membranous inflammation of the upper respiratory tract and toxin-induced damage to the myocardium and nervous system. Protection against disease attributable to C. diphtheriae is due to the development of neutralizing antibodies to diphtheria toxin. A serum diphtheria antitoxin level of 0.01 IU/mL is considered the lowest level giving some degree of protection. Antitoxin levels of at least 0.1 IU/mL are generally regarded as protective Levels of 1.0 IU/mL have been associated with long-term protection.<br />Tetanus is an acute and often-fatal disease caused by an extremely potent neurotoxin produced by C. tetani. The toxin causes neuromuscular dysfunction, with rigidity and spasms of skeletal muscles. Protection against disease attributable to C. tetani is due to the development of neutralizing antibodies to tetanus toxin. A serum tetanus antitoxin level of at least 0.01 IU/mL, measured by neutralization assay, is considered the minimum protective level. Levels of 1.0 IU/mL have been associated with long-term protection.<br />In a clinical trial in Canada (N = 324), protective levels of diphtheria and tetanus antitoxin antibodies were present in all but one participant after 3 doses of TRIPACELP&reg;P and in 100% after four doses.<br />Pertussis: Pertussis (whooping cough) is a respiratory disease caused by B. pertussis. This Gram-negative coccobacillus produces a variety of biologically active components, though their role in either the pathogenesis of, or immunity to, pertussis has not been clearly defined. The mechanism of protection from B. pertussis disease is not well understood. However, in a clinical trial in Sweden (Sweden I Efficacy Trial), the same pertussis components as in TRIPACELP&reg;P (i.e., PT, FHA, PRN and FIM) have been shown to prevent pertussis in infants with a protective efficacy of 85.2% using the World Health Organization (WHO) case definition (&ge;21 consecutive days of paroxysmal cough with&nbsp;culture or serologic confirmation or epidemiological link to a confirmed case). In the same study, the protective efficacy against mild disease was 77.9%.<br />Minimum serum antibody levels to specific pertussis vaccine components that confer protection against the development of clinical pertussis have not been identified. Nevertheless, a number of studies have demonstrated a correlation between the presence of serum antibody responses to pertussis vaccine components and protection against clinical disease. In a controlled clinical trial in Sweden (Sweden II Trial), the efficacy of a DTaP vaccine with a different formulation in pertussis antigens as TRIPACELP&reg;P was demonstrated to provide a two-fold to three-fold higher protection against pertussis with any cough compared to the three pertussis antigens vaccine. The observed difference supports the role of fimbriae types 2 and 3 in the protection against colonization of B. pertussis and mild disease.<br />Duration of Effect<br />To ensure optimal protection during childhood, 4 consecutive doses should be given at 2, 4, 6 and 18 months of age. A booster with a vaccine containing diphtheria, tetanus, acellular pertussis with or without IPV is required at 4 to 6 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No pharmacokinetic studies have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Data from animal studies revealed no unexpected findings and no target organ toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum Phosphate (adjuvant) (aluminum 0.33 mg) 1.5 mg<br />2-phenoxyethanol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This vaccine must not be mixed with other medicinal products except Act-HIBP&reg;P [Haemophilus b Conjugate Vaccine (Tetanus Protein-Conjugate)] as mentioned in section 4.5.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at 2&deg; to 8&deg;C (35&deg; to 46&deg;F). Do not freeze. Discard product if exposed to freezing.</p><p>Do not use after expiration date.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TRIPACELP&reg;P is supplied in single dose vials.<br />The vials are made of Type 1 glass. The vial stopper for this product does not contain latex (natural rubber).<br />TRIPACELP&reg;P is available in a package of<br />1 x 0.5 mL (single dose) vial</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inspect for extraneous particulate matter and/or discolouration before use. If these conditions exist, the product should not be administered.<br />Shake the vial well until a uniform, cloudy, suspension results. Cleanse the vial stopper with a suitable germicide prior to withdrawing the dose. Do not remove either the stopper or the metal seal holding it in place.<br />Aseptic technique must be used. Use a separate sterile syringe and needle or a sterile disposable unit, for each individual patient to prevent disease transmission. Needles should not be recapped but should be disposed of according to biohazard waste guidelines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sanofi Pasteur Limited
1755 Steeles Avenue West, Toronto, Ontario M2R 3T4.
Tel: +1(416) 667 2701
Fax: +1(416) 667 2912
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>